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Background: Dementia is one of the most common and serious disorders in later life and the economic 
and personal cost of caring for people with dementia is immense. There is a need to be able to evaluate 
interventions in dementia using cost-effectiveness analyses, but the generic preference-based measures 
typically used to measure effectiveness do not work well in dementia. Existing dementia-specific measures 
can effectively measure health-related quality of life but in their current form cannot be used directly to 
inform cost-effectiveness analysis using quality-adjusted life-years as the measure of effectiveness.
Objectives: The aim was to develop two brief health-state classifications, one from DEMQOL and one 
from DEMQOL-Proxy, to generate health states amenable to valuation. These classification systems 
consisted of items taken from DEMQOL and DEMQOL-Proxy so they can be derived from any study that 
has used these instruments.
Data sources: In the first stage of the study we used a large, clinically representative sample aggregated 
from two sources: a sample of patients and carers attending a memory service in south London and a 
sample of patients and carers from other community services in south London. This included 644 people 
with a diagnosis of mild/moderate dementia and 689 carers of those with mild/moderate dementia. For 
the valuation study, the general population sample of 600 respondents was drawn to be representative of 
the UK general population. Households were sampled in urban and rural areas in northern England and 
balanced to the UK population according to geodemographic profiles. In the patient/carer valuation study 
we interviewed a sample of 71 people with mild dementia and 71 family carers drawn from a memory 
service in south London. Finally, the instruments derived were applied to data from the HTA-SADD (Study 
of Antidepressants for Depression in Dementia) trial.
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Review methods: This was a complex multiphase study with four linked phases: phase 1 – derivation of 
the health-state classification system; phase 2 – general population valuation survey and modelling to 
produce values for every health state; phase 3 – patient/carer valuation survey; and phase 4 – application 
of measures to trial data.
Results: All four phases were successful and this report details this development process leading to the 
first condition-specific preference-based measures in dementia, an important new development in 
this field.
Limitations: The first limitation relates to the lack of an external data set to validate the DEMQOL-U and 
DEMQOL-Proxy-U classification systems. Throughout the development process we have made decisions 
about which methodology to use. There are other valid techniques that could be used and it is possible to 
criticise the choices that we have made. It is also possible that the use of a mild to moderate dementia 
sample has resulted in classification systems that do not fully reflect the challenges of severe dementia.
Conclusion: The results presented are sufficiently encouraging to recommend that the DEMQOL 
instruments be used alongside a generic measure such as the European Quality of Life-5 Dimensions (EQ-
5D) in future studies of interventions in dementia as there was evidence that they can be more sensitive for 
patients at the milder end of disease and some limited evidence that the person with dementia measure 
may be able to reflect deterioration.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Executive summary
Background
The challenge of dementia
Dementia is one of the most common and serious disorders in later life with a prevalence of 5% and an 
incidence of 2% per year in the over-65s. In the UK there are currently 750,000 people with dementia 
and 200,000 new cases every year. It causes irreversible decline in global intellectual, social and 
physical functioning. Abnormalities in behaviour, insight and judgement are part of the disorder, as are 
neuropsychiatric symptoms such as psychosis, anxiety and depression. The economic cost of caring for 
people with dementia is immense. In the UK, the cost of dementia is around £17B per year, greater than 
the costs of stroke (£3B), heart disease (£4B) and cancer (£2B). More importantly, the negative impacts 
of dementia on those with the disorder, in terms of deteriorating function, and on carers are profound. 
Worldwide there are 35 million people with dementia and this costs $600B per year; these numbers are 
set to double and the costs to at least triple in the next 20 years. The need to improve care for people with 
dementia is a policy priority.
Evaluation of clinical effectiveness in dementia
Given its importance in public health terms and its devastating effects, it is understandable that there 
is a large and growing volume of basic, translational and applied research under way investigating the 
effectiveness of interventions to help people with dementia. This includes evaluations of psychological, 
educational and social interventions as well as trials of pharmacological treatments. Given the complexity 
of the syndrome of dementia, there has been discussion about how best to measure the impact of 
interventions. There is an emerging consensus that we need to measure broad patient-reported outcomes 
such as health-related quality of life (HRQL) in dementia as well as discrete areas such as cognition or 
behaviour. A variety of instruments are available to measure discrete areas of function across many of the 
major domains including cognition, behavioural problems and psychological symptoms, activities of daily 
living and depression in dementia, often using proxy reports of observable behaviour.
Measuring quality of life in dementia is more challenging, not least because of poor recall, time 
perception, insight and communication. However, recent studies indicate that meaningful measurements 
can be made using condition-specific measures, using both subjective and proxy instruments.
Funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) 
programme, we developed the DEMQOL system, a condition-specific measure of HRQL in dementia. The 
DEMQOL system consists of two interviewer-administered tools: DEMQOL (28 items), which is completed 
by the person with dementia (score range 28–112, with a higher score indicating better HRQL); and 
DEMQOL-Proxy (31 items), a proxy report of the HRQL of the person with dementia, completed by the 
main carer (score range 31–124). A global quality-of-life item is also included in both instruments but does 
not contribute to the overall score. The system was designed according to best psychometric practice, and 
there is some evidence for the validity of the scale. DEMQOL has good psychometric properties for people 
with mild to moderate dementia [defined as a Mini Mental State Examination (MMSE) score of 10+]. 
DEMQOL-Proxy can be used across dementia severity, from mild to severe.
Economic evaluation in dementia
The last two decades have seen the increased use of economics to inform the allocation of resources 
between competing health-care interventions around the world and particularly the use of cost-
effectiveness, in which interventions are often assessed in terms of their cost per quality-adjusted life-year 
(QALY). The QALY provides a way of measuring the benefits of health-care interventions, including 
improvements in HRQL. Brief generic (i.e. not condition-specific) measures of HRQL are most commonly 
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used to put the ‘Q’ into the QALY. Such measures include the European Quality of Life-5 Dimensions 
(EQ-5D) and Short Form questionnaire-6 Dimensions (SF-6D); it is suggested that these are applicable to all 
interventions and patient groups. This claim has support across certain conditions, for example rheumatoid 
arthritis, for which it has passed conventional psychometric tests of reliability and validity, but is more 
questionable for others, such as visual impairment, hearing loss and schizophrenia.
There is reason to believe that the available brief generic measures of HRQL do not work well in dementia. 
The inherent impairments in dementia of recall, time perception, insight and expressive and receptive 
communication mean that it is not possible to assume that what works for a general non-cognitively 
impaired population will work for those with dementia. This means that instruments to be used in 
dementia need to be psychometrically tested in populations of people with dementia. When this has been 
done, the results have suggested that there are major potential difficulties in using such generic measures 
in dementia, with considerable error likely.
What then is needed to enable cost-effectiveness evaluation in dementia? If the use of the currently 
available brief generic measures is problematic because of the error inherent in their use, might it be 
possible to use instruments that can measure HRQL in dementia, such as DEMQOL and DEMQOL-Proxy? 
These instruments cannot directly be used in economic evaluation in their current form because they do 
not incorporate preference information. They therefore cannot yet be used to calculate QALYs for use in 
incremental cost-effectiveness analysis. This is a major limitation in the currently available measurement 
technology. To meet this need, this study aims to generate a preference-based single index for the two 
instruments that comprise the DEMQOL system (DEMQOL and DEMQOL-Proxy) for use in economic 
evaluation using general population values. In addition, we set out to generate patient and carer values for 
a sample of states to compare with the general population values and to test the new system using a trial 
data set.
Objectives
1. To derive health-state classification systems that are amenable to valuation from DEMQOL and 
DEMQOL-Proxy which can be used to categorise all patients with responses to the measures.
2. To generate utility values for every health state defined by the health-state classification systems 
developed from DEMQOL and DEMQOL-Proxy.
3. To examine whether or not utility values elicited from the general population differ from utility values 
elicited from patients and carers for dementia health states generated by the classification system.
4. To examine the psychometric performance of the dementia-specific preference-based measures using 
trial data.
Method and results
The overall aim was to develop two preference-based measures, one from DEMQOL and one from 
DEMQOL-Proxy. These measures use a subset of items from DEMQOL and DEMQOL-Proxy, respectively, 
to form classification systems so that utility scores can be produced for any study that has used the 
existing DEMQOL and/or DEMQOL-Proxy instruments. We have named the new measures DEMQOL-U and 
DEMQOL-Proxy-U, with the ‘U’ referring to the utility scores generated in this project. This was a complex 
multiphase study. The project had four linked phases:
 z phase 1 – derivation of the health-state classification system
 z phase 2 – general population valuation survey and modelling to produce values for every health state
 z phase 3 – patient/carer valuation survey
 z phase 4 – application of measures to trial data.
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Phase 1a: derivation of the health-state classification system – 
quantitative evaluation of DEMQOL and DEMQOL-Proxy dimension 
structure
The analysis used DEMQOL (n = 1189) and DEMQOL-Proxy (n = 1223) data drawn from two sources: 
routine data collected from a memory service and data collected from a study assessing HRQL in dementia.
Method 
We evaluated rates of missing data, maximum endorsement frequencies, adjacent endorsement 
frequencies and redundancy to evaluate the factor structure of DEMQOL and DEMQOL-Proxy and to 
determine the extent to which the conceptual domains are supported.
Results
We identified two separate five-factor models for DEMQOL and DEMQOL-Proxy. Both models reflect 
aspects of the original conceptual framework but also highlight important differences between self- and 
proxy reports. The factor structures were robust enough to provide the basis for the development of 
dementia-specific preference-based measures for patient self-report and proxy report by carers.
Phase 1b: derivation of the health-state classification system – 
development of a health-state classification system for DEMQOL AND 
DEMQOL-Proxy
The aim of this stage was to identify one item for each of the dimensions identified in DEMQOL and 
DEMQOL-Proxy.
Method
To identify the most robust items for use in the health-state classification system, five separate Rasch 
models were generated for both DEMQOL and DEMQOL-Proxy.
Results: final health-state classification systems
The five items selected to reflect the DEMQOL dimension structure form the basis for the DEMQOL 
classification system. This was named DEMQOL-U. Each dimension has four response levels that 
correspond to the options included on the original DEMQOL instrument. Therefore, the DEMQOL-U 
descriptive system generates a possible 1024 (i.e. 45) health states. The four items selected to reflect 
the DEMQOL-Proxy dimension structure form the basis of the DEMQOL-Proxy classification system. This 
was named DEMQOL-Proxy-U. It contains four dimensions each with four levels corresponding to those 
included in the original measure. Therefore, DEMQOL-Proxy-U generates 256 (i.e. 44) health states.
Phase 2: general population valuation survey and modelling to produce 
values for every health state
Preference-based measures have two components: first, a health-state classification system that can be 
used to categorise all patients with the condition of interest; and second, a means of obtaining a utility 
score for all states defined by the system. In this phase of the development we generated a preference-
based single index for each classification system.
Method
The first stage of generating the preference-based single index involved a valuation study in which a 
representative sample of the general population valued a sample of health states derived from each 
classification system. The sample of states that was valued was derived using simulation. The time trade-
off (TTO) technique, which asks respondents to trade off years in full health to avoid living in a particular 
health state, and ranking, in which respondents order health states from best to worst, were used for 
the valuation study. The analysis used a range of multivariate regression models including ordinary least 
squares and random-effects generalised least squares to produce a single-index measure from each 
classification system anchored on a full health–dead 1–0 scale, in which a value of 1 is equal to full health 
and a value of 0 is equal to being dead.
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Results
The data generated were subjected to multiple multivariate regression and preference weights were 
generated. These enable a health-state utility value to be estimated for every health state defined 
by each classification system. These preference weights can be used to generate a utility score for a 
person with dementia each time they complete the DEMQOL questionnaire or their carer completes the 
DEMQOL-Proxy questionnaire.
Phase 3: patient/carer valuation survey
In the previous stage of the study we estimated a preference-based single index for each classification 
system using values obtained from the general population. However, such values can be obtained from 
other sources; here, we investigated patients and carers.
Method
Health states matched with a selection of those valued by the general population were valued using TTO 
by samples of people with dementia and carers. The elicited values were compared with the general 
population values.
Results
People with dementia and carers of people with dementia gave systematically lower utility values than 
members of the general population. These results suggest that the population used to produce dementia 
health-state utility values may well impact on the results of cost-effectiveness analysis and potentially affect 
resource allocation decisions, and no systematic adjustment between values is possible.
Phase 4: application of measures to trial data
If the DEMQOL-U and DEMQOL-Proxy-U are to be used alongside or instead of generic preference-
based measures it is important to assess their psychometric validity, responsiveness and level of 
agreement between patient and carer report. This can be assessed by applying psychometric methods 
to data sets containing responses to the DEMQOL system alongside generic preference-based and non 
preference-based measures.
Method
We compared the validity, patient/proxy agreement and responsiveness of the EQ-5D and the DEMQOL-U 
and DEMQOL-Proxy-U utility measures. The data for these analyses were obtained from the HTA Study 
of Antidepressants for Depression in Dementia (HTA-SADD), a multicentre placebo-controlled pragmatic 
randomised controlled trial of the clinical effectiveness of sertraline and mirtazapine.
Results
There is some evidence for the acceptability of the DEMQOL system, in particular the DEMQOL-Proxy-U, 
which displays low missing data rates. There is no clear pattern regarding agreement between patients and 
carers. In terms of responsiveness, there is evidence that the DEMQOL utility measures and EQ-5D are less 
sensitive to change than the original DEMQOL and DEMQOL-Proxy. The psychometric performance of the 
DEMQOL utility measures may be impacted by the sample used, which focused on those with depression 
in dementia and so may not be representative of all those with dementia. The inconclusive nature of the 
results means that further testing on a range of samples is required.
Conclusions
We have detailed the development and application of two dementia-specific preference-based measures, 
one for self-completion (DEMQOL-U) and the other to be completed by carers (DEMQOL-Proxy-U). These 
measures can be used to generate health-state utility values on the QALY scale for use in economic 
evaluation of interventions in this group of patients. These are the first condition-specific preference-based 
measures in dementia. The results of the psychometric analysis are encouraging but the validity and 
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responsiveness of the instruments require further investigation; therefore, until more evidence is available, 
we would recommend that the DEMQOL instruments are used alongside a generic measure such as the 
EQ-5D in future evaluations of interventions for dementia.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National 
Institute for Health Research.
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Chapter 1 Introduction
Background
The challenge of dementia
Dementia is one of the most common and serious disorders in later life with a prevalence of 5% and an 
incidence of 2% per year in the over 65s.1,2 In the UK, there are currently 750,000 people with dementia3 
and 200,000 new cases every year. Dementia causes irreversible decline in global intellectual, social and 
physical functioning. Abnormalities in behaviour, insight and judgement are part of the disorder, as are 
neuropsychiatric symptoms such as psychosis, anxiety and depression. The economic cost of caring for 
people with dementia is immense. In the UK, the cost of dementia is around £17B per year,3 greater than 
that of stroke (£3B), heart disease (£4B) and cancer (£2B).4 More importantly, the negative impacts of 
dementia on those with the disorder, in terms of deteriorating function, and on carers5,6 are profound. 
Worldwide there are 35 million people with dementia, and this costs $600B per year; these numbers are 
set to double and the costs to at least triple in the next 20 years.7,8 The need to improve care for people 
with dementia is a policy priority.9–12
Evaluation of clinical effectiveness in dementia
Given dementia‘s importance in public health terms and its devastating effects, it is understandable that 
there is a large and growing volume of basic, translational and applied research under way investigating 
the effectiveness of interventions to help people with dementia. This includes evaluations of psychological, 
educational and social interventions as well as trials of pharmacological treatments. Given the complexity 
of the syndrome of dementia, there has been discussion about how best to measure the impact of 
interventions. There is an emerging consensus that we need to measure broad patient-reported outcomes 
such as health-related quality of life (HRQL) in dementia as well as discrete areas such as cognition or 
behaviour.13 There are a variety of instruments available across all of the major domains such as cognition, 
behavioural problems and psychological symptoms, activities of daily living and depression in dementia, 
often using proxy reports of observable behaviour.
Measuring quality of life in dementia is more challenging, not least because of poor recall, time 
perception, insight and communication.14 However, recent studies indicate that meaningful measurements 
can be made using both self- and proxy report condition-specific instruments.14–17
Funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) 
programme we developed the DEMQOL system, a condition-specific measure of HRQL in dementia.14,17 The 
DEMQOL system consists of two interviewer-administered tools: DEMQOL (28 items), which is completed 
by the person with dementia (score range 28–112, with a higher score indicating better HRQL); and 
DEMQOL-Proxy (31 items), a proxy report of the HRQL of the person with dementia completed by the main 
carer (score range 31–124). A global quality-of-life item is also included in both instruments but does not 
contribute to the overall score. DEMQOL has evidence of reliability and validity for people with mild to 
moderate dementia [defined as a Mini Mental State Examination (MMSE) score of 10+]. DEMQOL-Proxy 
can be used across dementia severity, from mild to severe.
The development of HRQL instruments has lagged behind the development of measures of discrete 
function; therefore, they have not yet been widely employed in randomised controlled trials (RCTs) of 
anti-dementia medication and other treatments, which have instead concentrated on discrete areas of 
function, most commonly cognition, with the assumption that these are acceptable surrogates for HRQL. 
We have analysed associations between commonly used measures of specific outcomes in dementia and 
HRQL.18 The data generated suggest that HRQL in dementia does not have a simple relationship with 
cognition or functional limitation. This and other studies19,20 suggest that cognitive impairment and activity 
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limitation are inadequate proxies for HRQL in dementia. These data confirm that HRQL in dementia is 
a complex construct and that simple proxy substitution of cognition or function is likely to miss many 
important dimensions. They suggest that there may be considerable value in including measures of HRQL 
along with measures of specific function such as cognition and behaviour in treatment trials in dementia. 
A failure to include broad outcome measures such as those measuring HRQL, and a reliance on measures 
of discrete function, could lead to the positive effects of interventions being overlooked or to potential 
negative effects of interventions being missed.21
Economic evaluation in dementia
The situation is not quite so clear for the economic evaluation of treatments in dementia. We may be 
relatively confident about the data on the clinical effectiveness of treatments for dementia, at least with 
respect to the cholinesterase inhibitors and memantine for cognition in dementia22 and carer interventions 
for psychosocial outcomes,23 yet there is a lack of directly relevant data with which to ascertain the cost-
effectiveness of such treatments.
The last two decades have seen the increased use of economics to inform the allocation of resources 
between competing health-care interventions around the world and particularly the use of cost-
effectiveness, in which interventions are commonly assessed in terms of their cost per quality-adjusted 
life-year (QALY). The QALY provides a way of measuring the benefits of health-care interventions, including 
improvements in HRQL. Brief generic (i.e. not condition-specific) preference-based measures of HRQL 
are most commonly used to put the ‘Q’ into the QALY. Such measures include the European Quality of 
Life-5 Dimensions (EQ-5D)24 and Short Form questionnaire-6 Dimensions (SF-6D),25 and it is suggested 
that these are applicable to all interventions and patient groups. This claim has support across certain 
conditions, for example rheumatoid arthritis, for which it has passed conventional psychometric tests of 
reliability and validity,26 but is more questionable for others, such as visual impairment,27 hearing loss,28 
and schizophrenia.29
There is reason to believe that the available brief generic measures of HRQL do not work well in dementia. 
As noted above the inherent impairments in dementia of recall, time perception, insight and expressive 
and receptive communication mean that it is not possible to assume that what works for a general 
non-cognitively impaired population will work for those with dementia. This means that instruments to be 
used in dementia need to be psychometrically evaluated in populations of people with dementia. In fact, 
when self-report or proxy report is needed, this generally means that condition-specific measures need to 
be generated which can measure accurately in dementia whatever attribute is under consideration. When 
brief generic measures of HRQL have been tested in dementia, the results have been equivocal at best.30–33
In practical terms, the unsatisfactory nature of the current evidence base is very clearly illustrated by 
the major difficulties presented to the National Institute for Health and Clinical Excellence (NICE) in 
generating its technology appraisal guidance (TA111).22 There has been a great deal of concern raised 
(including referral to judicial review) about the assumptions that had to be made with respect to the 
cost-effectiveness models. The challenges encountered can be attributed to a lack of direct data on cost 
and quality of life. The conclusions of TAG111 make clear the need for a measure that can be used in 
dementia trials to generate direct and accurate measurements of cost-effectiveness in quality-of-life terms. 
This conclusion is echoed in systematic reviews and trials in dementia.34–36
What then is needed to enable cost-effectiveness evaluation in dementia? If the use of the currently 
available generic preference-based measures is problematic, might it be possible to use instruments that 
are developed to measure HRQL in dementia such as DEMQOL and DEMQOL-Proxy? These instruments 
cannot directly be used in economic evaluation in their current form because they are too large to 
incorporate preference information. They therefore cannot yet be used to calculate QALYs for use in 
incremental cost-effectiveness analysis. This is a major limitation in the currently available measurement 
technology. However, the methodology is available to allow the benefits of the DEMQOL system to be 
applied to valuing the benefits of interventions for economic evaluation. This study aims to generate 
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a preference-based single index for these two instruments (DEMQOL and DEMQOL-Proxy) for use in 
economic evaluation using general population preference values. In addition, we generated patient and 
carer values to compare with the general population values and evaluated the preference-based measures 
developed in comparison with EQ-5D and other condition-specific indicators using a trial data set.
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Chapter 2 Plan of investigation
Overview
This is necessarily a complex multiphase study. For ease of understanding this chapter will set out the 
overall plan of the investigation and development of the preference-based measures from the DEMQOL 
system. Each of the major elements will then be reported and discussed in its own chapter before bringing 
the data together to draw conclusions from the programme as a whole.
The project had four linked phases:
 z phase 1 – derivation of the health-state classification systems
 z phase 2 – general population valuation survey and modelling to produce values for every health state 
defined by each classification system
 z phase 3 – patient and carer valuation survey
 z phase 4 – application of measures to trial data.
The methods of deriving a preference-based measure from an existing condition-specific measure are 
the subject of a recent HTA review.37 This identified six stages for this process (Figure 1). These stages are 
used as a guide to the key components in the development of a preference-based measure rather than 
a prescriptive methodology as it is not always practical or possible to follow each stage separately or 
sequentially. Furthermore, the precise technique used at each of the development stages used may differ 
depending on the size and structure of the original instrument. Derivatives of this approach have been 
applied successfully in deriving a preference-based index from the generic Short Form questionnaire-36 
items (SF-36)25 and Short Form questionnaire-12 items (SF-12)38 and condition-specific measures including 
the King’s Health Questionnaire,39 the Asthma Quality of Life Questionnaire,40,41 and the Overactive 
Bladder Questionnaire.42
The problem with deriving preference-based measures from existing measures of HRQL such as DEMQOL 
and DEMQOL-Proxy is that they are simply too large. The instruments include multiple dimensions and 
numerous items measuring a range of HRQL constructs and therefore would define many millions of 
potential health states, which would be too many and complex for preference valuation by respondents. 
The first challenge in this type of work is therefore to fashion a health-state classification system that is 
amenable to valuation by sampling items from the original instruments (like the EQ-5D in structure with a 
small number of dimensions and minimum number of items per dimension). The process of developing a 
health-state classification system is stages I–IV in Figure 1. To carry out stages I–IV, we identified and used 
existing data sets that included DEMQOL and DEMQOL-Proxy data (however, we were unable to identify 
data to carry out the validation required for stage IV).
The aim of phase 1 is to develop two brief health-state classification systems, one from DEMQOL and 
one from DEMQOL-Proxy, that could be used to generate health states for valuation. These classification 
systems consist of items taken from DEMQOL and DEMQOL-Proxy, respectively, and so can be derived 
from any study that has used the existing DEMQOL and/or DEMQOL-Proxy instruments. The classification 
systems and corresponding preference weights have been named DEMQOL-U and DEMQOL-Proxy-U, with 
the ‘U’ referring to the utility scores generated for every health state.
Organisations such as NICE and other similar agencies around the world charged with providing 
judgements on the cost-effectiveness of health-care interventions mostly require HRQL to be valued using a 
choice-based technique.43 There are a range of choice-based techniques available including time trade-off 
(TTO), standard gamble (SG), ranking, and discrete choice experiments (DCEs). In TTO, respondents are 
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asked how many years they would be willing to sacrifice in order to be in full health in comparison with a 
set number of years (usually 10) in an impaired health state described by the classification system. The time 
spent in full health is varied until the respondent is indifferent between the options. SG asks respondents 
how big a risk of death they are willing to take in order to have a chance of ending up in full health. 
Ranking asks respondents to rank a number of health states from best to worst and DCE asks respondents 
to choose which is better out of two health states produced by the classification system. For the valuation 
studies described in this report we used TTO and ranking. TTO was selected for this study over SG to avoid 
asking respondents how much they would be willing to risk their life. We used the TTO protocol developed 
in York,44 which was used to derive the EQ-5D value set currently recommended for use in studies of cost-
effectiveness by NICE.45 This was done to allow for some level of comparability between the utility values 
produced by the DEMQOL measures and the EQ-5D value set and to hence best meet the reference case 
of NICE.
The question of whose values should be used to value health is an interesting one, but ultimately 
political,39 and so beyond the scope of this project. The main valuation survey in this study used a 
representative sample of the general public to conform to the requirements of NICE and the majority of 
other reimbursement authorities around the world. General population values are typically used because 
they reflect the views of society as a whole, which funds the services, and to enhance comparability 
between programmes. Data from the general population survey were modelled using regression 
techniques to estimate preference-based scoring algorithms that can be applied to existing and future 
DEMQOL and DEMQOL-Proxy data to generate a utility score for each instrument.
Stage I
Establish dimensions
Stage II
Eliminate and select items
per dimension 
Stage III
Explore item level reduction
Stage IV
Validation – repeat stages I to III
on other data sets
Stage V
Valuation exercise to elicit health-state
values for a sample of states 
Stage VI
Model valuation results to produce utility
values for all health states
FIGURE 1 The six stages for deriving a preference-based HRQL measure.
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However, there are important questions about whether or not the general population is the right 
valuation group in dementia given the complex nature of the disorder and the error often inherent in 
public attitudes and understandings of dementia.11 In preparing the design of this study we engaged in 
conversation with the Alzheimer’s Society through its Quality Research in Dementia forum. It was clear 
that it wanted the values of people with dementia and their family carers to be investigated directly as 
part of this research. We therefore took this opportunity to complete a supplementary valuation survey of 
people with dementia and their carers to explore the size and direction of any deviation from the general 
public valuations.
In the final phase of the study we applied the general population algorithms to a trial data set that was 
completed during the project [HTA Study of Antidepressants for Depression in Dementia (HTA-SADD), a 
placebo-controlled RCT of the treatment of depression in dementia, Chief Investigator SB]46 to investigate 
the psychometric performance of the DEMQOL utility measures. We had hoped to do the same for the 
MRC-DOMINO trial data set [DOnepezil and Memantine IN mOderate to severe Alzheimer’s Disease, a 
placebo-controlled RCT of donepezil and memantine (Ebixa®, Lundbeck) alone and in combination for the 
treatment of patients whose treatment response is questioned, Chief Investigator RH]. However, the data 
set was not available for analysis by the end of this project and so we focused our analyses on the HTA-
SADD data alone. This provided an opportunity to examine the psychometric properties of the indices in 
comparison with EQ-5D, the original DEMQOL measures and also other dementia-specific indicators.
Phase 1: derivation of health states from DEMQOL and DEMQOL-Proxy
The first task was to construct two health-state classification systems, one from DEMQOL and the other 
from DEMQOL-Proxy. This corresponds to stages I–IV in Figure 1:
 z I – confirm the dimensional structure of DEMQOL and DEMQOL-Proxy
 z II – select items from each dimension to construct the DEMQOL and DEMQOL-Proxy health-state 
classification systems
 z III – explore item-level reduction
 z IV – carry out validation of the classification systems.
Stage I: dimensional structure
The development of the DEMQOL system was based around a five-domain conceptual framework 
incorporating daily activities, health and well-being, cognitive functioning, social relationships and 
self-concept. Factor analysis has been used to investigate the dimensional structure of DEMQOL and 
DEMQOL-Proxy.47 This technique attempts to identify underlying factors that explain the pattern of 
correlations within a set of observed variables. This analysis suggested that DEMQOL has four factors and 
DEMQOL-Proxy two. However, the factor structure proved inconclusive and difficult to define. Therefore, 
the first stage in this research was to carry out exploratory factor analysis (EFA) on two new data sets 
in which DEMQOL and DEMQOL-Proxy had been used. These were the Croydon Memory Service (CMS) 
clinical audit evaluation data set, which has over 1000 cases,48 and further baseline data of over 100 
people with dementia collected in a separate cohort study. These data were used to derive a final set of 
dimensions for the health-state classification systems using the factor analysis as a guide. Other techniques 
could have been used to support this stage, such as cluster analysis, but previous experience of the 
research team found this one to be most helpful. Rasch analysis was also used to confirm whether or not 
the proposed dimensions did indeed each reflect a unidimensional concept (see the following section for a 
full explanation).
Stage II: item selection
Each dimension of a health-state classification system is usually represented by one or occasionally 
two items from the original instrument. The selection of items must be undertaken with great care. 
This process has been assisted in past research undertaken by the Sheffield team by a combination of 
conventional psychometric methods and Rasch analysis.37 Rasch analysis is a mathematical technique that 
converts qualitative (categorical) responses to a continuous (unmeasured) latent scale using a logit model. 
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The theory underlying this approach is that the probability of an affirmative response to each item (or each 
response to each item) depends on the degree of difficulty of the item (or severity in the case of health) 
and the ability of the respondent. In the development of a health-state classification system, Rasch analysis 
can then be used to eliminate items that poorly represent the underlying latent scale. Techniques based on 
item response theory (IRT) could have been used instead of Rasch analysis.
The process of selecting items in a number of studies has been broken down into two components. The 
first is the elimination of poorly performing items that do not meet key criteria tested for using Rasch 
analysis. This can leave a number of items in some dimensions and so the second component involves 
selecting the best item for each dimension.
To choose which items to eliminate in each dimension, separate Rasch models need to be fitted to each 
of the dimensions established in stage I. This is because Rasch analysis assumes unidimensionality and 
so it would not have made sense to consider all items together in a single analysis. The assumption of 
unidimensionality was also tested for each dimension using a Rasch procedure. In deriving the DEMQOL-U 
and DEMQOL-Proxy-U, Rasch models were fitted and items eliminated using three criteria. First, items 
unable to display item-level ordering were eliminated from consideration in the classification system as 
these items demonstrate an inability to distinguish between item response levels. Second, differential item 
functioning (DIF) was used to establish whether or not respondents with different characteristics respond 
differently to items. Items that display DIF are of limited value across subgroups of patients defined by the 
characteristic (as often would be required in an economic evaluation) and are therefore excluded. Third, 
items that do not fit the underlying Rasch model were eliminated as they do not represent the underlying 
dimension. These items are identified using Rasch model goodness of fit statistics.
Once items had been eliminated from the selection process, Rasch analysis and traditional psychometric 
methods were applied to select the ‘best’ items for the health-state classification system. The item 
selection criteria included item-level coverage across the latent space using the Rasch model (an indicator 
of how much of the underlying severity scale an item covers), item goodness of fit using the Rasch model, 
feasibility (level of missing data) and distribution of responses across response categories.
Stage III: explore item-level reduction
In practice, respondents may not be able to distinguish between item response choices and this is 
investigated at stage III of the development process. However, items from the DEMQOL instruments had 
only four response choices and the Rasch analyses for the items used for the health-state classification 
systems confirmed that respondents were able to distinguish between them. Therefore, there was no need 
to explore the possibility for further reductions.
Stage IV: validation of the classification system
The application of stages I–III produced health-state classifications for the two DEMQOL instruments. 
Before proceeding with the valuation process it is recommended that the analysis is repeated on an 
independent sample (stage IV of the development process) or a subsample of the data. However, no other 
samples were available during the development of the health-state classification system and the sample 
size of the data used for the Rasch analysis was not sufficient to allow a subsample to be generated. 
Therefore, this stage was omitted from the development process.
Phase 2: generation of utility values for all health states
Phase 2 of the project involved the generation of population-based utility values for all of the health states 
generated by the DEMQOL-U and DEMQOL-Proxy-U classification systems. This forms stages V and VI of 
the development process detailed in Figure 1.
Stage V: general population valuation study
The aim of this phase of the project was to obtain valuations of a selection of health states generated 
by the DEMQOL-U and DEMQOL-Proxy-U classification systems using the TTO and ranking elicitation 
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techniques. The key design issues were the sampling of states for valuation, the sampling of respondents 
and the content of the interviews.
Sample of states
The DEMQOL-U and DEMQOL-Proxy-U health-state classification systems define many health states and 
so only a sample of health states produced by each system was valued. The selection of health states used 
a novel approach based on simulation rather than the conventional approaches based on an orthogonal 
array or a balanced design in order to provide a more efficient basis for selecting states into blocks (i.e. 
combinations of health states an individual respondent will value) for use in TTO interviews.
Respondents
The main sample of respondents in this survey was drawn to be representative of the UK general 
population in terms of characteristics such as age and socioeconomic status. Households were 
sampled in urban and rural areas in northern England and balanced to the UK population according to 
geodemographic profiles.
The interview
At the interview, respondents self-completed the classification system of the instrument they were valuing 
(i.e. either the DEMQOL-U or the DEMQOL-Proxy-U) to familiarise themselves with the classification system. 
They were then asked to rank eight states alongside full health and dead and then value these eight 
health states using TTO. Respondents were guided through one practice TTO exercise to ensure that they 
understood the task. They were also asked a number of sociodemographic questions. In the sample size 
calculation undertaken before phase 1 of the project, we assumed that there would be up to 100 states 
to value for each classification system and each state was to be valued 30 times, which implies a required 
sample size for one health-state classification of 375. This sample size or less has been successfully used to 
value a number of descriptive systems.25,39,42 We initially assumed the same level of complexity for the items 
derived from DEMQOL-Proxy-U and so this required a further 375 interviews, suggesting a final sample size 
of 750. In the event, the final DEMQOL-U and DEMQOL-Proxy-U designs required fewer states to be valued 
and therefore a smaller total sample size was used.
Stage VI: modelling health-state values
Econometric models were then fitted to the health-state TTO valuations using the TTO value as the 
dependent variable and each level of each domain, other than the baseline, entered as dummy variables. 
A range of different specifications were explored, including aggregate models using mean health-state 
values and ordinary least squares (OLS) and random-effects generalised least squares (GLS) models using 
individual-level data.25 The impact of adding interaction terms and various transformations was explored. 
Rank data were modelled using the rank-ordered logit model and anchored onto the 1–0 full health–dead 
scale required to produce QALYs using the modelled TTO value of the worst health state. All models were 
subjected to the standard tests of goodness of fit.25 The best TTO models were selected and converted 
into scoring algorithms to be applied to existing and future DEMQOL and DEMQOL-Proxy data sets. The 
algorithms have been produced in SPSS (SPSS Inc., Chicago, IL, USA) and are publicly available free of 
charge on the DEMQOL website (www.kcl.ac.uk/iop/depts/hspr/research/ciemh/mha/demqol/index.aspx).
Phase 3: patient and carer valuation survey
The aim of phase 3 was to examine whether or not health-state values elicited from patients and carers for 
health states defined by DEMQOL-U and DEMQOL-Proxy-U, respectively, differed significantly from those 
provided by the general public. Respondents from these two groups were recruited from clinical contacts 
in south London. We recruited people with a clinical diagnosis of mild dementia, with mild severity of 
dementia defined by a MMSE score of > 18. Their main family carer was also recruited when possible.
Respondents were asked to value a set of eight states using the same methods as the general population 
valuation survey. These interviews were undertaken in people’s homes at a time that was convenient for 
them by research workers trained in the TTO valuation method.
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Assuming a power of 0.8, significance level of 0.05, standard deviation (SD) of 0.3 and expected difference 
of 0.1, this required a sample of 71 interviews to compare with mean valuations per state from the main 
general population survey for each of the measures. Mean values obtained from different populations (i.e. 
general population vs carer and general population vs patients) were compared using simple t-tests.
Econometric models were also estimated for each classification system to estimate the impact of 
population, health-state severity and respondent sociodemographic characteristics on elicited health-state 
utility values.
Phase 4: application to trial data
If the preference-based single index developed as part of this study is used instead of or alongside generic 
preference-based measures it is important that it is valid, reliable and responsive in a dementia patient and 
carer population. This can be assessed by applying psychometric methods to data sets containing both 
generic and condition-specific preference-based measures. The issue of how condition-specific preference-
based measures compare with generic preference-based measures is particularly important as this indicates 
the likely impact of using condition-specific preference-based measures compared with generic measures 
to generate QALY values for use in economic evaluation. The recently completed HTA-SADD trial – a 
multicentre randomised double-blind, placebo-controlled trial of the clinical effectiveness of sertraline and 
mirtazapine – was used to conduct such an investigation.
The aim of this phase was to compare the validity and responsiveness of DEMQOL-U and DEMQOL-Proxy-U 
with those of the EQ-5D and other dementia-specific indicators. In looking at these measures we will seek 
to determine (1) if the utility scores derived from the DEMQOL-U and DEMQOL-Proxy-U perform less well 
than the original measures and (2) the performance of the condition-specific preference-based measures in 
comparison with a generic preference-based measure.
Source of data
The data for the analyses shown in this chapter were obtained from the HTA-SADD study of the use of 
antidepressants for depression in dementia. Clinical measures available included the Cornell Scale for 
Depression in Dementia (CSDD),49 the MMSE,50 the Bristol Activity of Daily Living Scale (BADLS),51 the 
Neuropsychiatric Inventory (NPI),52 DEMQOL and DEMQOL-Proxy14,17 and the EQ-5D.53
Statistical analyses
Summary statistics were used to describe the distribution of responses on the self-report EQ-5D, carer 
report EQ-5D (CEQ-5D), DEMQOL-U and DEMQOL-Proxy-U. Agreement between measures (EQ-5D/
DEMQOL-U and CEQ-5D/DEMQOL-Proxy-U) was assessed. The utility values generated from self-report 
HRQL data were then compared with those generated from carer reports to examine the extent of 
agreement between the two sets of values. Construct validity was next examined in light of the absence 
of a gold standard for utility measurement in populations with cognitive impairment. Specifically, the 
construct validity of the EQ-5D, DEMQOL-U and their proxy equivalents was examined in terms of 
convergent validity to quantify the association between the utility values and measures of cognitive 
impairment (MMSE), depression in dementia (CSDD), neurobehavioural problems (NPI) and daily 
functioning (BADLS). Construct validity was also further examined using known group differences based on 
recommended thresholds for the MMSE54 and CSDD.55 Responsiveness to change was examined using the 
minimal clinically important difference (MCID) thresholds recommended by the DOMINO trial group.56
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Outline of chapters in this report
The remainder of this report presents the methods used in more detail, the rationale for the methods 
used, the findings and the implications of the findings for the conduct of economic evaluation in this area. 
Chapter 3 presents a quantitative evaluation of the DEMQOL and DEMQOL-Proxy dimensional structure. 
This evidence was used to establish the dimensions used for the health-state classification systems. 
Chapter 4 presents the Rasch analyses completed to inform the selection of items used to construct the 
health-state classification systems. The general population valuation survey is presented in Chapter 5 along 
with the econometric analyses generating utility values for all states described by the classification systems. 
The comparison of patient and carer health-state values with those of the general population is described 
in Chapter 6. The DEMQOL-U and DEMQOL-Proxy-U indices are then evaluated in Chapter 7. Chapter 8 
provides a brief discussion of the work and how the resultant preference-based measures can be used in 
economic evaluation.
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Chapter 3 Quantitative evaluation of the DEMQOL 
and DEMQOL-Proxy dimensional structure
The analyses reported in this chapter used classical psychometric techniques to conduct item analyses to inform the development of the DEMQOL and DEMQOL-Proxy health-state classification systems. 
We evaluated the dimensional structure of DEMQOL and DEMQOL-Proxy to provide a basis for the 
generation of patient- and carer-reported disease-specific descriptive systems. This represents stage I of 
the development process described in Chapter 2. The analyses reported here replicate a selection of those 
conducted as part of the original development of DEMQOL and DEMQOL-Proxy47 but use a substantially 
bigger and independent sample.
Background to the DEMQOL system
The DEMQOL system14,17 is a measure of HRQL in dementia. It consists of two interviewer-administered 
instruments: DEMQOL (self-reported by the patient) and DEMQOL-Proxy (proxy reported by a carer). 
DEMQOL and DEMQOL-Proxy can be used for all types of dementia and were developed from a five-
domain conceptual framework. This was based on in-depth qualitative interviews with people with 
dementia and their carers47 and includes health and well-being, cognitive functioning, social relationships, 
daily activities and self-concept. Items were drafted to represent each of the conceptual framework 
domains. The items developed were piloted with patients and carers and subsequently evaluated in two-
stage field testing (item reduction followed by psychometric evaluation).
DEMQOL contains 28 items reported on a four-point Likert scale (a lot/quite a bit/a little/not at all); all 
items refer to the last week. A global quality-of-life item is also included but does not contribute to the 
overall score. Items are scored from 1 to 4, with higher scores indicating better HRQL. In the original 
psychometric evaluation there was some evidence of content validity (four of the original conceptual 
domains were represented in the item-reduced version). DEMQOL was also found to have high reliability 
(internal consistency and test–retest) and moderate validity (convergent and discriminant) in mild and 
moderate dementia.14,17 In terms of acceptability, there was some evidence of missing data but floor 
and ceiling effects were not apparent. Factor analyses established a four-factor solution (defined as daily 
activities, memory, positive emotion and negative emotion), but the factor model was inconclusive and did 
not fully support the original conceptual framework.
DEMQOL-Proxy has 31 items reported on a four-point Likert scale (a lot/quite a bit/a little/not at all) and 
also includes an additional global quality-of-life item. The original psychometric evaluation found that 
DEMQOL-Proxy has good reliability (internal consistency and test–retest) and acceptable content validity 
(all five conceptual domains are represented in the item-reduced final version) and that there is some 
evidence for convergent and discriminant validity across the full range of severity. There is also evidence 
for acceptability in mild/moderate and severe dementia. Factor analysis suggested a two-factor solution 
(functioning and emotion), but this did not support the original conceptual framework.
Method
The current analysis used DEMQOL (n = 1189) and DEMQOL-Proxy (n = 1223) data drawn from two 
sources: routine data collected from a memory service48 and data collected from an unpublished study 
assessing HRQL in dementia. To be consistent with the original DEMQOL development, we excluded those 
without a definite diagnosis of dementia (n = 451) and also those with a MMSE score < 10, indicating 
severe memory problems (n = 80). Although DEMQOL-Proxy can be used for those with severe dementia, 
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data from carers of patients with severe dementia were also excluded from the analysis so that the patient 
and proxy samples used for the development of the preference-based measures were consistent in terms 
of diagnosis and severity. Analyses reported below on non-imputed data are based on this sample of 658 
for DEMQOL and 692 for DEMQOL-Proxy.
For the factor analyses we used imputed data. We therefore excluded those for whom imputation (using 
the standard rule outlined in the DEMQOL scoring) could not be undertaken (DEMQOL: n = 14; DEMQOL-
Proxy: n = 10). The final sample for factor analysis was therefore 644 for DEMQOL and 682 for DEMQOL-
Proxy. The demographic characteristics of the sample used for the factor analyses are shown in Table 1.
First, we conducted item analysis on non-imputed data. To do this we evaluated rates of missing data, 
maximum endorsement frequencies (MEFs), adjacent endorsement frequencies (AEFs) and redundancy 
using the criteria outlined below. Next, we imputed responses for missing data (using the imputation rule 
specified in the standard scoring instructions for DEMQOL) to evaluate the factor structure of DEMQOL 
and DEMQOL-Proxy and to determine the extent to which the conceptual domains are supported. The 
criteria for item analyses are based on well-established techniques and also our own previous psychometric 
work.14,57–61
Item analysis (pre imputation)
Missing data 
We selected a more stringent criterion for missing data than the original DEMQOL development study. This 
was based on consideration of the range of rates of missing data across the sample. In general, the current 
TABLE 1 DEMQOL and DEMQOL-Proxy demographics of patient group
Characteristic DEMQOL DEMQOL-Proxy
n 644 682
Female (%) 69.9 60.4
Age (years), mean (SD) 78.83 (7.59) 79.23 (7.69)
Age range (years) 44–97 44–106
Ethnicity (%)
 White 85.3 85.7
 Asian 4.9 4.9
 Black 7.5 6.8
 Other 2.3 2.6
MMSE, mean (SD) 20.81 (4.67) 20.59 (4.58)
MMSE severity, n (%)
 Mild 272 (42.2) 308 (45.2)
 Moderate 372 (57.8) 374 (54.8)
Diagnosis, n (%)
 Late-onset AD 286 (44.4) 307 (44.9)
 Atypical/mixed 154 (23.9) 166 (24.3)
 Other 204 (31.7) 209 (30.8)
AD, Alzheimer’s disease.
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sample was found to have fewer missing data than in the original development study and so we used the 
criterion of < 5% for acceptable rates of missing data. This is similar to other work of this type. The high 
number of missing data in the original development study meant that items were originally selected using 
more lenient missing data criteria of < 30% for DEMQOL and < 10% for DEMQOL-Proxy.
Maximum endorsement frequencies and adjacent endorsement frequencies
We evaluated the proportion of respondents who endorse each response category, including floor and 
ceiling effects (i.e. response categories with high endorsement rates at the bottom/top ends of the 
response scale respectively). The MEF should be < 80%. The sum of any two AEFs should be ≥ 10%.
Redundancy 
Redundancy was assessed using inter-item correlations. Items were defined as redundant if the inter-item 
correlation is > 0.75.
Next, we conducted exploratory factor analyses on imputed data.
Factor analysis (post imputation)
Exploratory factor analysis (principal axis factoring with varimax rotation) was used to provide a preliminary 
evaluation of the extent to which the a priori conceptual domains were quantitatively supported in 
DEMQOL and DEMQOL-Proxy. The data were screened by specifying that the Kaiser–Meyer–Olkin (KMO) 
statistic should be > 0.5 and that Bartlett’s test of sphericity should be non-significant. Several factor-
analytic models were considered based on eigenvalues > 1 and scree plots and also by considering the 
conceptual meaningfulness of alternative models obtained by requesting specific numbers of factors. 
Items were removed from the model if they did not load ≥ 0.40 on any factor, or cross-loaded within 0.20 
on more than one factor.62 These item-removal criteria were also used in the original development of the 
DEMQOL system. The factor analysis was repeated on randomly generated split-half samples to test the 
stability of the models. There was no significant difference for either the DEMQOL or the DEMQOL-Proxy 
total scores across the split halves, which was tested using analysis of variance (ANOVA). Furthermore, 
there were no conceptual differences between the models produced across the split halves, and therefore 
the results presented here will focus on the whole sample analysis.
Results
DEMQOL item analysis (pre imputation)
Missing data 
No items display missing data rates above the maximum accepted level (5%).
Maximum endorsement frequencies and adjacent endorsement frequencies
All DEMQOL items passed the criterion for MEFs. Ten items had AEFs below the criterion (10%) for the 
response options ‘quite a bit’ and ‘a lot’ (feeling distressed, forgetting who people are, thoughts being 
muddled, not having enough company, how you get on with other people, having enough affection, 
people not listening, making yourself understood, getting help when you need it, getting to the toilet 
on time).
Redundancy 
All item pairs met the criterion for redundancy. No pairs were correlated ≥ 0.75.
DEMQOL factor analysis (post imputation)
The five-factor model explained 45.5% of the variance and was supported by the eigenvalue > 1 rule and 
the scree plots. The four- and six-factor models were also considered but as the factors were conceptually 
difficult to interpret they were rejected. The five factors were defined as cognition (factor 1; six items), 
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negative emotion (factor 2; five items), positive emotion (factor 3; five items), social relationships 
(factor 4; six items) and loneliness (factor 5; two items). There were four non-loading items, and these 
were excluded from all of the dimensions and also from consideration for inclusion in the health-state 
classification system. Table 2 displays the model for both the overall sample and the two split halves (split 
half 1: five-factor model explained 46.29% of the variance; split half 2: five-factor model explained 51.92% 
of the variance). There is broad similarity between the overall and split-half models and factor scores were 
therefore derived from the overall model. All three samples met the data screening criteria (KMO statistic 
> 0.5; Bartlett’s test of sphericity non-significant). We derived dimension scores for each of the factors by 
adding the (unweighted) items loading on each factor. These were labelled cognitive functioning, negative 
emotion, positive emotion, social relationships and loneliness.
DEMQOL-Proxy item analysis (pre imputation)
Missing data
Eleven DEMQOL-Proxy items (feeling frustrated, feeling full of energy, feeling sad, feeling content, feeling 
distressed, feeling lively, feeling fed up, having things to look forward to, getting what you want from the 
shops, using money to pay for things, looking after your finances) had missing data frequencies above 
the criterion.
Maximum endorsement frequencies and adjacent endorsement frequencies
One DEMQOL-Proxy item (keeping yourself clean) displayed a MEF above the criterion (80%). For the 
majority of the items assessing cognition, daily activities and social relationships the most highly endorsed 
response option was ‘not at all’. Eight items displayed AEFs below the criterion for the response options 
‘quite a bit’ and ‘a lot’ (forgetting things that happened a long time ago, forgetting where you are, 
keeping yourself clean, keeping yourself looking nice, getting what you want from the shops, using money 
to pay for things, getting in touch with people, not being able to help other people).
Redundancy
All item pairs met the criterion for redundancy as no pairs were correlated ≥ 0.75.
DEMQOL-Proxy factor analysis (post imputation)
A five-factor model (explaining 49.3% of the variance) also provided the best fit for DEMQOL-Proxy. This 
was supported by the eigenvalue > 1 rule and the scree plot. The five factors were defined as cognition 
(factor 1; nine items), negative emotion (factor 2; six items), daily activities (factor 3; three items), positive 
emotion (factor 4; three items) and appearance (factor 5; two items). The four- and six-factor models were 
also considered but the factors could not be clearly interpreted and so they were rejected. There were two 
cross-loading items and five non-loading items, and these were eliminated from the dimensional structure 
and were not considered further for inclusion in the health-state classification system. Table 3 shows the 
five-factor models for the whole sample and also both split-half samples. All of the other factor analysis 
specifications were met (KMO statistic > 0.5; Bartlett’s test of sphericity non- significant).
Discussion
This chapter provides an evaluation of each of the items and also the dimension structure of DEMQOL 
and DEMQOL-Proxy to determine the extent to which the original conceptual framework is supported 
by quantitative data. The analysis replicates part of the original development work14 for DEMQOL and 
DEMQOL-Proxy using a large, clinically representative sample. This factor analysis provides the basis for the 
dimensions represented in the dementia-specific preference-based measures developed.
We have identified two separate five-factor models for DEMQOL and DEMQOL-Proxy. Both models 
reflect aspects of the original conceptual framework but also highlight important differences between 
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self- and proxy reports. The potential for one dimension (self-concept) to be represented was limited 
by the particular items that were retained in the final versions of DEMQOL and DEMQOL-Proxy. The 
four original domains (daily activities, health and well-being, cognitive functioning, social relationships) 
that were operationalised in the questionnaire were represented in the model for either DEMQOL or 
DEMQOL-Proxy, but neither model supported all four of these original domains. This supports using 
DEMQOL and DEMQOL-Proxy as complementary measures in trials and research settings. For example, 
the domain of health and well-being split into two factors (representing positive and negative emotion) 
for both DEMQOL and DEMQOL-Proxy. The domain of daily activities was more strongly supported in 
DEMQOL-Proxy than in DEMQOL, probably reflecting the seven items retained for this domain in the final 
DEMQOL-Proxy compared with two items in DEMQOL. Similarly, social relationships is evident as a factor 
in DEMQOL but not in DEMQOL-Proxy, reflecting the five items retained for this domain in DEMQOL 
compared with two items in DEMQOL-Proxy. However, the emphasis on daily activities and looking after 
yourself in DEMQOL-Proxy and social relationships in DEMQOL is also consistent with the differences found 
between self- and proxy reports in previous qualitative work.14 In addition, the factor analyses reported 
here suggest that in self-reported data (DEMQOL) social relationships consists of two separate parts (which 
we have labelled ‘social relationships’ and ‘loneliness’) and in proxy-reported data (DEMQOL-Proxy) daily 
activities and looking after yourself consists of two separate parts (which we have labelled ‘daily activities’ 
and ‘appearances’).
The factor structure reported here better supports the original conceptual domains than the earlier factor 
analysis conducted during the development of the DEMQOL system. This more positive result is possibly 
due to the much larger sample used for this study (approximately six times larger than that used for the 
original validation).
In the development of the classification systems we used EFA rather than confirmatory factor analysis (CFA) 
to investigate the dimensionality of DEMQOL and DEMQOL-Proxy. We recognise that CFA would also be 
a valid way to investigate the dimensionality of the DEMQOL system. However, we used EFA because the 
factor analysis carried out during the development of the DEMQOL system on a much smaller sample 
was inconclusive and did not clearly match the original conceptual framework, and therefore we did not 
have an established a priori factor structure to confirm. There are some features of the EFA method used 
that may impact on the dimension structure established for DEMQOL and DEMQOL-Proxy. First, factors 
with more items are more likely to be clearly defined using EFA, and this has implications for the item 
loadings of the smaller factors both within and across factors. Second, factors are based around inter-item 
correlations and so a minimum of two items is required to generate a factor. However, factors with only 
two items are not strong, and five or more strongly loading items are recommended.63 In this study we 
used EFA as a guide to the dimensionality and after running a range of models selected the five-factor 
models that fitted the data conceptually and did not contain a high number of non- or cross-loading 
items. The DEMQOL and DEMQOL-Proxy models both contain a factor with two items but we believe that 
the items in each of these factors can be clearly defined as a dementia-specific HRQL concept. Also, as 
the aim is to develop a multiattribute instrument that retains many of the key HRQL concepts from the 
original instrument, we believe that using the factor model including only strong factors with five or more 
items would have resulted in a classification system with reduced sensitivity, which has implications for the 
preference weights derived from the valuation stage.
The factor analysis used orthogonal rotation, which assumes independence between the factors extracted. 
It could be argued that, as the instruments are measuring constructs relating to dementia, the factors are 
related, and therefore we should use oblique rotation, which takes into account the relationship between 
factors. For the DEMQOL system, the factor structures produced using both rotation methods were similar 
and so orthogonal was used. For both DEMQOL and DEMQOL-Proxy there were items that loaded on 
more than one factor. However, as we use factor analysis to also exclude items from consideration for the 
reduced classification system, we followed guidelines used in the development of DEMQOL to exclude 
items (i.e. items loading within 0.2 of each other across factors or < 0.4 on any factor).
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TABLE 2 DEMQOL factor analysisa
Item
Original 
domain
Cognition Negative emotion Positive emotion Social relationships Loneliness
All Half 1 Half 2 All Half 1 Half 2 All Half 1 Half 2 All Half 1 Half 2 All Half 1 Half 2
Q1. Felt cheerful Health and 
well-being
0.134 0.112 0.176 0.273 0.235 0.242 0.449 0.449 0.465 0.147 0.135 0.214 0.259 0.237 0.234
Q2. Felt worried Health and 
well-being
0.309 0.316 0.311 0.418 0.376 0.393 0.256 0.270 0.289 0.258 0.232 0.260 0.083 –0.002 0.249
Q3. Felt that you are 
enjoying life
Health and 
well-being
0.108 0.108 0.115 0.243 0.198 0.225 0.579 0.571 0.604 0.033 0.034 0.070 0.289 0.297 0.263
Q4. Felt frustrated Health and 
well-being
0.157 0.119 0.282 0.634 0.561 0.581 0.224 0.258 0.237 0.163 0.163 0.060 0.030 0.057 0.103
Q5. Felt confident Health and 
well-being
0.188 0.230 0.191 0.190 0.113 0.135 0.568 0.594 0.604 0.096 0.096 0.027 0.009 0.028 0.037
Q6. Felt full of energy Health and 
well-being
0.034 0.000 0.092 0.131 0.164 0.093 0.751 0.721 0.754 0.056 0.020 0.058 –0.001 –0.021 0.001
Q7. Felt sad Health and 
well-being
0.242 0.197 0.315 0.458 0.449 0.361 0.235 0.229 0.265 0.144 0.102 0.143 0.336 0.342 0.395
Q8. Felt lonely Health and 
well-being
0.164 0.130 0.226 0.170 0.181 0.084 0.096 0.111 0.095 0.167 0.134 0.176 0.739 0.742 0.801
Q9. Felt distressedb Health and 
well-being
0.340 0.316 0.397 0.370 0.304 0.117 0.125 0.190 0.208 0.251 0.289 0.315 0.270 0.272 0.329
Q10. Felt lively Health and 
well-being
0.039 0.060 0.024 0.106 0.131 0.043 0.787 0.725 0.836 0.053 –0.075 –0.011 0.054 0.057 0.000
Q11. Felt irritable Health and 
well-being
0.232 0.283 0.230 0.536 0.413 0.662 0.109 0.186 0.107 0.138 0.170 0.116 0.072 0.181 –0.041
Q12. Felt fed up Health and 
well-being
0.202 0.190 0.274 0.609 0.469 0.673 0.242 0.274 0.282 0.128 0.129 0.126 0.297 0.387 0.257
Q13. Things wanted to 
do but couldn’tb
Health and 
well-being
0.136 0.132 0.107 0.355 0.451 0.321 0.270 0.162 0.368 0.210 0.115 0.291 0.088 0.099 0.128
Q14. Forgetting things 
that happened recently
Cognitive 
functioning
0.605 0.630 0.610 0.229 0.191 0.224 0.117 0.130 0.106 0.104 0.085 0.015 0.103 0.103 0.146
Q15. Forgetting who 
people are
Cognitive 
functioning
0.539 0.527 0.589 0.107 0.124 0.079 0.037 0.045 0.037 0.230 0.195 0.184 0.095 0.114 0.051
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Item
Original 
domain
Cognition Negative emotion Positive emotion Social relationships Loneliness
All Half 1 Half 2 All Half 1 Half 2 All Half 1 Half 2 All Half 1 Half 2 All Half 1 Half 2
Q16. Forgetting what 
day it is
Cognitive 
functioning
0.612 0.604 0.648 0.089 0.047 0.115 0.080 0.067 0.089 0.199 0.156 0.194 0.103 0.045 0.125
Q17. Thoughts being 
muddled
Cognitive 
functioning
0.682 0.681 0.698 0.220 0.180 0.190 0.052 0.057 0.082 0.194 0.154 0.232 0.130 0.092 0.122
Q18. Difficulty making 
decisions
Cognitive 
functioning
0.504 0.536 0.531 0.242 0.290 0.142 0.143 0.181 0.118 0.340 0.310 0.275 0.101 0.093 0.122
Q19. Poor 
concentration
Cognitive 
functioning
0.627 0.607 0.693 0.217 0.207 0.184 0.165 0.138 0.193 0.168 0.138 0.076 0.039 0.071 0.047
Q20. Not having 
enough company
Social 
relationships
0.114 0.131 0.135 0.087 0.044 0.080 0.116 0.126 0.118 0.260 0.134 0.237 0.656 0.677 0.656
Q21. How you get on 
with people close to 
you
Social 
relationships
0.185 0.168 0.264 0.200 0.276 0.122 0.051 0.015 0.095 0.567 0.549 0.778 0.168 0.101 0.089
Q22. Getting the 
affection that you 
want
Social 
relationships
0.081 0.072 0.163 0.113 0.223 0.023 0.028 –0.017 0.064 0.637 0.692 0.643 0.257 0.198 0.244
Q23. People not 
listening to you
Social 
relationships
0.133 0.111 0.262 0.097 0.055 0.136 0.023 0.070 0.009 0.664 0.749 0.427 0.148 0.174 0.131
Q24. Making yourself 
understood
Cognitive 
functioning
0.337 0.398 0.370 0.208 0.111 0.260 0.030 –0.002 0.086 0.487 0.537 0.386 0.039 0.078 0.018
Q25. Getting help 
when you need it
Social 
relationships
0.313 0.343 0.338 0.110 0.078 0.146 0.092 0.099 0.086 0.527 0.589 0.397 0.159 0.167 0.138
Q26. Getting to the 
toilet on time
Daily activities 0.213 0.252 0.203 0.121 0.255 0.045 0.047 0.047 0.021 0.450 0.432 0.384 –0.040 –0.087 0.073
Q27. How you feel in 
yourselfb
Health and 
well-being
0.338 0.267 0.457 0.359 0.445 0.280 0.178 0.088 0.233 0.388 0.391 –0.011 0.064 0.073 0.162
Q28. Health overallb Health and 
well-being
0.272 0.213 0.355 0.397 0.576 0.284 0.267 0.150 0.350 0.264 0.207 0.236 0.012 –0.004 0.089
a Highlighted items load > 0.4. 
b These items are non-loaders.
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TABLE 3 DEMQOL-Proxy factor analysisa
Item
Original 
domain
Cognition Negative emotion Daily activities Positive emotion Appearance
All Half 1 Half 2 All Half 1 Half 2 All Half 1 Half 2 All Half 1 Half 2 All Half 1 Half 2
Q1. Felt cheerfulb Health and 
well-being
0.034 –0.008 0.066 0.499 0.392 0.556 0.072 0.099 0.022 0.471 0.592 0.326 –0.027 0.021 –0.022
Q2. Felt worried Health and 
well-being
0.270 0.309 0.266 0.632 0.600 0.649 0.123 0.134 0.127 0.088 0.114 0.044 0.004 –0.052 0.081
Q3. Felt frustrated Health and 
well-being
0.237 0.257 0.216 0.618 0.627 0.579 0.079 0.073 0.072 0.143 0.178 0.063 0.050 0.058 0.099
Q4. Felt full of energy Health and 
well-being
0.023 0.063 –0.015 0.105 0.073 0.164 0.000 0.029 –0.038 0.810 0.790 0.797 0.021 0.028 0.013
Q5. Felt sad Health and 
well-being
0.172 0.169 0.155 0.687 0.741 0.662 0.110 0.123 0.104 0.101 0.142 0.062 0.111 0.026 0.225
Q6. Felt contentb Health and 
well-being
–0.00 –0.064 0.058 0.541 0.460 0.605 0.089 0.072 0.113 0.401 0.463 0.336 0.021 0.062 –0.077
Q7. Felt distressed Health and 
well-being
0.269 0.294 0.245 0.681 0.708 0.648 0.156 0.104 0.208 0.014 0.034 –0.029 0.096 0.084 0.134
Q8. Felt lively Health and 
well-being
0.037 0.093 –0.003 0.141 0.127 0.174 0.002 0.009 –0.022 0.833 0.817 0.836 0.002 –0.008 0.028
Q9. Felt irritable Health and 
well-being
0.121 0.146 0.095 0.531 0.482 0.566 0.045 0.024 0.041 0.103 0.164 0.006 0.113 0.232 0.044
Q10. Felt fed up Health and 
well-being
0.205 0.163 0.254 0.666 0.688 0.638 0.091 0.060 0.130 0.197 0.238 0.138 0.087 0.097 0.112
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Item
Original 
domain
Cognition Negative emotion Daily activities Positive emotion Appearance
All Half 1 Half 2 All Half 1 Half 2 All Half 1 Half 2 All Half 1 Half 2 All Half 1 Half 2
Q11. Things to look 
forward to
Health and 
well-being
0.017 –0.012 0.042 0.314 0.140 0.514 0.073 0.036 0.134 0.454 0.508 0.402 0.010 0.003 0.024
Q12. Memory in 
general
Cognitive 
functioning
0.661 0.631 0.699 0.193 0.193 0.174 0.028 0.064 0.022 –0.003 0.027 –0.021 –0.015 –0.032 0.030
Q13. Forget things 
that happened long 
ago
Cognitive 
functioning
0.457 0.519 0.375 0.106 0.086 0.106 0.138 0.127 0.164 –0.024 0.027 –0.092 0.105 0.153 0.116
Q14. Forget things 
that happened recently
Cognitive 
functioning
0.755 0.766 0.731 0.182 0.176 0.182 0.046 0.084 0.038 0.018 0.023 –0.006 –0.017 –0.029 0.021
Q15. Forgetting 
people’s names
Cognitive 
functioning
0.604 0.586 0.602 0.091 0.112 0.066 0.032 0.087 –0.014 –0.049 –0.017 –0.084 0.146 0.155 0.153
Q16. Forgetting where 
he/she is
Cognitive 
functioning
0.295 0.343 0.182 0.209 0.149 0.286 0.373 –0.072 0.352 –0.056 0.379 –0.052 0.058 0.145 0.043
Q17. Forgetting what 
day it is
Cognitive 
functioning
0.575 0.575 0.550 0.196 0.241 0.166 0.173 0.287 0.084 0.053 0.050 0.059 0.102 0.086 0.119
Q18. Thoughts being 
muddled
Cognitive 
functioning
0.695 0.697 0.696 0.263 0.323 0.186 0.163 0.161 0.180 0.083 0.084 0.067 0.084 0.065 0.113
Q19. Difficulty making 
decisions
Cognitive 
functioning
0.651 0.644 0.639 0.184 0.187 0.180 0.224 0.212 0.247 0.111 0.101 0.104 0.107 0.154 0.066
Q20. Making him/
herself understood 
Cognitive 
functioning
0.471 0.543 0.442 0.206 0.178 0.190 0.204 0.154 0.245 –0.012 0.002 –0.067 0.120 0.230 0.040
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Item
Original 
domain
Cognition Negative emotion Daily activities Positive emotion Appearance
All Half 1 Half 2 All Half 1 Half 2 All Half 1 Half 2 All Half 1 Half 2 All Half 1 Half 2
Q21. Keeping him/
herself clean
Daily 
activities
0.174 0.198 0.150 0.121 0.087 0.108 0.092 0.085 0.096 –0.009 –0.016 –0.015 0.730 0.848 0.705
Q22. Keeping him/
herself looking nice
Daily 
activities
0.146 0.143 0.149 0.148 0.105 0.166 0.114 0.122 0.095 0.040 0.026 0.055 0.772 0.671 0.773
Q23. Getting what he/
she wants from the 
shops
Daily 
activities
0.207 0.311 0.116 0.117 0.101 0.101 0.518 0.516 0.508 0.003 0.054 –0.042 0.279 0.231 0.349
Q24. Using money to 
pay for things
Daily 
activities
0.185 0.247 0.086 0.110 0.076 0.136 0.810 0.832 0.778 0.039 0.065 –0.012 0.058 0.061 0.095
Q25 Looking after his/
her finances 
Daily 
activities
0.229 0.186 0.247 0.172 0.157 0.203 0.655 0.659 0.688 0.015 0.042 0.005 0.005 0.049 –0.027
Q26. Things taking 
longer than they used 
to
Daily 
activities
0.430 0.398 0.383 0.145 0.085 0.123 0.258 0.290 0.274 0.143 0.147 0.138 0.122 0.313 0.311
Q27. Getting in touch 
with peoplec
Daily 
activities
0.097 0.034 0.341 –0.029 –0.05 0.092 0.154 0.188 0.307 0.026 –0.003 0.069 0.231 0.131 0.396
Q28. Not having 
enough companyc
Social 
relationships
0.222 0.175 0.233 0.264 0.339 0.190 0.183 0.266 0.264 0.101 0.071 0.138 0.371 0.342 0.372
Q29. Not being able to 
help other peoplec
Social 
relationships
0.318 0.326 0.269 0.090 0.078 0.128 0.084 0.002 0.073 0.052 0.102 0.014 0.235 0.058 0.263
Q30. Not playing a 
useful part in thingsc
Self 0.349 0.377 0.270 0.161 0.184 0.134 0.081 0.040 0.116 0.081 0.059 0.094 0.190 0.007 0.384
Q31 Physical healthc Health and 
well-being
0.226 0.158 0.279 0.236 0.297 0.209 0.011 0.147 –0.025 0.120 0.101 0.106 0.317 0.300 0.312
a Highlighted items load > 0.4.
b These items are cross-loaders.
c These items are non-loaders.
TABLE 3 DEMQOL-Proxy factor analysisa (continued)
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There are a number of other methods that we could use to investigate the factor structure of the DEMQOL 
system, including the use of a polychoric matrix or IRT techniques such as Rasch analysis. Using a multiple-
factor IRT approach within the six-step guide to developing a condition-specific preference-based measure 
would mean that both the investigation of dimensionality (step I) and item elimination and selection (steps 
II–IV) could be based around the same underlying latent model. Further research may assess differences in 
the factor structures produced using IRT and traditional factor analysis to inform the use of both processes 
in the development of condition-specific health-state classification systems.
The item analyses revealed that all of the DEMQOL items were robust in terms of missing data and 
redundancy, although 10 items failed the AEF criterion. There are 17 items in DEMQOL-Proxy that failed 
at least one of the item analysis criteria. This does not necessarily mean that they are uninformative items, 
and indeed all items passed all of the criteria in the original development study. These classical item 
analyses are considered alongside the Rasch analyses in Chapter 3 to inform the final selection of items for 
the system.
Conclusion
The factor structures established here provide support for dimensions that are similar but not identical to 
the domains of the original conceptual framework. The work reported here has not evaluated whether or 
not the dimensions can be used as scores alongside the overall scores for DEMQOL and DEMQOL-Proxy. 
This would require a prospective study including carefully chosen validating measures. The factor structures 
are robust enough to provide the basis for the development of dementia-specific preference-based 
measures for patient self-report and proxy report by carers.
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Chapter 4 Development of a health-state 
classification system for DEMQOL and DEMQOL-Proxy
Introduction
This chapter presents stages II and III of the development process described previously (see Figure 1). The 
aim of the analysis was to identify one item to represent each dimension in the health-state classification 
system. This involved the application of Rasch methods to evaluate the performance of each of the items 
within each dimension.
Rasch analysis is one of a number of IRT techniques that could be used to assess the performance of 
items included in a range of questionnaires and tests, including measures of HRQL. Rasch converts ordinal 
or categorical responses to items into a continuous unidimensional latent scale. This is done using logit 
modelling. When items fitted to the scale assess HRQL, the latent scale represents a continuous measure 
of quality of life covering the full severity range for the particular HRQL construct being measured. 
Respondents are also modelled on the logit scale, and an individual’s position on the scale represents 
their level of severity in terms of the construct being measured. Responses to items are assumed to be 
a function of both the position of the person and the item on the overall latent scale. This means that 
respondents at the more severe end of the logit scale should be more likely to indicate more severe 
problems on the items included in the dimension than those at the lower end of the scale. The Rasch 
model for each dimension allows for an assessment of item performance at the overall dimension and 
individual response category levels. Therefore, Rasch can be used to inform the selection of items from 
existing condition-specific measures of HRQL to generate a condition-specific health-state classification 
system.40,64 A range of Rasch statistics are used to first eliminate poorly performing items and subsequently 
select items for each dimension. The tests used are outlined below.
Method
To identify the most robust items to use in the health-state classification system, Rasch models were fitted 
separately to each of the dimensions established by the factor analysis at stage I (Tables 4 and 5). The 
Rasch model assumes unidimensionality and, as DEMQOL and DEMQOL-Proxy are not unidimensional (see 
Chapter 3), it would not be appropriate to fit a single Rasch model encompassing all DEMQOL/DEMQOL-
Proxy items. Five separate Rasch models were therefore generated for both DEMQOL and DEMQOL-Proxy. 
Stage II of the development process described in this chapter includes two parts. First, we eliminated items 
across each dimension by assessing the performance of the items included in each model. We assessed 
item response level ordering, DIF and goodness of fit of items to the Rasch model. Next, we used Rasch 
criteria to select one item for each dimension. This included the range of item responses on the logit scale 
and the spread of item responses at logit 0 (the average item difficulty on the severity scale). Each of 
these processes is described in detail below. Rasch analysis was carried out using Rasch Unidimensional 
Measurement Models (RUMM2020, 1997–2004 RUMM Laboratory Pty Ltd, www.rummlab.com.au/).
Stage II: selecting items
Item elimination
Item-level ordering 
For each model we evaluated the ordering of the responses to each individual item. Item responses are 
disordered if respondents cannot differentiate between the response choices and therefore the observed 
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response is not in line with the expected response (Figure 2). This can be assessed as item responses are 
mapped across the logit or severity scale and should be endorsed by respondents who display similar 
amounts of severity of the underlying construct. If respondents can distinguish between the response 
choices included on an instrument, responses to the items will be ordered as the observed response will 
be in line with the expected response at any point of the severity scale. If disordering occurs (i.e. the 
observed response is different to the expected response at that point of the logit scale), adjacent response 
levels are collapsed to artificially impose ordering, and the Rasch model is reapplied (Figure 3). Items for 
which disordering occurs are not considered for inclusion in the health-state classification system as it is 
important that respondents can distinguish between the different levels of the health dimensions used for 
the preference-based measure. Although items are excluded from further consideration for use as part of 
TABLE 4 DEMQOL: factor analysis revalidation
Factor Item Loading
Cognition Q17. How worried have you been about your thoughts being muddled? 0.682
Q19. How worried have you been about poor concentration? 0.627
Q16. How worried have you been about forgetting what day it is? 0.612
Q14. How worried have you been about forgetting things that happened recently? 0.605
Q15. How worried have you been about forgetting who people are? 0.539
Q18. How worried have you been about difficulty making decisions? 0.504
Negative 
emotion
Q4. Have you felt frustrated? 0.634
Q12. Have you felt fed up? 0.609
Q11. Have you felt irritable? 0.536
Q7. Have you felt sad? 0.458
Q2. Have you felt worried? 0.418
Positive 
emotion 
Q10. Have you felt lively? 0.787
Q6. Have you felt full of energy? 0.751
Q3. Have you felt that you are enjoying life? 0.579
Q5. Have you felt confident? 0.568
Q1. Have you felt cheerful? 0.449
Social 
relationships
Q23. How worried have you been about people not listening to you? 0.664
Q22. How worried have you been about getting the affection that you want? 0.637
Q21. How worried have you been about how you get on with people close to you? 0.567
Q25. How worried have you been about getting help when you need it? 0.527
Q24. How worried have you been about making yourself understood? 0.487
Q26. How worried have you been about getting to the toilet on time? 0.450
Loneliness Q8. Have you felt lonely? 0.739
Q20. How worried have you been about not having enough company? 0.656
Non- and 
cross-loaders
Q9. Have you felt distressed? Non
Q13. Have you felt that there are things that you wanted to do but couldn’t? Non
Q27. How worried have you been about how you feel in yourself? Non
Q28. How worried have you been about your health overall? Non
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FIGURE 2 Item with disordered response options.
FIGURE 3 Item (from Figure 2) with reordered response options.
the health-state classification system they remain in the Rasch model to allow for the whole dimension to 
be modelled.
Examination of differential item functioning
We investigated each item for DIF. DIF occurs when item responses systematically differ according to 
a range of patient characteristics when equal amounts of the underlying characteristic are present (at 
different points of the latent scale). In this study the characteristics analysed were gender and age (split 
into two groups: < 65 and ≥ 65 years). We considered two categories of DIF – uniform and non-uniform. 
Uniform DIF occurs when one of the subgroups belonging to each characteristic consistently exhibits 
a difference in response across the full severity range of the construct being assessed by the item. For 
example, women may consistently display higher levels of depression as assessed by an individual item 
than men, and this is the case across the full severity scale of the underlying construct, from mild to 
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TABLE 5 DEMQOL-Proxy: factor analysis revalidation
Factor Item Loading
Cognition Q14. How worried would you say [patient] has been about forgetting things that 
happened recently?
0.755
Q18. How worried would you say [patient] has been about his/her thoughts being 
muddled?
0.695
Q12. How worried would you say [patient] has been about his/her memory in general? 0.661
Q19. How worried would you say [patient] has been about difficulty making decisions? 0.651
Q15. How worried would you say [patient] has been about forgetting people’s names? 0.604
Q17. How worried would you say [patient] has been about forgetting what day it is? 0.575
Q20. How worried would you say [patient] has been about making him/herself 
understood?
0.471
Q13. How worried would you say [patient] has been about forgetting things that 
happened a long time ago?
0.457
Q26. How worried would you say [patient] has been about things taking longer than 
they used to?
0.430
Negative 
emotion
Q5. Would you say that [patient] has felt sad? 0.687
Q7. Would you say that [patient] has felt distressed? 0.681
Q10. Would you say that [patient] has felt fed up? 0.666
Q2. Would you say that [patient] has felt worried? 0.632
Q3. Would you say that [patient] has felt frustrated? 0.618
Q9. Would you say that [patient] has felt irritable? 0.531
Daily 
activities
Q24. How worried would you say [patient] has been about using money? 0.810
Q25. How worried would you say [patient] has been about looking after his/her 
finances?
0.655
Q23. How worried would you say [patient] has been about getting what he/she wants 
from the shops? 
0.518
Positive 
emotion
Q8. Would you say that [patient] has felt lively? 0.833
Q4. Would you say that [patient] has felt full of energy? 0.810
Q11. Would you say that [patient] has felt that there are things to look forward to? 0.454
Appearance Q21. How worried would you say [patient] has been about keeping him/herself clean? 0.772
Q22. How worried would you say [patient] has been about keeping him/herself 
looking nice?
0.720
Non- and 
cross-loaders
Q1. Would you say that [patient] has felt cheerful? Non
Q6. Would you say that [patient] has felt content? Non
Q16. How worried would you say [patient] has been about forgetting where he/she is? Cross
Q27. How worried would you say [patient] has been about getting in touch with 
people?
Cross
Q28. How worried would you say [patient] has been about not having enough 
company?
Cross
Q29. How worried would you say [patient] has been about not being able to help 
other people? 
Cross
Q30. How worried would you say [patient] has been about not playing a useful part in 
things? 
Cross
Q31. How worried would you say [patient] has been about his/her physical health? Cross
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severe. Non-uniform DIF occurs when responses between characteristic subgroups systematically diverge 
depending on the level of the attribute present. For example, responses between genders to a depression 
item may systematically differ depending on the underlying severity. Items for which either form of 
DIF is present are split into component factors (e.g. male and female subgroups) and the Rasch model 
is reapplied with each subgroup included separately. Items displaying DIF are not considered for the 
health-state classification as systematic differences in responses to the items across person characteristics 
compromises their ability to compare across subgroups.
Examination of goodness of fit 
We evaluated the goodness of fit to the Rasch model of individual items included in each factor. Goodness 
of fit is assessed by analysing fit residuals and item–trait interactions. Fit residuals assess the discrepancy 
between the expected and observed responses at both the respondent and the item level. Divergence 
residuals > l2.5l were considered high. Respondents outside these boundaries were also removed from 
the analysis and the model refitted. When all of the misfitting respondents had been removed, the fit 
of items was assessed. Items with residuals above the minimum level were excluded from the descriptive 
system. The overall mean fit residual for each dimension should be approximately 0 and the SD should be 
approximately 1.
Item–trait interactions measure overall differences between observed and expected responses for 
subgroups of responders (which are grouped dependent on where responders lie on the logit scale). The 
chi-squared test statistic (which is > 0.01 for a well-fitting model, i.e. non-significant) was used to assess 
item–trait interactions. Items with the highest level of significance (i.e. the largest divergence between the 
observed and expected responses) were removed one by one, with the Rasch model reapplied after every 
item was removed. This process continued until only items that fitted the model remained and the overall 
goodness of fit statistic was non-significant.
Item selection
To select one item per dimension two main criteria were used. We assessed the range of the item on the 
logit scale and the spread of the item at logit 0. A large range indicates that an item covers the full severity 
range of the underlying construct. Items were selected that incorporate both positive and negative values. 
This indicates that the item is sensitive to responses for both more severe and less severe respondents. In 
Rasch analysis, the latent scale is centred at zero. This point is the average difficulty on the latent scale 
relating to a particular item included in the final dimension model. Item levels should be distributed across 
the latent space depending on the severity of the response level. Therefore, a large spread of levels at logit 
0 indicates items for which respondents endorse the full range of possible responses at the average severity 
or difficulty level. Item goodness of fit statistics and classical psychometric analyses, including MEFs, AEFs 
and missing data rates (alongside input from clinicians, dementia experts and the original instrument 
developers), were also used to guide the item selection process.
Stage III: exploration of item-level reduction
Stage III of the six-step guide to developing a condition-specific preference-based measure is to explore 
item-level reduction using Rasch analysis to examine whether or not respondents can distinguish between 
the response choices of the items selected for the health-state classification system. This was done 
by evaluating the ordering of the responses to each individual item selected using the item threshold 
probability curve.
Stage IV: validation of the classification system
It is recommended that the Rasch analysis described above is repeated on another sample before 
proceeding with the valuation study. To do this it is possible to use an independent data set or a 
subsample of the data used for stages I–III (if the sample size is large enough).
NIHR Journals Library
DEVELOPMENT OF A HEALTH-STATE CLASSIFICATION SYSTEM FOR DEMQOL AND DEMQOL-PROXY
30
Results
Sample 
The sample used for the missing data and MEF and AEF analyses was the same as the pre-imputation 
sample used in Chapter 3 (DEMQOL: n = 658; DEMQOL-Proxy: n = 692). The sample used for the Rasch 
analyses was the post-imputation sample used to establish the dimensional structure of DEMQOL (n = 644) 
and DEMQOL-Proxy (n = 683), as described in Chapter 3.
DEMQOL
Cognition factor (six candidate items)
The responses to all six items were ordered and none of the items displayed evidence of DIF by either age 
group or gender (Table 6). Item 17 (‘worry about thoughts being muddled’) did not fit the model and was 
excluded. Of the five remaining items that could be included in the descriptive system, items 15 (‘worry 
about forgetting who people are’), 16 (‘worry about forgetting what day it is’) and 18 (‘worry about 
difficulty making decisions’) displayed good fit to the Rasch model. However, the severity range covered 
by the items and the spread at logit 0 were lower than for items 14 (‘worry about forgetting things that 
happened recently’) and 19 (‘worry about poor concentration’) and so items 15, 16 and 18 were not 
included in the descriptive system. Item 14 was selected for the health-state classification as it displays 
the largest range and spread at logit 0 of the remaining items. It also measures a key characteristic of 
dementia and therefore had high face validity suggesting that conceptually it would be a valid item to use 
for the descriptive system.
Negative emotion factor (five candidate items)
The response categories were ordered on the logit scale and all items displayed good fit to the dimension-
level Rasch model (Table 7). Item 11 (‘felt irritable’) showed evidence of uniform DIF by gender, with 
women scoring at a higher level irrespective of underlying severity. As the stem for most of the DEMQOL 
items asks, ‘how worried have you been about . . .’, we did not consider item 2 for the descriptive system 
because it asks directly about worry and we wanted to avoid double counting. The remaining items – item 
4 (‘felt frustrated’), item 7 (‘felt sad’) and item 12 (‘felt fed up’) – all cover a large range and spread at 
logit 0. Item 4 was selected as it was considered to be the most clinically relevant item, has low rates of 
missing data and displays acceptable MEF and AEF statistics.
Positive emotion factor (five candidate items)
The responses to all five items were ordered and none of the items displayed evidence of DIF. Items 3 (‘felt 
that you are enjoying life’), 6 (‘felt full of energy’) and 10 (‘felt lively’) cover a high range of the logit scale 
and had high spread at logit 0 (Table 8). These items were excluded as items 1 (‘felt cheerful’) and 5 (‘felt 
confident’) displayed better statistics and are clearer constructs to allow for a better overall classification 
of positive emotion. Item 1 was selected on conceptual grounds as item 5 could be misconstrued as a 
personality trait rather than as a component of positive emotion. Item 1 also had the lowest missing data 
rates and displayed acceptable MEF and AEF statistics.
Social relationships factor (six candidate items)
The item responses of three items – item 21 (‘worry about how you get on with people’), 22 (‘worry about 
getting affection’) and 25 (‘worry about getting help’) – were disordered between the responses ‘quite 
a bit’ and ‘a lot’, and item 26 (‘worry about getting to the toilet on time’) did not fit the Rasch model 
(Table 9). Of the remaining items – items 23 (‘worry about people not listening to you’) and 24 (‘worry 
about making yourself understood’) – neither displayed evidence of good severity coverage indicated 
by the item range and both items displayed AEF statistics below the minimum accepted level. Overall, 
however, item 24 covered more of the severe end of the logit scale and had a better fit to the model and 
was therefore selected for the classification system.
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TABLE 7 Psychometric and Rasch results for DEMQOL negative emotion dimension
Item
Missing 
data MEF AEF
Responses 
ordered? No DIF?
Good fit 
(χ2< 0.01) Item range Fit residual χ2 p-value Spread at logit 
Q2. Felt worried 3 3 3 3 3 3 –1.262 to 1.564 1.164 0.030 0.17 to 0.78
Q4. Felt frustrated 3 3 3 3 3 3 –0.753 to 1.348 –0.626 0.155 0.21 to 0.68
Q7. Felt sad 3 3 3 3 3 3 –0.916 to 0.980 0.877 0.866 0.27 to 0.71
Q11. Felt irritable 3 3 3 3 7 3 N/A N/A N/A N/A
Q12. Felt fed up 3 3 3 3 3 3 –0.979 to 1.400 –1.558 0.031 0.20 to 0.73
N/A, not applicable.
TABLE 8 Psychometric and Rasch results for DEMQOL positive emotion dimension
Item
Missing 
data MEF AEF
Responses 
ordered? No DIF?
Good fit 
(χ2 < 0.01) Item range Fit residual χ2 p-value Spread at logit 
Q1. Felt cheerful 3 3 3 3 3 3 –3.104 to 2.427 1.208 0.165 0.08 to 0.96
Q3. Felt that you are 
enjoying life 
3 3 3 3 3 3 –2.757 to 2.104 –0.267 0.348 0.11 to 0.94
Q5. Felt confident 3 3 3 3 3 3 –2.747 to 2.843 0.839 0.915 0.06 to 0.94
Q6. Felt full of energy 3 3 3 3 3 3 –1.387 to 2.474 –0.907 0.326 0.08 to 0.80
Q10. Felt lively 3 3 3 3 3 3 –1.421 to 2.962 –1.575 0.181 0.05 to 0.81
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Loneliness factor (two candidate items) 
The response categories were ordered and neither item displayed DIF by gender or age group (Table 10). 
Item 20 (‘worry about not having enough company’) had higher spread at logit 0 but displayed AEF 
statistics below the minimum accepted level. Item 8 (‘felt lonely’) covered more of the severe end of 
the scale, asking directly about loneliness rather than a particular aspect of loneliness, and displayed 
acceptable MEF and AEF statistics; therefore, item 8 was chosen for the classification system.
DEMQOL-Proxy
Cognition (nine candidate items)
Item 20 (‘worry about making self understood’) was disordered between the response levels ‘quite a bit’ 
and ‘a lot’ and so was excluded from the descriptive system (Table 11). Item 12 (’worry about memory in 
general’) displayed evidence of uniform DIF by age, with those < 65 years scoring lower than those aged 
≥ 65 years across the full logit scale. Items 14 (’worry about forgetting things that happened recently’), 
15 (’worry about forgetting people’s names’), 18 (’worry about thoughts being muddled’) and 19 (’worry 
about difficulty making decisions’) did not fit the model and so were removed from the descriptive system. 
Of the remaining items, item 13 (’worry about forgetting things that happened a long time ago’) was 
excluded as it assesses a memory problem that occurs late in the course of dementia; this was supported 
by the small range and large ceiling effect displayed by the item. Of the two remaining items, item 17 
(’worry about forgetting what day it is’) was selected for the descriptive system as the context of the item 
is more relevant to proxy reporting of memory and cognition than item 26 (’worry about things taking 
longer than they used to’). The chosen item did not display high rates of missing data and had acceptable 
MEF and AEF statistics.
Negative emotion (six candidate items)
All of the items were ordered and none displayed evidence of DIF. Item 9 (’felt irritable’) displayed poor 
fit to the model and was removed from the descriptive system (Table 12). Item 2 (’felt worried’) was also 
excluded to avoid double counting as the stem to most of the DEMQOL-Proxy items uses the phrase, 
‘how worried have you been about . . .’. Items 5 (‘felt sad’) and 10 (‘felt fed up’) were also excluded as 
the content of the items may reflect on aspects of comorbid depression, which is prevalent in those with 
dementia.65,66 Of the remaining items, item 7 (‘felt distressed’) had low item fit and both items 7 and 
3 (‘felt frustrated’) displayed missing data rates slightly above the minimum accepted level. Item 3 was 
chosen for the descriptive system as it displayed strong fit statistics and good range and spread and was 
also repeated across both the DEMQOL and the DEMQOL-Proxy descriptive systems.
Daily activities (three candidate items)
Item 23 (‘worry about getting what he/she wants from the shops’) displayed disordering between ‘quite 
a bit’ and ‘a lot’, and items 24 (‘worry about using money’) and 25 (‘worry about looking after his/her 
finances’) did not fit the Rasch model (Table 13). Therefore, no items remained for this factor and it could 
not be included in the classification system for DEMQOL-Proxy.
Positive emotion (three candidate items)
All three items were ordered and there was no evidence of DIF but item 11 (‘felt that there are things 
to look forward to’) displayed poor fit to the Rasch model (Table 14). Of the remaining items – item 4 
(‘felt full of energy’) and item 8 (‘felt lively’) – item 8 displayed considerably better range, spread and fit 
statistics and was therefore chosen for the descriptive system.
Appearance (two candidate items)
Both items were ordered and there was no DIF. The fit of item 21 (‘worry about keeping self clean’) 
was approaching significance, but this item displayed lower range and spread statistics and higher MEF 
and AEF than item 22 (‘worry about keeping self looking nice’); therefore, as it performed better on all 
indicators, item 22 was chosen for the descriptive system (Table 15).
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TABLE 9 Psychometric and Rasch results for DEMQOL social relationships dimension
Item
Missing 
data MEF AEF
Responses 
ordered? No DIF?
Good fit 
(χ2 < 0.01) Item range Fit residual χ2 p-value Spread at logit 
Q21. Worry about how 
you get on with 
people close to 
you
3 3 7 7 3 3 N/A N/A N/A N/A
Q22. Worry about 
getting the 
affection that you 
want 
3 3 7 7 3 3 N/A N/A N/A N/A
Q23. Worry about 
people not 
listening to you 
3 3 7 3 3 3 –0.681 to 1.025 –1.754 0.027 0.26 to 0.66
Q24. Worry about 
making yourself 
understood
3 3 7 3 3 3 –0.205 to 1.280 –0.087 0.472 0.22 to 0.55
Q25. Worry about 
getting help 
when you need it
3 3 7 7 3 3 N/A N/A N/A N/A
Q26. Worry about 
getting to the 
toilet on time
3 3 7 3 3 7 N/A N/A N/A N/A
N/A, not applicable.
TABLE 10 Psychometric and Rasch results for DEMQOL loneliness dimension
Item
Missing 
data MEF AEF
Responses 
ordered? No DIF?
Good fit 
(χ2 < 0.01) Item range Fit residual χ2 p-value Spread at logit 
Q8. Felt lonely 3 3 3 3 3 3 –1.044 to 2.309 0.293 0.256 0.09 to 0.74
Q20. Worry about not 
having enough 
company 
3 3 7 3 3 3 –2.228 to 1.624 1.154 0.153 0.16 to 0.90
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TABLE 11 Psychometric and Rasch results for DEMQOL-Proxy cognition dimension
Item
Missing 
data MEF AEF
Responses 
ordered? No DIF?
Good fit 
(χ2 < 0.01) Item range Fit residual χ2 p-value Spread at logit 
Q12. Worry about his/
her memory in 
general
3 3 3 3 7 3 N/A N/A N/A N/A
Q13. Worry about 
forgetting things 
that happened a 
long time ago
3 7 3 3 3 3 –2.203 to –0.904 –0.967 0.175 0.71 to 0.90
Q14. Worry about 
forgetting things 
that happened 
recently
3 3 3 3 3 7 N/A N/A N/A N/A
Q15. Worry about 
forgetting 
people’s names
3 3 3 3 3 7 N/A N/A N/A N/A
Q17. Worry about 
forgetting what 
day it is
3 3 3 3 3 3 –0.947 to 0.324 –0.628 0.211 0.42 to 0.72
Q18. Worry about his/
her thoughts 
being muddled
3 3 3 3 3 7 N/A N/A N/A N/A
Q19. Worry about 
difficulty making 
decisions
3 3 3 3 3 7 N/A N/A N/A N/A
Q20. Worry about 
making 
him/herself 
understood
3 3 3 7 3 3 N/A N/A N/A N/A
Q26. Worry about 
things taking 
longer than they 
used to
3 3 3 3 3 3 –1.75 to 0.52 0.555 0.393 0.52 to 0.85
N/A, not applicable.
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TABLE 12 Psychometric and Rasch results for DEMQOL-Proxy negative emotion dimension
Item
Missing 
data (%) MEF AEF
Responses 
ordered? No DIF?
Good fit 
(χ2 < 0.01) Item range Fit residual χ2 p-value Spread at logit 
Q2. Felt worried 3 3 3 3 3 3 –1.287 to 2.284 0.823 0.976 0.10 to 0.79
Q3. Felt frustrated 7 3 3 3 3 3 –1.007 to 1.923 1.126 0.695 0.15 to 0.76
Q5. Felt sad 7 3 3 3 3 3 –2.005 to 1.411 –0.902 0.091 0.22 to 0.84
Q7. Felt distressed 7 3 3 3 3 3 –2.081 to 0.655 –1.614 0.014 0.34 to 0.89
Q9. Felt irritable 3 3 3 3 3 7 N/A N/A N/A N/A
Q10. Felt fed up 7 3 3 3 3 3 –1.243 to 2.047 0.624 0.606 0.11 to 0.78
N/A, not applicable.
TABLE 13 Psychometric and Rasch results for DEMQOL-Proxy daily activities dimension
Item
Missing 
data (%) MEF AEF
Responses 
ordered?
No 
DIF?
Good fit 
(χ2 < 0.01) Item range Fit residual χ2 p-value Spread at logit 
Q23. Worry about 
getting what he/
she wants from 
the shops 
7 3 7 7 3 3 N/A N/A N/A N/A
Q24. Worry about 
using money
7 3 7 3 3 7 N/A N/A N/A N/A
Q25. Worry about 
looking after his/
her finances 
7 3 3 3 3 7 N/A N/A N/A N/A
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Stage III: exploration of item-level reduction
The item threshold probability curves indicated that patients were able to distinguish across the four 
responses that form the levels of the chosen items of the two descriptive systems. Therefore, it was not 
necessary to explore item-level reduction further.
Stage IV: validation
It was not possible in this study to validate the classification systems developed either on a subsample of 
the data or on an external data set. This is because randomly splitting the data used in this chapter into 
two samples would have resulted in a sample size that was smaller than the optimum recommended for 
Rasch analysis (n = 500). Furthermore, as Rasch excludes extreme scores (in which respondents answer at 
the most severe or least severe level for the overall dimension), the sample size for the dimensions with 
two to three items would be reduced further. At the time of development, no external data set including 
DEMQOL or DEMQOL-Proxy was available to validate the classification systems.
Final health-state classification systems
The 10 DEMQOL and DEMQOL-Proxy dimension Rasch models from which the items were selected 
all displayed overall goodness of fit (Table 16). The final health-state classification systems that were 
developed following the item selection process outlined in the sections above are displayed in Table 17 
(with health states ordered as they appear in the valuation study). The five items selected to reflect the 
DEMQOL dimension structure form the basis of the DEMQOL classification system. This was named 
DEMQOL-U. Each dimension has four response levels that correspond to the options included on the 
original DEMQOL instrument. Therefore, the DEMQOL-U descriptive system generates a possible 1024 
(i.e. 45) health states.
The four items selected to reflect the DEMQOL-Proxy dimension structure form the basis of the DEMQOL-
Proxy classification system. This was named DEMQOL-Proxy-U. The four-dimension structure each with 
four response levels means that DEMQOL-Proxy-U generates 256 (i.e. 44) health states.
Discussion
This chapter describes the development of condition-specific descriptive systems for dementia for patient 
self-report (DEMQOL-U) and carer proxy report (DEMQOL-Proxy-U). We selected items to represent all of 
the five DEMQOL dimensions and four of the five DEMQOL-Proxy dimensions established during stage I of 
the development process. The methodology used builds on previous work that has applied Rasch analysis 
to non-preference-based condition-specific instruments to develop condition-specific classification systems 
that are amenable to valuation.64,67 This is the first part of the process in developing a condition-specific 
preference-based measure. The second part is to obtain preference weights so that the measure can be 
used in the economic evaluation of interventions for dementia. This stage is described in Chapter 5.
This chapter also describes the first attempt to derive a condition-specific health-state classification system 
specifically for proxy report by carers. The descriptive systems reflect both similarities and differences in 
the factors that are the key focus for patients and carers in terms of evaluating HRQL in dementia. For 
example, both measures included cognition and emotion dimensions and this reflects the importance of 
cognitive functioning and mood both for the person with dementia and for those involved in their care. 
There are discrepancies between patient and proxy report of HRQL in dementia68 and some evidence 
suggests that agreement is lower for more subjective domains such as emotional well-being.69 The 
development of a proxy-specific measure in which all of the dimensions are meaningful to carers may 
address some of the concerns about using generic measures for proxy report by carers in dementia.
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TABLE 14 Psychometric and Rasch results for DEMQOL-Proxy positive emotion dimension
Item
Missing 
data (%) MEF AEF
Responses 
ordered?
No 
DIF?
Good fit 
(χ2 < 0.01) Item range Fit residual χ2 p-value Spread at logit 
Q4. Felt full of energy 7 3 3 3 3 3 –2.694 to 2.545 0.221 0.142 0.07 to 0.94
Q8. Felt lively 7 3 3 3 3 3 –3.243 to 3.276 0.629 0.735 0.04 to 0.96
Q11. Felt that there 
are things to 
look forward to
7 3 3 3 3 7 N/A N/A N/A N/A
N/A, not applicable.
TABLE 15 Psychometric and Rasch results for DEMQOL-Proxy appearance dimension
Item
Missing 
data (%) MEF AEF
Responses 
ordered?
No 
DIF?
Good fit 
(χ2 < 0.01) Item range Fit residual χ2 p-value Spread at logit 
Q21. Worry about 
keeping self 
clean
3 7 7 3 3 3 –0.782 to 0.703 0.310 0.044 0.33 to 0.69
Q22. Worry about 
keeping self 
looking nice
3 7 3 3 3 3 –1.630 to 1.452 0.903 0.938 0.19 to 0.84
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TABLE 17 Health-state classification systems: DEMQOL and DEMQOL-Proxy 
DEMQOL DEMQOL-Proxy
Positive emotion Positive emotion
1. I feel cheerful a lot 1. I feel lively a lot
2. I feel cheerful quite a bit 2. I feel lively quite a bit
3. I feel cheerful a little 3. I feel lively a little
4. I do not feel cheerful at all 4. I do not feel lively at all
Cognition Cognition
1. I do not worry at all about forgetting things that 
happened recently
1. I do not worry at all about forgetting what day it is
2. I worry a little about forgetting things that happened 
recently
2. I worry a little about forgetting what day it is
3. I worry quite a bit about forgetting things that happened 
recently
3. I worry quite a bit about forgetting what day it is
4. I worry a lot about forgetting things that happened 
recently 
4. I worry a lot about forgetting what day it is
Relationships Appearance
1. I do not worry at all about making myself understood 1. I do not worry at all about keeping myself looking nice
2. I worry a little about making myself understood 2. I worry a little about keeping myself looking nice
3. I worry quite a bit about making myself understood 3. I worry quite a bit about keeping myself looking nice
4. I worry a lot about making myself understood 4. I worry a lot about keeping myself looking nice
Negative emotion Negative emotion
1. I do not feel frustrated at all 1. I do not feel frustrated at all
2. I feel frustrated a little 2. I feel frustrated a little
3. I feel frustrated quite a bit 3. I feel frustrated quite a bit
4. I feel frustrated a lot 4. I feel frustrated a lot
Loneliness
1. I do not feel lonely at all
2. I feel lonely a little
3. I feel lonely quite a bit
4. I feel lonely a lot
The results of the Rasch analysis used to select the items for the descriptive system have not been validated 
on an external sample and this is a limitation of the development process described in this chapter. 
It was not possible to carry out validation analyses as the sample size was not sufficient to randomly 
allocate responses to two subgroups. Furthermore, the data used in Chapter 7 of this report to assess 
the psychometric performance of DEMQOL-U and DEMQOL-Proxy-U were not available to validate the 
descriptive system. The DEMQOL system is being used in a number of studies and so further work 
validating the classification systems may be possible in the future.
It is also possible to carry out factor analysis using IRT-based techniques and this would enable us to 
combine stage I of the development process with stages II and III and base the full classification system 
development on one underlying model. This approach and the differences in factor structure that might 
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lead from it need further investigation. Indeed, other IRT techniques could be used to select items for the 
classification system and further research could investigate differences in the items selected using a range 
of techniques and determine which technique produces the classification system that retains the most 
information from the original HRQL measure.
There are also concerns around the use of condition-specific preference-based measures, including the 
extent to which they capture comorbidities.39 This issue may be addressed by investigating the performance 
of condition-specific preference-based measures in relation to generic measures such as the EQ-5D in trials 
and settings where both instruments have been used together. Both DEMQOL-U and DEMQOL-Proxy-U 
cover a broad range of HRQL issues in dementia. The absence of an activity limitation dimension may be 
a concern; this was because the Rasch analysis found that the original daily activities items did not meet 
the minimum threshold for inclusion. Another important limitation is that it has not been possible to 
consider item responsiveness during the development of the descriptive system. The ability of items to 
detect change over time is an important psychometric characteristic and so responsiveness needs to be 
addressed in future research that includes DEMQOL and DEMQOL-Proxy as outcome measures at multiple 
time points.
It could also be argued that the resultant classification systems reflect a mild description of dementia. This 
is a result of both the development process (in which the items that performed well reflected mild aspects 
of HRQL in dementia) and also the sample used, which was patients with a mild or moderate diagnosis. 
Future work could investigate qualitatively the acceptability and characteristics of the classification system 
with independent clinical experts and patient groups.
There are a number of strengths of the process described in this chapter. The descriptive systems were 
based on representative samples from memory and community services where many of the clients have 
mild to moderate dementia. Although it is widely acknowledged that people with dementia are often 
able to self-report it is often also necessary to use a proxy report.31 Administering measures in an interview 
setting with response cards (as is done with the DEMQOL system) may help to maximise the reliability and 
validity of such reports. The data also included demographic information that enabled us to investigate 
DIF characteristics and this helped to strengthen the item selection process and provide a set of descriptive 
systems that cover as broad a range of HRQL issues in dementia based on the non-preference-based 
instruments as possible.
Conclusion
In conclusion, item selection procedures have identified robust items to represent all five of the DEMQOL 
dimensions and four of the five DEMQOL-Proxy dimensions. Using validated measures (DEMQOL and 
DEMQOL-Proxy) along with a representative sample of patients and carers we have created a classification 
system that is an appropriate representation of HRQL in dementia. The descriptive systems are amenable to 
valuation and the next part of the process in developing a condition-specific preference-based measure is 
to obtain preference weights so that the measure can be used in the economic evaluation of interventions 
in dementia.
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Chapter 5 General population valuation survey 
and modelling to produce values for every health 
state: estimating preference-based single-index 
measures for dementia
Introduction
Cost–utility analysis measures the benefits of treatment using the QALY, which captures changes in both 
quantity of life and HRQL. The ‘Q’ quality adjustment weight is typically derived using a preference-based 
measure. A preference-based measure has two components: first, a health-state classification system 
that can be used to categorise all patients with the condition of interest; second, a means of obtaining 
a utility score for all states defined by the system. This chapter reports on work to estimate a preference-
based single index for each classification system. First, this chapter reports the valuation study in which 
a representative sample of the general population valued a sample of health states derived from each 
classification system using ranking and the TTO elicitation technique. Second, the chapter reports on 
modelling using the valuation results to produce utility values for all health states described by each 
classification system. This analysis uses a range of multivariate regression models to produce a single-index 
measure from each classification system anchored on a full health–dead 1–0 scale, in which a value of 1 
is equal to full health and 0 is equal to being dead. Values were obtained from the general population in 
accordance with recommendations of agencies such as NICE43,54 and the Washington Panel70 for use in 
economic evaluation.
Method
Health-state descriptions for the valuation study were generated using the DEMQOL-U and DEMQOL-
Proxy-U classification systems described in Chapter 4. Table 17 presents an overview of the two 
classification systems. Each health state is generated using one level of each dimension. Box 1 includes an 
example health state for each classification system.
The DEMQOL-U health-state classification describes 1024 health states and the DEMQOL-Proxy-U 
classification describes 256 health states. The large number of health states means that it is impractical 
to value every state and therefore only a sample of states were selected for valuation. Respondents 
cannot value a large number of health states because of the nature of the preference elicitation task. 
In accordance with many previous valuation studies,37,40,42,67,70–72 each respondent valued eight health 
states. The study design needs to determine both the total sample of all health states to be included 
in the valuation study and the combinations of eight health states to be valued by respondents. To get 
more precise estimates of the worst state and to have a common state valued by all respondents, each 
combination of health states for valuation included the worst state plus seven other states. Previous 
valuation surveys have used a variety of methods to select health states for valuation, such as an 
orthogonal array,37,71 balanced design40,42 and the Rasch vignette approach.66,73 None of these approaches 
selects the combinations of health states to be valued by respondents, and only the Rasch vignette 
approach avoids implausible health states. Here, a new approach was used to select health states, which 
offered the following advantages over existing approaches: (1) it selected the combinations of health 
states to be valued by respondents; (2) it avoided implausible health states; and (3) it selected the health 
states that produce the most accurate modelled utility estimates using simulation. The last advantage 
is gained because the process involves simulation of alternative selections of health states that could be 
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chosen and hypothetical values for those health states (given some assumptions about how people value 
health states). The hypothetical values were modelled using similar modelling to the analysis that was 
applied to the actual utility values in the general population valuation survey. The accuracy of the model 
predictions for each of the alternative selections of health states was compared using predictions for 
health states that would not be valued. The best performing selection of health states was chosen. For 
each selection of health states these are separated into combinations of health states for valuation. Each 
combination is called a block and each block consisted of seven health states of different severity plus the 
worst state. The steps used in this process are explained further below; the process was undertaken for 
each classification system.
The selection of health states can involve a different number of blocks, for example five blocks of seven 
health states plus the worst state, or six blocks of seven health states plus the worst state, or seven blocks, 
etc. Furthermore, within each block design, alternative health states could be selected, for example there 
are many different combinations of health states that could be selected within the five-block design, 
within the six-block design, etc. Therefore, the first step in the process derived 100 approximate optimal 
Federov designs74 for each block design of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 blocks (i.e. 100 designs for 
five blocks, 100 designs for six blocks, etc.). For each block size the optimal design was selected using the 
D-criterion and the worst state was added to each block. There were 11 designs remaining for inclusion in 
step 2, one for each block design.
Assuming that the sample size of the valuation study will remain the same, this means that each health 
state in the 15-block design will be valued fewer times than health states in the 14-block design. It is 
expected that each block design will involve different health states as well as different numbers of health 
states in total (e.g. the five-block design will have 35 health states and the six-block design will have 42 
health states, assuming that there is no repetition in health states). All of these factors may impact on the 
reliability and robustness of the modelled utility values. Therefore, the second step in the process involved 
the simulation of hypothetical utility values for each of the block designs selected in step 1. Utility values 
were simulated for each block design for 50 sets of 300 individuals using utility functions. The utility 
function assumed a logarithmic transformation between ‘severity’ and utility in which severity of a health 
state was generated using a linear function of the dimensions with equal weights for each dimension 
and equidistance between levels with random measurement errors. As respondents do not always trade 
DEMQOL-U state 23424
You feel cheerful quite a bit
You worry quite a bit about forgetting things that happened recently
You worry a lot about making yourself understood
You feel frustrated a little
You feel lonely a lot
DEMQOL-Proxy-U state 1341
You feel lively a lot
You worry quite a bit about forgetting what day it is
You worry a lot about keeping yourself looking nice
You do not feel frustrated at all
BOX 1 Example health states
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life-years to avoid mild health states, non-trading behaviour was simulated using a logistic model of 
severity [such that approximately 10% of the scores would be 1 to represent non-traders (proportion 
selected using previous valuation studies)].
The third step in the process involved the estimation of a linear regression model for each block design 
using the appropriate simulated utility data set. The regression model was used to produce predictions 
of health-state utility values for all health states not selected in the block design. These predictions were 
compared with the ‘true values’, the hypothetical values that were generated using the same utility 
functions explained above, using the sum of squared residuals and average mean sum of squares.
Fourth, the block design was selected that achieved the best predictions of health-state utility values for 
health states outside the set of health states to be valued (i.e. all health states that were not selected in 
that block design).
The selected designs involved a sample of 87 unique states across 13 blocks for DEMQOL-U and a sample 
of 70 unique states across 12 blocks for DEMQOL-Proxy-U. For each measure one block was selected to be 
valued by a minimum of 71 individuals to enable mean values for these states to be statistically compared 
with mean values elicited from people with dementia and carers of patients with dementia as reported in 
Chapter 6.
Valuation study
Sample 
Each classification system was valued by a representative sample of the general population. This is in 
accordance with recommendations by agencies such as NICE43,54 and the Washington Panel,70 who 
recommend the use of general population values to produce QALY estimates for economic evaluation. The 
sample size for each measure was selected on the basis of previous valuation studies for similar measures 
[e.g. for the cancer-specific EORTC-8D (European Organisation for Research and Treatment of Cancer 
Core Quality of Life Questionnaire) a sample of 344 respondents valued 85 states; for the asthma-specific 
AQL-5D (Asthma Quality of Life Utility Index) a sample of 307 respondents valued 99 states; and for the 
overactive bladder-specific OAB-5D (Overactive Bladder Questionnaire-5 Dimensions) a sample of 312 
respondents valued 99 states]. The sample size was selected as 310 for DEMQOL-U and 290 for DEMQOL-
Proxy-U. The sample size for DEMQOL-U was larger as the classification system describes more states and 
had a larger selected study design.
The sample was obtained by sampling 600 households in urban and rural areas in northern England using 
the AFD Names and Numbers version 3.1.25 database (AFD Software Limited, Ramsey, UK). The sample 
was balanced to the UK population according to geodemographic profiles. Trained and experienced 
interviewers conducted home interviews in which respondents valued states from one of the classification 
systems determined using a card block system. Interviewers worked systematically through blocks; odd and 
even blocks contained DEMQOL-U and DEMQOL-Proxy-U states respectively. This approach was used to try 
and ensure that there were no systematic differences across the geodemographic profiles of the samples 
for each classification system.
Procedure
At the start of the interview respondents first self-completed the EQ-5D to report their own health and 
then whichever classification system would be used subsequently in the valuation task (DEMQOL-U or 
DEMQOL-Proxy-U). Respondents were asked to complete the questions for their own health and this was 
done to help familiarise them with the classification system. Respondents were not informed that the 
health state was associated with dementia as there are concerns that naming the condition can affect 
elicited utility values. A recent study found that introducing condition labels into health-state descriptions 
impacted on health-state utility values elicited from the general population.37,71 The impact differed by 
condition and health-state severity but as the study was quantitative the reasoning behind why these 
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differences occurred was not determined. Further qualitative research is recommended to examine why 
these differences occurred and until these findings are available it is recommended that condition labels 
are not included in health-state descriptions to ensure that elicited utility values are not affected by factors 
that should not affect the quality of life of health states.
Second, respondents ranked eight health states, as well as full health and dead, in order from the best 
to the worst. This rank task further familiarised respondents with the classification system and the health 
states to be valued later using TTO.
Third, respondents undertook a practice TTO task using a hypothetical ‘practice’ state and subsequently 
valued the (ranked) eight health states using TTO. The intuition underlying the TTO task is that it is 
designed to determine whether or not respondents are willing to sacrifice time to avoid living in the 
dementia health state. Essentially this is undertaken by asking respondents whether they would rather 
live in the dementia health state for 10 years or full health for a shorter time duration than 10 years. If 
respondents believe that the health state is severe, they should be willing to sacrifice a larger time duration 
than if they believe that the health state is mild. For some respondents they may not be willing to sacrifice 
any time at all to avoid the dementia health state. Some respondents may believe that some health states 
are so severe that they would rather die than live in that health state.
The TTO task for each health state asks first whether respondents prefer to live in a given health state 
for 10 years after which they will die, or to die immediately. This determines whether the respondent 
values the health state as better, worse or equal to being dead. For health states considered better than 
dead, respondents choose between (a) the health state for 10 years, after which they will die, or (b) full 
health for x years (x ≤ 10), after which they will die. Years in full health, x, is varied until respondents are 
indifferent between the two options. For health states considered worse than being dead, respondents 
choose between (a) the health state for w years followed by full health for x years, after which they will 
die, or (b) immediate death. Both years in full health, x, and years in the health state, w = 10 – x, are 
varied until respondents are indifferent between the two options. Utility values are generated using the 
formula x/10 for states better than being dead and –x/10 for states worse than being dead.45 A sample 
TTO scripting for one TTO task is included in Appendix 1. The Measurement and Valuation of Health 
(MVH) study version of TTO was used, including a visual prop designed by the MVH group (University of 
York),45 which has been reproduced in Figure 4 (although note that in the MVH study respondents valued 
more than eight health states). All TTO questions follow an iterative procedure to determine the point 
of indifference, with the task completed only when the respondent switches his or her choice between 
(a) and (b) or reaches the point at which he or she is indifferent between (a) and (b). The TTO elicitation 
technique was selected in accordance with the UK valuation of the EQ-5D,45 which also meets the 
reference case recommended by NICE54 for use in economic evaluation.
Finally, respondents rated how difficult they found the rank and TTO tasks and answered questions about 
sociodemographic characteristics and health service use.
Before conducting the full survey a small number of interviews were conducted and the interviewer 
discussed the findings with one of the research team. As no problems were identified with the survey, the 
main survey was started without amendment and these interviews were included in the main sample. The 
survey was approved by the School of Health and Related Research (ScHARR) Research Ethics Committee at 
the University of Sheffield.
Analysis of time trade-off data
Descriptive statistics of health-state utility values for all health states included in the valuation study are 
presented and plotted for each measure.
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Modelling to obtain preference weights for the health-state classification
The valuation study elicited health-state utility values for a sample of health states described by each 
classification system. These values need to be modelled in order to produce estimated health-state utility 
values for every state defined by each classification system. Regression models were used to estimate 
a preference weight, known as a ‘utility decrement’, for every severity level of every dimension of the 
classification system using level 1 as the baseline. These models assume that full health is assigned a value 
of 1 and instrument-specific full health is assigned a value of 1 minus the constant term. These models can 
be used to estimate a utility value for each state, for example DEMQOL-U state 21111 has an estimated 
utility value of 1 minus the constant term and the utility decrement for level 2 of the positive emotion 
dimension, and DEMQOL-U state 22111 has an estimated utility value of 1 minus the constant term and 
the utility decrement for level 2 of the positive emotion dimension and level 2 of the memory dimension.
The regression models used the following general specification:
U
ij
 = g(β‘x
i
) + ε
ij
 (1)
where U represents TTO disvalue (generated as 1 – TTO), i = 1, 2, . . ., n represents individual health states, 
j =1, 2, . . ., m represents respondents, g is a function specifying the appropriate form, x
i
 is a vector of 
binary dummy variables for each level λ of dimension δ of the descriptive system in which the best level 
of each dimension represents the baseline for that dimension, and ε
ij
 is an error term, whose properties 
depend on the assumptions of the model (see below).
A variety of mean- and individual-level multivariate regression models were fitted to the valuation data for 
each classification system. First, models were estimated on observational-level data using OLS. However, 
OLS does not take into account the structure of the data, as there are repeated observations for each 
individual as each individual valued eight health states. Random- and fixed-effects models were estimated 
using GLS maximum likelihood estimation in order to take into account the structure of the data with 
P H
Full health
0 1 2 3 4 5
Number of years
LIFE A
TIME BOARD 1
LIFE B
6 7 8 9 10
0 1 2 3 4 5
Number of years
6 7 8 9 10
You do not feel cheerful at all
You worry a lot about forgetting
things that happened recently
You worry a lot about making
yourself understood
You feel frustrated a lot
You feel lonely a lot
31Q
FIGURE 4 Time trade-off visual prop [MVH group (4)]. Progeny of the University of Sheffield – 58 © Copyright MVH 
Group University of York, 1992.
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repeated observations for each individual.25 For the random-effects model the error term,
 
ε
ij
, is subdivided 
as follows:
ε
ij
 = u
j
 + e
ij
 (2)
where u
j
 represents the individual random effect and e
ij
 represents the random error term for the ith 
health-state valuation of the jth individual. The choice of whether to use the random- or fixed-effects 
specification depends on the sample design and the purpose of the study. In this valuation study 
respondents were randomly sampled and the assumptions of the random-effects specification are met 
when we assume that any differences in valuations across individuals are random. Fixed effects can be 
interpreted as using dummy variables for each individual, yet here we do not have reason to believe that 
each individual will be sufficiently distinct. However, the choice will be determined empirically using the 
Hausman test.
Time trade-off valuation data typically have a large proportion of values at 1, where individuals are not 
prepared to trade any time to avoid living in the impaired dementia health state. This means that the 
data can be interpreted as being bounded at 1 and the data are further bounded at –1, although there 
are typically fewer observations at –1 than at 1. This structure of the data is not taken into account using 
the OLS and GLS models. A random-effects Tobit model was estimated to take account of the bounded 
nature of the data; however, the Tobit models had poorer performance and predictive ability and are 
not reported here (results available from authors on request). Models were also estimated using OLS on 
mean-level data, with the data consisting of one mean value per state (n = 87 for DEMQOL-U, n = 70 for 
DEMQOL-Proxy-U).
Performance of the regression models was assessed using the number of inconsistent coefficients and 
number of significant coefficients. Predictive ability was assessed using root-mean-squared error (RMSE) of 
health-state predictions at the health-state level, mean absolute error (MAE) at the state level, number of 
states with absolute error (AE) > 5% and > 10%, plots of actual and predicted health-state utility values 
and the Ljung–Box (LB) test to examine autocorrelation. Autocorrelation is present if there is a correlation 
between the errors when these are ordered by observed mean health-state utility value. The error indicates 
the difference between observed and predicted utility values.
Analysis of rank data
Modelling to obtain preference weights for the health-state classification 
Regression analysis was also used to estimate preference weights using the rank data. The rank data need 
to be modelled in order to produce estimated health-state utility values for every state defined by each 
classification system. The rank data were analysed using the rank-ordered logit model (also referred to as 
the conditional logit model).39 The model states that individual j has a latent utility function for health state 
i, which is U
ij
. When the individual is asked to rank two states j and k, the individual will rank state i over 
state k if the utility of state i is higher than the utility of state k: U
ij
 > U
kj
.
The model specification for rank data has a similar format to the model specification used for the TTO 
data in Equation 1. However, unlike TTO data, rank data are not anchored onto the 1–0 full health–dead 
utility scale required for the estimation of QALYs. Instead, modelled rank data lie on an unanchored latent 
utility scale. To anchor the latent scale onto the 1–0 full health–dead utility scale, two approaches are 
used in the literature. The first approach excludes the data from rankings of the state ‘dead’ and estimates 
Equation 1.75 The estimated coefficients are normalised onto the full health–dead scale using the estimated 
TTO value of the worst state. This means that the value of the worst state in the rank model is anchored 
at the value of the worst state in the preferred TTO model. The second approach includes the state ‘dead’ 
in the regression equation and its coefficient is used to anchor all other coefficients. The general model 
specification for analysis of the ranking data using the second approach is:75,76
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U
ij
 = f(β‘x
i
 + φ
D
) + ε
ij
 (3)
where U represents utility, i = 1, 2, . . ., n represents individual health states, j = 1, 2, . . ., m represents 
respondents, f is a function specifying the appropriate form, x
i
 is a vector of binary dummy variables for 
each level λ of dimension δ of the descriptive system in which the best level of each dimension represents 
the baseline for that dimension, D is a dummy variable for the state ‘dead’ (equals 1 for ‘dead’ and 0 for 
all other states) and ε
ij
 is an error term, whose properties depend on the assumptions of the model (see 
below). To anchor the values onto the 1–0 full health–dead scale the coefficients for the levels of each 
dimension are normalised by dividing each level coefficient by the coefficient relating to dead: β
rλδ = βλδ/ , 
where β
rλδ is the rescaled coefficient for level λ of dimension δ, βλδ is the coefficient for level λ of dimension δ and φ is the coefficient for dead.
Results
Valuation data
A total of 600 interviews were successfully conducted across both classification systems, providing a 
response rate of 41.5% of suitable respondents who answered their door to the interviewers. Respondents 
who valued the worst state higher than all other states, who valued all states worse than being dead 
or who valued all states identically but < 1 were excluded from the analysis. Seven respondents were 
excluded as they valued all states identically and < 1; two of these respondents also valued all states as 
worse than being dead. The analysis therefore included 306 respondents for DEMQOL-U and 287 for 
DEMQOL-Proxy-U. Table 18 compares respondents across each classification system with the general 
population in South Yorkshire and England. The valuation study sample has a lower proportion of 
individuals aged 18–40 years, a higher proportion of respondents aged 41–65 years, women, retired 
individuals and homeowners and a lower mean EQ-5D score in comparison with the general population in 
South Yorkshire. The DEMQOL-U sample contains a higher proportion of women and a lower proportion 
of retired individuals than the DEMQOL-Proxy-U sample.
Time trade-off descriptive statistics
Tables 19 and 20 report descriptive statistics of observed TTO values for DEMQOL-U and DEMQOL-Proxy-U 
respectively. The number of observations per intermediate health state varied from 18 to 78, with 306 and 
287, respectively, for the worst DEMQOL-U and DEMQOL-Proxy-U states. The range of mean values was 
larger for DEMQOL-U (from 0.954 to 0.184) than for DEMQOL-Proxy-U (from 0.961 to 0.331), although 
only two DEMQOL-U states had mean values outside the DEMQOL-Proxy-U range. Each classification 
system had one or more states with a mean value lower than that of the worst state defined by the 
classification system. In addition, DEMQOL-Proxy-U had two states with a mean value higher than that 
of the best state. These apparent contradictions are most likely observed because of the much smaller 
number of observations for some states in comparison with worst state and best state. Figures 5 and 6 
present the distribution of observed TTO values for DEMQOL-U and DEMQOL-Proxy-U respectively. There 
were a large proportion of TTO values at 1 for both measures (26.9% for DEMQOL-U and 28.8% for 
DEMQOL-Proxy-U) and the distribution of the data was negatively skewed for both measures.
Modelled time trade-off health-state utility values
Regression models estimating preference weights are reported in Table 21 for DEMQOL-U and Table 22 
for DEMQOL-Proxy-U. Random-effects models are reported as the Hausman test confirmed for both 
classifications that fixed-effects models would produce similar estimates at reduced efficiency. Models 
including sociodemographic variables and interaction terms were explored, but the inclusion of these 
terms did not affect the coefficients of the main effects or improve the predictive performance of the 
model at the health-state level.
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The coefficients of the main effects variables indicate the utility decrement for every severity level of every 
dimension of the classification system using level 1 as the baseline. For coefficients to be consistent they 
must be positive and increasing in size for each subsequent severity level within each dimension. For the 
DEMQOL-U models all coefficients were positive as expected. The standard OLS models estimated using 
pooled observations and mean level data [models (1) and (3)] had inconsistent coefficients for negative 
emotion at levels 2 and 3, but the random-effects GLS model [model (2)] had consistent coefficients. 
Model (2) was preferred to standard OLS estimated using pooled observations [model (1)] as it takes into 
account the structure of the data with repeated observations per respondent. The mean model [model 
(3)] does not suffer from the theoretical bias occurring when estimating models on data containing a 
large proportion of values at 1, yet performed similarly to model (2), with a large number of significant 
coefficients and good predictive ability.
Model (2), the random-effects GLS model, was selected as the preferred model because of its strong 
relative performance. Model (2) had a high number of significant variables, no inconsistent coefficient 
estimates and good predictive ability with low RMSE and the lowest percentage of AEs at the state level 
TABLE 18 Characteristics of all respondentsa
Characteristic
DEMQOL-U 
(n = 306)
DEMQOL-Proxy-U 
(n = 287) South Yorkshireb Englandb
Age (years), mean (SD) 48.96 (16.60) 49.38 (17.22) N/A N/A
Age distribution (%)
 18–40 years 31.0 32.4 41.2 41.6
 41–65 years 51.6 47.4 39.1 39.1
 > 65 years 17.3 20.2 19.7 19.3
Female (%) 63.1 54.7 51.2 51.3
Married/partner (%) 64.7 66.6 N/A N/A
Employed or self-employed (%) 50.3 51.2 56.1 60.9
Unemployed (%) 2.6 1.7 4.1 3.4
Long-term sick (%) 6.2 3.5 7.7 5.3
Full-time student (%) 4.9 4.5 7.5 7.3
Retired (%) 23.2 28.9 14.4 13.5
Own home outright or with a 
mortgage (%)
79.4 77.0 64.0 68.7
Renting property (%) 20.6 23.0 36.0 31.3
Secondary school is highest level of 
education (%)
31.7 32.4 N/A N/A
EQ-5D score (SD) 0.83 (0.24) 0.81 (0.26) N/A 0.86 (0.23)c
TTO completion rate (%) 100 96.6
N/A, not available.
a Seven respondents excluded: all valued every state identically and at < 1, and two of these respondents further valued 
all states as worse than being dead. Remaining in the analysis are 306 respondents for the DEMQOL-U derived from 
the DEMQOL and 287 for the DEMQOL-PROXY-U derived from the DEMQOL-Proxy.
b Statistics for South Yorkshire Health Authority and for England in the 2001 Census. Questions used in this study and 
in the census are not identical. The census includes those aged ≥ 16 years whereas this study surveys only those aged 
≥ 18 years. Age distribution is here reported as the percentage of all adults aged ≥ 18 years.
c Interviews conducted in the MVH study in 1993.
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TABLE 19 Descriptive statistics of observed TTO values for DEMQOL-U
Health state Mean SD Median Count
11111 0.954 0.153 1.000 78
14231 0.934 0.093 0.975 19
11231 0.930 0.139 1.000 20
11312 0.918 0.098 0.950 19
13221 0.913 0.105 0.950 18
14311 0.909 0.134 0.950 19
12241 0.903 0.153 1.000 19
12231 0.894 0.160 1.000 78
14431 0.888 0.140 0.950 19
24231 0.860 0.182 0.963 18
13432 0.858 0.187 0.938 18
23411 0.845 0.225 1.000 20
12323 0.845 0.159 0.875 19
21241 0.845 0.253 0.998 19
21143 0.836 0.170 0.875 18
21213 0.835 0.230 0.913 18
41111 0.822 0.228 0.925 19
21233 0.819 0.191 0.875 19
22123 0.818 0.204 0.925 19
12432 0.818 0.278 0.925 18
31331 0.817 0.235 1.000 19
34221 0.812 0.181 0.888 20
12123 0.804 0.118 0.813 20
14233 0.801 0.226 0.850 18
13142 0.800 0.199 0.863 18
32131 0.799 0.251 0.900 19
23413 0.796 0.219 0.813 20
12342 0.790 0.228 0.813 20
32112 0.789 0.217 0.875 19
33431 0.789 0.265 0.925 19
21322 0.786 0.261 0.925 19
23214 0.784 0.271 0.925 37
34123 0.782 0.289 0.925 19
21132 0.773 0.306 0.850 20
14223 0.770 0.221 0.850 19
12243 0.768 0.255 0.800 18
continued
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Health state Mean SD Median Count
32441 0.767 0.212 0.813 18
23441 0.754 0.240 0.775 19
21342 0.753 0.250 0.800 19
34142 0.751 0.345 0.925 18
14133 0.742 0.433 0.925 19
13242 0.741 0.264 0.788 20
22414 0.732 0.222 0.688 18
32142 0.730 0.280 0.775 19
44322 0.728 0.251 0.700 19
34132 0.728 0.276 0.813 20
34313 0.721 0.315 0.813 18
23314 0.685 0.353 0.725 39
14323 0.685 0.296 0.650 20
24313 0.680 0.301 0.750 19
31433 0.675 0.340 0.775 18
32143 0.673 0.302 0.663 78
13413 0.670 0.474 0.800 19
32314 0.661 0.352 0.800 19
33421 0.661 0.313 0.625 19
31413 0.655 0.216 0.650 20
24144 0.654 0.335 0.675 19
41233 0.640 0.329 0.575 18
43122 0.629 0.299 0.675 19
43231 0.621 0.257 0.500 19
34423 0.617 0.225 0.600 19
41212 0.611 0.364 0.625 78
23344 0.609 0.362 0.675 19
22334 0.605 0.340 0.625 20
42243 0.592 0.357 0.625 19
43321 0.591 0.387 0.663 56
41241 0.589 0.480 0.725 18
31444 0.587 0.399 0.525 19
42321 0.576 0.300 0.513 20
41231 0.573 0.397 0.675 39
24434 0.568 0.432 0.675 19
23424 0.566 0.340 0.600 78
43123 0.548 0.400 0.588 20
44221 0.544 0.367 0.525 78
TABLE 19 Descriptive statistics of observed TTO values for DEMQOL-U (continued)
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Health state Mean SD Median Count
41423 0.534 0.482 0.500 19
44341 0.528 0.356 0.550 20
34234 0.525 0.486 0.600 18
43432 0.462 0.525 0.600 19
43434 0.449 0.429 0.463 18
44242 0.418 0.549 0.500 19
41314 0.417 0.477 0.475 19
43442 0.403 0.412 0.475 78
43344 0.397 0.422 0.500 19
43343 0.364 0.561 0.500 20
41224 0.339 0.542 0.425 20
44444 0.234 0.501 0.200 306
43244 0.184 0.475 0.200 20
TABLE 20 Descriptive statistics of observed TTO values for DEMQOL-Proxy-U
Health state Mean SD Median Count
1132 0.961 0.062 1.000 19
2221 0.944 0.108 1.000 20
1111 0.918 0.185 1.000 77
2141 0.918 0.172 1.000 20
2421 0.896 0.151 1.000 39
1143 0.893 0.149 0.963 20
1141 0.892 0.153 1.000 19
2312 0.884 0.154 1.000 19
1131 0.869 0.218 1.000 18
1222 0.869 0.174 0.925 77
3121 0.855 0.213 1.000 19
2212 0.846 0.248 0.950 20
3311 0.846 0.181 0.925 19
1214 0.839 0.227 0.925 38
1333 0.833 0.191 0.863 20
1231 0.830 0.267 0.950 19
2131 0.821 0.241 0.888 18
1233 0.821 0.194 0.925 19
1341 0.806 0.236 0.900 77
3112 0.804 0.255 0.925 77
continued
TABLE 19 Descriptive statistics of observed TTO values for DEMQOL-U (continued)
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Health state Mean SD Median Count
1223 0.799 0.256 0.888 20
3221 0.796 0.224 0.900 19
1422 0.791 0.308 0.900 38
1322 0.789 0.190 0.875 19
2431 0.763 0.396 0.900 19
3331 0.763 0.221 0.775 19
1432 0.751 0.269 0.825 20
2422 0.750 0.349 0.825 19
1313 0.721 0.277 0.800 38
3432 0.719 0.263 0.775 18
2342 0.716 0.304 0.850 18
3341 0.714 0.309 0.788 20
3431 0.705 0.294 0.800 19
1334 0.700 0.256 0.700 19
3342 0.699 0.287 0.750 38
4111 0.697 0.326 0.775 19
2234 0.692 0.279 0.675 19
1324 0.688 0.398 0.775 19
2243 0.684 0.350 0.788 38
3224 0.684 0.305 0.775 58
1423 0.682 0.341 0.800 19
2224 0.676 0.259 0.725 19
3312 0.674 0.256 0.700 19
3133 0.664 0.239 0.575 19
2424 0.662 0.342 0.725 97
4212 0.655 0.412 0.800 40
3234 0.654 0.287 0.675 95
4322 0.645 0.331 0.638 20
3344 0.634 0.370 0.675 20
4123 0.629 0.271 0.625 19
3144 0.625 0.339 0.663 20
4141 0.614 0.310 0.725 19
4342 0.603 0.468 0.788 20
3424 0.596 0.357 0.538 20
2344 0.593 0.410 0.675 19
3443 0.589 0.288 0.588 38
TABLE 20 Descriptive statistics of observed TTO values for DEMQOL-Proxy-U (continued)
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Health state Mean SD Median Count
2214 0.588 0.336 0.675 18
4411 0.580 0.395 0.625 77
4242 0.578 0.289 0.500 19
2423 0.552 0.375 0.488 18
2334 0.533 0.352 0.638 18
4133 0.532 0.330 0.400 18
4214 0.505 0.309 0.425 19
3314 0.484 0.356 0.350 19
4311 0.478 0.421 0.500 36
4333 0.476 0.378 0.488 58
4434 0.434 0.477 0.500 19
4443 0.383 0.458 0.425 18
4444 0.357 0.439 0.325 287
4343 0.331 0.492 0.450 18
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FIGURE 5 Histogram of observed TTO values for DEMQOL-U.
TABLE 20 Descriptive statistics of observed TTO values for DEMQOL-Proxy-U (continued)
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FIGURE 6 Histogram of observed TTO values for DEMQOL-Proxy-U.
> 0.05 and > 0.10. Figure 7 plots observed and predicted TTO values at the health-state level for model 
(2). The figure shows that there was no systematic bias in the predictions by severity, but some health 
states had large prediction errors. The range of predicted values for this model was from 0.986 (best state 
11111) to 0.243 (worst state 44444), which was similar to the observed range for these states (from 
0.954 to 0.234).
For DEMQOL-Proxy-U, all models have at least one inconsistent coefficient and at least one negative 
coefficient for the appearance dimension. These inconsistencies mean that health worsens but predicted 
utility increases, for example deterioration in appearance from level 1 to level 2 leads to a higher predicted 
utility value. Other valuation studies in which this has occurred have resolved this issue by merging 
adjacent inconsistent levels and re-estimating the model to produce a consistent model [see model (10) for 
example]. This approach was used to estimate models (8) and (10), consistent versions of models (7) and 
(9), respectively, in which adjacent levels of the appearance dimension have been merged.
For DEMQOL-Proxy-U, the standard OLS model estimated using pooled observations [model (6)], the 
consistent random-effects GLS model [model (8)] and the consistent mean model [model (10)] performed 
similarly in terms of predictive ability. As explained above, the consistent version of the random-effects GLS 
model [model (8)] and the mean-level model [model (10)] are preferred on a theoretical basis to model 
(6). Both models suffer from autocorrelation between errors to some degree using the LB test, but this is 
significant only for model (8) (at the 10% level). Despite this finding, Figure 8 demonstrates little difference 
in the pattern of the predictions by severity for these models. Therefore, model (8) was selected as the 
preferred model because of its higher number of significant coefficients. The range of predicted values 
for this model was from 0.937 (best state 1111) to 0.363 (worst state 4444), which was similar to the 
observed range for these states (from 0.918 to 0.357).
Modelled rank health-state utility values
Regression models estimating normalised preference weights using the rank data are also reported in 
Table 21 for DEMQOL-U and Table 22 for DEMQOL-Proxy-U. The sample is identical to the sample used 
in the models estimated using TTO data for comparability. Additional exclusion criteria were explored: 
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FIGURE 7 Observed and predicted TTO for DEMQOL-U using model (2).
FIGURE 8 Observed and predicted TTO for DEMQOL-PROXY-U using models (8) and (10).
respondents ranking the worst state higher than all other states, respondents ranking all states worse 
than dead or respondents ranking all states identically. No respondents were excluded using these criteria. 
These coefficients are interpreted in the same way as the TTO coefficients as explained above. The rank 
coefficients were normalised onto the 1–0 full health–dead scale using the first approach outlined above, 
using the modelled TTO values of the worst state generated using the preferred model [model (2) for 
DEMQOL-U and model (8) for DEMQOL-Proxy-U]. It was not possible to normalise the coefficients using 
the second approach outlined above, using the coefficient of the dead dummy variable. For DEMQOL-U 
only 4.9% of individuals ranked one or more states as worse than dead, and for DEMQOL-Proxy-U only 
1.0% of individuals ranked one or more states as worse than dead. This meant that the coefficient for the 
dead dummy variable could not be estimated because of insufficient variance in the ranking of the dead 
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TABLE 21 Regression models estimating preference weights for DEMQOL-U
TTO Rank
(1) OLS (2) RE GLS
(3) Mean 
model (4) ROL
(5) ROL 
consistent
Positive emotion2 0.016 0.025 0.024 0.102a Positive emotion2 0.101a
Positive emotion3 0.085a 0.087a 0.097a 0.129a Positive emotion3 0.129a
Positive emotion4 0.285a 0.284a 0.275a 0.308a Positive emotion4 0.309a
Memory2 0.002 0.000 0.001 0.075a Memory23 0.068a
Memory3 0.024 0.027b 0.038b 0.065a
Memory4 0.046c 0.055a 0.041c 0.116a Memory4 0.117a
Relationships2 0.023 0.024 0.033 0.084a Relationships23 0.074a
Relationships3 0.033 0.042c 0.046c 0.063a
Relationships4 0.083a 0.083a 0.073a 0.110a Relationships4 0.107a
Negative emotion2 0.047c 0.035c 0.042b 0.031a Negative emotion2 0.031a
Negative emotion3 0.039b 0.048a 0.040b 0.046a Negative emotion3 0.052a
Negative emotion4 0.102a 0.102a 0.092a 0.072a Negative emotion4 0.075a
Loneliness2 0.054c 0.055a 0.063a 0.089a Loneliness2 0.086a
Loneliness3 0.095a 0.104a 0.105a 0.112a Loneliness3 0.113a
Loneliness4 0.217a 0.219a 0.216a 0.152a Loneliness4 0.150a
Constant 0.023 0.014 0.007
Observations 2448 2448 87 2742 2742
Number of subjects 306 306 306
R2 0.263 0.875
No. of inconsistencies 1 0 1 2 0
No. of significant variables 10 12 12 15 13
RMSE 0.060 0.060 0.058
MAE 0.044 0.045 0.044
% states with AE > 0.05 37.9 34.5 36.8
% states with AE > 0.10 9.2 8.0 8.0
LB test 5.751 5.370 4.184
RE GLS, random-effects generalised least squares; ROL, rank order list.
a Significant at 1%.
b Significant at 10%.
c Significant at 5%.
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TABLE 22 Regression models estimating preference weights for DEMQOL-Proxy-U
TTO Rank
(6) OLS (7) RE GLS
(8) RE GLS 
consistent 
model
(9) Mean 
model
(10) Mean 
consistent 
model (11) ROL
Positive emotion2 0.043a 0.037a 0.037a 0.058b 0.059b 0.069b
Positive emotion3 0.093b 0.091b 0.092b 0.100b 0.101b 0.110b
Positive emotion4 0.261b 0.263b 0.265b 0.262b 0.266b 0.289b
Memory2 0.027 0.029c 0.028c 0.031 0.030 0.083b
Memory3 0.088b 0.085b 0.085b 0.092b 0.093b 0.143b
Memory4 0.110b 0.104b 0.102b 0.117b 0.113b 0.145b
Appearance2 –0.020 –0.006 –0.019 0.024b
Appearance3 0.007 –0.002 0.008 0.019 0.054b
Appearance4 0.036c 0.045b 0.047b 0.027 0.037c 0.074b
Negative emotion2 0.024 0.027c 0.026c 0.016 0.016 0.054b
Negative emotion3 0.118b 0.119b 0.119b 0.123b 0.120b 0.069b
Negative emotion4 0.160b 0.161b 0.160b 0.163b 0.162b 0.129b
Constant 0.067b 0.065b 0.063b 0.062a 0.051a
Observations 2295 2295 2295 70 70 2573
Number of subjects 287 287 287
R2 0.212 0.860 0.858
No. of inconsistencies 1 2 0 1 0 0
No. of significant variables 9 11 11 8 9 12
RMSE 0.056 0.057 0.057 0.055 0.055
MAE 0.042 0.042 0.042 0.042 0.042
% states with AE > 0.05 35.7 35.7 35.7 32.9 32.9
% states with AE > 0.10 11.4 8.6 8.6 10.0 12.9
LB test 12.365 14.193 14.301 9.142 9.757
RE GLS, random-effects generalised least squares; ROL, rank order list.
a Significant at 5%.
b Significant at 1%.
c Significant at 10%.
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state across individuals. We expect that this occurred because the severity of the worst state is perceived 
as being unanimously better than being dead, and this represents the fact that the DEMQOL-U and 
DEMQOL-Proxy-U have condition-specific classification systems that do not fully capture all dimensions of 
HRQL. However, the same problem was not encountered for an asthma-specific preference-based measure 
and an overactive bladder preference-based measure.77
For the DEMQOL-U all normalised rank coefficients were positive as expected and significant at the 1% 
level [models (4) and (5)]. However, in contrast to the models estimated using the TTO data, there were 
inconsistent coefficients for the memory dimension at levels 2 and 3 and the relationships dimension at 
levels 2 and 3 in model (4). As explained above, adjacent inconsistent levels were merged and the model 
was re-estimated to produce a consistent model [model (5)]. The normalised coefficients were larger than 
the coefficients for the preferred model estimated using the TTO data [model (2)] with the exception of 
one coefficient.
For the DEMQOL-Proxy-U all normalised rank coefficients were positive and significant at the 1% level 
[model (11)]. Contrary to the models estimated using the TTO data there were no inconsistent coefficients. 
As explained above, adjacent inconsistent levels were merged and the model was re-estimated to produce 
a consistent model [model (5)]. The majority of normalised coefficients were larger than the coefficients for 
the preferred model estimated using the TTO data [model (8)].
Errors have not been generated for the rank models as they represent the difference in observed and 
predicted utilities and for rank data there are no directly observed latent utility estimates that the 
predictions can be compared with.
Discussion
In this chapter we have reported on the estimation of preference weights for the two dementia-specific 
classification systems derived in Chapter 4: DEMQOL-U derived from DEMQOL and DEMQOL-Proxy-U 
derived from DEMQOL-Proxy. These preference weights enable a health-state utility value to be estimated 
for every health state defined by each classification system. These preference weights can be used to 
generate a utility score for a patient with dementia each time the patient completes the DEMQOL 
questionnaire or their carer completes the DEMQOL-Proxy questionnaire. These utility scores can then be 
used as the ‘Q’ quality adjustment weight of the QALY to inform economic evaluation. The use of both 
the DEMQOL-U and DEMQOL-Proxy-U measures enables utilities to be generated appropriately across the 
full severity range of dementia. These dementia-specific measures and corresponding utility scores have 
been designed specifically for use in a cognitively impaired population, offering an advantage over generic 
measures such as the EQ-5D and SF-36.
The valuation study included rank and TTO tasks. Both rank and TTO data can be used to estimate 
preference weights that can be used to generate utility values for all health states defined by the 
classification system. Here, the regression models estimated using the rank data had more significant 
coefficients than the models estimated using the TTO data, yet had inconsistent coefficients for two 
DEMQOL-U dimensions. We recommend that the preferred models estimated using TTO data should 
be used to generate the preference weights. This is in accordance with recommendations from NICE 
stating that the valuation protocol used to estimate the preference weights should be the protocol used 
to produce the UK values of the EQ-5D. This promotes comparability of utility values generated using 
different classification systems from different preference-based measures.
There is currently no accepted standard on the minimum number of observations required for each health 
state to ensure reliability and robustness of the modelling output. It is possible that more observations per 
health state may have improved the reliability and robustness of the modelling output and further research 
into this issue is encouraged. However, the regression models estimated using the TTO data had good 
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predictive ability (e.g. MAE 0.042–0.045) and performed comparably with regression models estimated for 
other preference-based measures including the generic EQ-5D (MAE 0.039),45 generic SF-6D (MAE 0.073–
0.079),38 asthma-specific AQL-5D (0.046–0.057),40 overactive bladder-specific OAB-5D (0.044–0.076)42 
and cancer-specific EORTC-8D (0.046–0.054).72
Each measure taps three common dimensions (although not using all of the same items) in its 
classification system: positive emotion, negative emotion and memory. DEMQOL-U has two additional 
dimensions of relationships and loneliness and DEMQOL-Proxy-U has an additional appearance dimension. 
The appearance dimension had small and inconsistent coefficients across all DEMQOL-Proxy-U regression 
models, suggesting that deterioration in this dimension did not have a large or stable impact on utility. The 
coefficients for the dimensions common to both measures were consistently larger for DEMQOL-Proxy-U 
than for DEMQOL-U (with the exception of negative emotion level 2). This finding is consistent with 
research which found that adding an extra dimension to a classification system reduced the preference 
weights for existing dimensions.78 This suggests that the coefficients of the DEMQOL-U measure with 
five dimensions may be smaller in the common dimensions than the coefficients of the DEMQOL-Proxy-U 
measure because of the larger number of dimensions. However, this finding may also be due to differences 
in the wording of the items selected for each classification system.
Observed and modelled utility scores for DEMQOL-U have a larger range and lower bound than those for 
DEMQOL-Proxy-U, meaning that DEMQOL-U has the larger severity range. This is likely due to differences 
in the classification systems: DEMQOL-Proxy-U had fewer dimensions and the appearance dimension 
had small preference weights. Yet this produces an apparent contradiction as DEMQOL and DEMQOL-U 
were designed for use in people with mild to moderate dementia whereas DEMQOL-Proxy and DEMQOL-
Proxy-U were designed to be appropriate for all levels of dementia. However, the possible range of utility 
scores for each measure is likely to be different from utility scores of patients because this depends on the 
distribution of responses to the classification system. This will be evaluated further in Chapter 7.
Conclusion
The data presented here suggest that DEMQOL-U and DEMQOL-Proxy-U, dementia-specific preference-
based single-index measures derived from DEMQOL and DEMQOL-Proxy, respectively, are suitable to be 
used to generate utility scores for use in health technology assessment across the full severity range of 
dementia when both measures are used. Algorithms are presented on the DEMQOL website that generate 
DEMQOL-U and DEMQOL-Proxy-U utility scores when applied to DEMQOL and DEMQOL-Proxy data (www.
kcl.ac.uk/iop/depts/hspr/research/ciemh/mha/demqol/index.aspx). These algorithms use the preference 
weights generated using modelled TTO data.
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Chapter 6 Patient and carer valuation survey
Introduction
In the preceding chapters we have detailed the development of DEMQOL-U and DEMQOL-Proxy-U, 
dementia-specific preference-based single-index measures from DEMQOL and DEMQOL-Proxy. In Chapter 5 
we reported the estimation of a preference-based single index for each classification system using values 
obtained from the general population. However, such values can also be obtained from other sources 
including patients, carers and health-care professionals. Values are typically obtained from the general 
population in accordance with recommendations from agencies such as NICE and the Washington Panel. 
General population values are often advocated because public preferences are considered appropriate 
when health care is publicly funded (partly or fully, depending on a country’s health system). In addition, 
the general population is considered to have no vested interest as they do not have prior knowledge about 
the future health states they may experience. However, it can also be argued that the general population 
do not fully understand hypothetical health states because of their lack of experience of similar health 
states, meaning that patients are more able to provide accurate valuations. This is important because 
patients often provide different values from those provided by the general population. This means that the 
source of the values may affect the values obtained and thus have an impact on any economic evaluation 
based on such data.79
A recent review and meta-analysis found that patient values of health states were significantly lower than 
general population values using the TTO elicitation technique.80 However, other papers have found that 
patients provide higher values for health states using a variety of valuation techniques.79,81 Reasons for 
these differences can be summarised as (1) valuing different states because of differences in understanding 
or interpretation of the description; (2) different scales of measurement because of a response shift in 
different populations; and (3) adaptation to the state by patients. Patients may better understand what 
it is like to be in the health state than a member of the general population who has to imagine the 
health state. Furthermore, patients may value the health state differently because they are bringing to the 
valuation additional information that is not included in the health-state description. However, patients may 
also not recall experiences of full health or mild health states, and may have lowered their expectations as 
a result. Knowledge and consideration of adaptation is one important difference between patients and 
members of the general population. Patients may also have different sociodemographic characteristics 
from the general population and this may also affect how they value health states.
Much of the literature examining differences between patient and general population preferences has 
focused on physical health states, and the relationship may differ for conditions affecting mental health 
and cognition. In two studies people experiencing a range of different health states gave mental health 
greater weight than physical health, which was the opposite for members of the general public trying to 
imagine the health states.82 Public attitudes and understandings of dementia in particular may mean that 
patient and general population values differ for dementia health states. There may also be differences 
in values provided by carers of patients with dementia, as carers have experience of how the condition 
impacts on the patient without the health problems experienced by the patient that may affect their 
understanding of the valuation techniques. The contrast in weightings of physical and mental health by 
the general population and patients is important for policy. If general population values are used to inform 
policy and these are higher than patient values for mental health and cognition states, then mental health 
and cognition may be given lower priority than people with these conditions feel is warranted. The higher 
relative weighting of physical health to mental health by the general population potentially prioritises 
physical health at the expense of mental health.
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The literature is also limited as typically studies ask respondents to value only a small number of states, 
meaning that the data cannot be examined to determine whether or not there are systematic differences 
across all health states or whether or not the difference varies by health-state severity. Even those studies 
that value a large sample of health states have not examined whether or not differences vary by severity. 
For example, one study estimated different value sets for patients and the general population for EQ-5D 
but when combining data from both populations to estimate a combined value set included only a 
dummy variable to capture patient effects rather than including interaction effects for the severity levels of 
each dimension.83 However, one study did find that differences in visual analogue scale (VAS) values vary 
by the severity of the health state between members of the general population with no health problems, 
those with mild health problems and those with moderate health problems.84 It is also important to 
control for sociodemographic characteristics of the samples84 as it has been found that elicited TTO values 
vary by sociodemographic characteristics,85 and it is possible that this explains some of the variation in 
values across populations.
To address these general limitations and to investigate the difference in values that might be obtained 
between the general population and people with dementia and their carers we undertook a comparative 
study comparing health-state utility values from samples of the general population, people with dementia 
and carers of people with dementia for a range of dementia health states of differing severity. The analysis 
here explores whether population, health-state severity and respondent sociodemographic characteristics 
impact on elicited utility values.
Methods
Health-state description
Health-state descriptions were generated using the DEMQOL-U and DEMQOL-Proxy-U classification 
systems as described in Chapter 3. The DEMQOL-U classification system is derived from the DEMQOL 
questionnaire, which is completed by people with dementia, whereas the DEMQOL-Proxy-U classification 
system is derived from the DEMQOL-Proxy questionnaire, which is completed by carers using proxy report. 
These classification systems are presented in Table 14.
Selection of health states
In Chapter 5 we described the selection of health states and blocks of combinations of states that were 
included in the general population valuation study used to estimate a preference-based single index. We 
selected one of these blocks each for DEMQOL-U and DEMQOL-Proxy-U. For each classification system we 
chose the block that contained the best health state defined by the classification system (states 11111 and 
1111 respectively) and so along with the worst state this ensured that the selected health states covered 
the full severity range of the classification system.
Samples
To maintain the involvement of each population in the valuation of each classification system, health 
states for each classification were valued by the population who completed the questionnaire and who 
were involved in the initial development of the questionnaire. DEMQOL-U was valued by patients and 
DEMQOL-Proxy-U was valued by carers. In addition, both classification systems were valued by the general 
population in phase 2 of the project as described in Chapter 5. Sample size was chosen to ensure sufficient 
power for comparison of mean health-state utility values across the different populations for each 
classification system using simple t-tests. This required a total of 71 completed interviews per population 
per classification system, assuming a power of 0.8, significance level of 0.05, SD of 0.3 and an expected 
difference of 0.1.
General population
The general population sample and recruitment process is described in detail in Chapter 5. The analysis 
conducted in this chapter uses a subset sample of the 600 general population respondents, consisting of 
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Mulhern et al. under the terms of a commissioning contract issued by the Secretary of State for 
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17050 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 5
65
all respondents valuing our selected card block. To ensure that there were no systematic differences across 
the geodemographic profiles of the subsamples used here interviewers worked systematically through all 
card blocks.
People with dementia and their carers 
To recruit the sample of people with mild dementia and their carers, two research workers visited clinical 
teams who were part of the Mental Health for Older Adults and Dementia Clinical Service at the South 
London and Maudsley NHS Foundation Trust. This included the Croydon Memory Service, the Southwark 
and Lambeth Memory Service and the community mental health teams in Croydon and Lewisham. The 
research workers explained the study to the clinical teams and invited team members to refer suitable 
patients. Letters and information sheets were then sent to all referred patients, after which the research 
workers contacted them by telephone to arrange appointments. Participants who agreed to take part in 
the study were visited in their own homes by both research workers. If both the person with dementia and 
his or her carer were participating, interviews were conducted separately, each in a different room where 
possible. The research workers received the same training as the interviewers who carried out the general 
population survey.
Valuation task
For the valuation survey the TTO technique was chosen in accordance with the UK valuation study 
design of the EQ-5D,54 which also meets the reference case recommended by NICE (see Chapter 5 for a 
detailed overview of the TTO technique and Appendix 1 for a sample script for one health state). For each 
classification system all respondents valued the same health states.
At the interview respondents first self-completed the EQ-5D and then whichever classification system 
would be used subsequently in the valuation task (DEMQOL-U or DEMQOL-Proxy-U). This familiarises 
respondents with the classification system by using the system to describe their own health. General 
population respondents then undertook a ranking task of eight health states plus full health and dead. 
People with dementia and carers did not undertake a rank task because of concerns that this task would 
be too complex. Ranking requires the respondent to consider all health states simultaneously and, given 
that dementia is a condition that affects memory, this was considered inappropriate for patients with 
dementia. Although carers may have been able to successfully undertake the ranking task, the same 
protocol was used for both people with dementia and carers, for consistency and to ensure that people 
with dementia felt that they were treated in the same way as their carers.
To familiarise respondents with the TTO task, respondents undertook a practice TTO task using a 
hypothetical ‘practice’ state and subsequently valued eight states using TTO. The MVH study version of 
TTO was used, including a visual prop designed by the MVH group (University of York) (see Figure 4). 
Finally, respondents rated how difficult they found the rank and TTO tasks and answered questions about 
their sociodemographic characteristics and health service use.
Before conducting the full survey a small number of interviews were conducted and the interviewers 
discussed their findings with one of the research team. As no problems were identified with the survey, 
the main survey was started without amendment and these interviews were included in the main sample. 
The person with dementia and carer survey was approved by the London Research Ethics Committee and 
the general population survey was approved by the ScHARR Research Ethics Committee at the University 
of Sheffield.
Analysis of time trade-off data
Significant differences in the observed variation of respondent characteristics across the different 
populations were analysed for each measure using a factorial ANOVA estimated using a generalised 
linear model. Descriptive statistics of health-state utility values across the different populations (general 
population, people with dementia, carers) were presented for each measure. Mean health-state utility 
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values were compared across the different populations for each measure using simple t-tests and Wilcoxon 
rank-sum tests.
Regression analysis was used to examine the impact of population (general population or people 
with dementia, general population or carer) on elicited health-state utility values. The analysis further 
determined the impact of population and health-state severity while controlling for the sociodemographic 
characteristics of respondents. The standard model specification was:
y
ij
 = α + βs
j
 + γq
i
 + θr
ij
 + δz
i
 + ε
ij
 (4)
where i = 1, 2, . . ., n represents individual respondents and j = 1, 2, . . ., m represents the eight health 
states. The dependent variable, y, represents the TTO utility value, s represents the vector of dummy 
variables for the health states, q represents the dummy variable capturing the population (equals 1 for 
persons with dementia and carers, 0 for general population), r represents the vector of interaction terms to 
jointly capture population and severity effects (e.g. in the DEMQOL-U regression analysis a dummy variable 
equals 1 for state 12231 valued by a person with dementia), z represents the vector of sociodemographic 
characteristics of respondents and ε
ij
 represents the error term. OLS regressions were estimated but these 
do not take into account the structure of the data, as there are multiple observations per individual, and 
these models are not reported here. Random-effects and fixed-effects GLS models were estimated as 
these take into account the structure of the data when all respondents have multiple observations.86 Refer 
to Chapter 5 for an overview of random-effects and fixed-effects models. The choice of whether to use 
random- or fixed-effects models was determined empirically using the Hausman test.
Four model specifications were estimated in which each model contained additional explanatory variables: 
first, regressions were estimated containing only health-state dummies as independent variables; second, 
the dummy variable capturing population was added to the model specification; third, interaction terms 
capturing population and severity effects were added; and finally, sociodemographic characteristics of 
respondents were added. This procedure was undertaken to determine the additive impact of population 
across all states regardless of severity, and to then determine whether or not model performance was 
improved by expanding the model specification to include interactions that allowed for impact of 
population to vary by state severity. This procedure was also used to determine whether or not population 
effects are important when the differences in sociodemographic characteristics of respondents and across 
population samples are controlled for, as some differences in values across populations may be due to the 
difference in sociodemographic composition of the samples rather than the populations per se. The final 
model specification was also estimated using a sample excluding respondents whose understanding of the 
TTO task was doubted by the interviewers.
The selection of sociodemographic characteristics for inclusion in the models was informed using the 
ANOVA analysis (as described above), Spearman rank correlation coefficients, significance of coefficients 
and performance of the regression models (described below). Spearman rank correlation coefficients were 
used to indicate the sociodemographic variables that were appropriate for inclusion in the models (which 
are variables most highly correlated with the TTO utility value) and to indicate sociodemographic variables 
that should not appear in the models alongside each other (which are variables with high correlations with 
other variables, for example age and different categories of employment status).
Performance of the regression models was assessed using within R-squared, between R-squared, 
overall R-squared, RMSE of predictions and the Wald chi-squared test. Stata version 11 was used for all 
regression analysis (StatCorp LP, College Station, TX, USA) and SPSS version 15 was used for the descriptive 
statistical analysis.
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Results
Samples
Recruitment of the general population sample is summarised in Chapter 5. The samples of people with 
dementia and carers were recruited between 7 November 2010 and 23 May 2011. During this time the 
teams referred a total of 196 people diagnosed with dementia. Of these, 93 patients and 73 carers agreed 
to be interviewed and were assessed as suitable by the research workers. On some occasions patients were 
seen without carers, and a few carers participated alone. Recruitment continued until 71 patients and 71 
carers had completed the interview. During the process 21 partial interviews were undertaken, 19 with 
patients and two with carers, and three patients were not able to participate at the time of the arranged 
interview. These partial interviews were terminated before the end of the TTO tasks because of respondent 
fatigue, misunderstanding or distress, and these interviews are therefore excluded from the analysis. Of 
those that completed the full TTO study, 49 were patient/carer dyads.
Respondents who valued the worst state higher than all other states, who valued all states worse than 
being dead or who valued all states identically but < 1 were excluded from the analysis. No patients with 
dementia or carers were excluded but one general population respondent was excluded for valuing all 
states identically but < 1.
Table 23 shows a comparison of respondents by population and classification system. The comparison 
of respondents valuing the DEMQOL-U classification system shows that the patient population sample is 
significantly older (at the 10% level) using the chi-squared p-value, with a mean (SD) age of 78.4 (7.7) 
years, than the general population sample, with a mean (SD) age of 49.6 (17.0) years. The samples have 
significant differences in employment status and education, with the patient sample having a much higher 
proportion of retired individuals and individuals for whom secondary school was their highest level of 
education. EQ-5D scores were similar between the general population and patient DEMQOL-U samples.
The comparison of respondents valuing the DEMQOL-Proxy-U classification system shows that the carer 
population sample was significantly older, with a mean (SD) age of 69.8 (12.7) years in comparison to 
a mean (SD) age of 50.7 (16.2) years for the general population sample. The samples have significant 
differences in employment status (using chi-squared p-values), marital status and homeownership (using 
ANOVA), with the carer sample including a significantly lower proportion of employed and unemployed 
individuals and students, but a significantly higher proportion of retired individuals, married individuals 
and individuals owning their own home. EQ-5D scores were similar between the general population and 
carer DEMQOL-Proxy-U samples.
The differences in sociodemographics may affect elicited values and these differences can be taken into 
account when modelling the data using the inclusion of sociodemographic characteristics in the model 
specification. Overall, the person with dementia and carer samples had a significantly higher proportion of 
respondents for whom the interviewers reported that it was doubtful that they understood the TTO tasks. 
This can be taken into account by estimating the preferred regression model excluding respondents for 
whom it was doubtful that they understood the TTO tasks.
Descriptive statistics of health-state utility values
Table 24 presents descriptive statistics of observed TTO values for DEMQOL-U elicited from the general 
population (as also reported in Chapter 5) and from people with dementia. For every health state, the 
mean and median TTO values are higher for the general population sample than for the patient sample. 
The range of mean utility values is larger for the patient sample (from 0.816 to –0.023) than for the 
general population sample (from 0.955 to 0.190). The ordering of states differs by population. The 
ordering is logically consistent for each population as for many states it is not possible to determine a 
logical ordering as one state is not consistently better across all dimensions.
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TABLE 23 Characteristics of respondents by population and classification system
Characteristic
DEMQOL-U, 
general 
population 
(n = 78)
DEMQOL-U, 
patient 
population 
(n = 71)
ANOVA 
p-value
DEMQOL-
Proxy-U, 
general 
population 
(n = 77)
DEMQOL-
Proxy-U, 
carer 
population 
(n = 71)
ANOVA 
p-value
Age (years), mean (SD) 49.6 (17.0) 78.4 (7.7) < 0.001 50.7 (16.2) 69.8 (12.7) < 0.001
Age distribution (%)a < 0.001 < 0.001
 18–40 years 30.8 0.0 32.5 0.0
 41–65 years 48.7 8.5 45.4 33.8
 > 65 years 20.5 91.5 22.1 66.2
Female (%) 52.6% 54.9% 0.77 51.9% 63.4 0.16
Married/partner (%) 66.7 62.0 0.55 74.0 85.9 0.07
Employment status (%)a < 0.001 0.002
 Employed or self-employed 53.8 2.8 45.5 29.6
 Unemployed 2.6 0.0 2.6 0.0
 Long-term sick 3.8 0.0 1.3 0.0
 Full-time student 1.3 0.0 5.2 0.0
 Retired 24.4 90.1 33.8 62.0
Own home outright or with a 
mortgage (%)
79.5 87.3 0.20 72.7 94.4 < 0.001
Secondary school is highest 
level of education (%)
34.6 50.7 0.05 35.1 38.0 0.71
Interviewer reported that 
was doubtful respondent 
understood TTO tasks (%)
1.3 12.7 0.001 0.0 7.0 0.02
EQ-5D score (SD) 0.87 (0.19) 0.85 (0.14) 0.79 (0.25) 0.78 (0.19)
a To adhere to statistical assumptions categories are merged if there are zero observations or fewer than five expected 
observations and chi-squared p-values are reported.
TABLE 24 Descriptive statistics of observed TTO values for DEMQOL-U
Health state
General population (n = 78) Patient population (n = 71)
Mean SD Median Mean SD Median
11111 0.955 0.153 1.000 0.816 0.241 0.900
12231 0.894 0.160 1.000 0.633 0.297 0.700
32143 0.673 0.302 0.663 0.399 0.398 0.500
41212 0.611 0.364 0.625 0.436 0.347 0.500
23424 0.566 0.340 0.600 0.435 0.327 0.500
44221 0.544 0.367 0.525 0.327 0.439 0.475
43442 0.403 0.412 0.475 0.161 0.455 0.225
44444 0.190 0.484 0.250 –0.023 0.456 0.000
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Table 25 reports descriptive statistics of observed TTO values for DEMQOL-Proxy-U elicited from the 
general population (as also reported in Chapter 5) and from carers of people with dementia. For every 
health-state mean and median TTO values are higher for the general population sample than for the carer 
sample. The range of mean utility values is larger for the carer sample (from 0.857 to 0.049) than for the 
general population sample (from 0.918 to 0.370). The ordering of states differs by population, but the 
ordering is logically consistent for each population. Figure 9 shows differences in the distribution of TTO 
values by population for each measure. General population TTO values are negatively skewed with a large 
proportion of responses at 1, whereas patient and carer TTO values are also negatively skewed but peak 
at 0.5.
Simple t-tests revealed that health-state utility values for the general population and for people with 
dementia are significantly different for DEMQOL-U [general population mean (SD) 0.604 (0.410), 
person with dementia mean (SD) 0.398 (0.447), t = 8.279, degrees of freedom (df) = 1153, p < 0.001] 
and health-state utility values for the general population and for carers are significantly different 
for DEMQOL-Proxy-U [general population mean (SD) 0.707 (0.350), carer mean (SD) 0.531 (0.410), 
t = 7.946, df = 1120, p < 0.001]. Wilcoxon rank-sum tests reached the same conclusions (p < 0.001 and 
p < 0.001 respectively).
Regression analysis
Regression analysis examining the relationship between elicited health-state utility values, population, 
health-state severity and sociodemographic characteristics of respondents is presented in Table 26 for 
DEMQOL-U and Table 27 for DEMQOL-Proxy-U. Random-effects models are reported as the Hausman 
test confirmed for both classification systems that fixed-effects models would produce similar estimates 
at reduced efficiency. For the DEMQOL-U classification system, TTO values were regressed on state-level 
dummy variables in model (1); state-level dummy variables and a population dummy variable in model 
(2); state-level dummy variables and interaction terms to reflect the interaction between the specific 
health state and population in model (3); and explanatory variables used in model (3) while controlling 
for sociodemographic characteristics in model (4). Model (5) used the same specification as model (4) and 
was estimated on a sample excluding respondents whose understanding of the TTO task was doubted by 
the interviewers. Models (6), (7), (8), (9) and (10) estimated for the DEMQOL-Proxy-U classification system 
have the same specification and criteria for sample selection as models (1), (2), (3), (4) and (5) respectively. 
Models using a range of sociodemographic variables as explanatory variables were estimated and the best 
models (using significance of coefficients, within R-squared, between R-squared, overall R-squared, RMSE 
of predictions and Wald chi-squared) are presented here.
TABLE 25 Descriptive statistics of observed TTO values for DEMQOL-Proxy-U
Health state
General population (n = 77) Carer population (n = 71)
Mean SD Median Mean SD Median
1111 0.918 0.185 1.000 0.857 0.211 1.000
1222 0.869 0.174 0.925 0.731 0.251 0.700
3112 0.804 0.255 0.925 0.666 0.313 0.725
1341 0.807 0.236 0.900 0.640 0.250 0.700
3234 0.672 0.272 0.700 0.458 0.361 0.500
2424 0.638 0.341 0.700 0.464 0.364 0.500
4411 0.580 0.395 0.625 0.380 0.406 0.500
4444 0.370 0.482 0.400 0.049 0.465 0.000
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TABLE 26 Regression analysis of DEMQOL-U health-state values across general population and patient respondents
(1) (2) (3) (4) (5)
States
12231 –0.119a –0.119a –0.061 –0.061 –0.061
32143 –0.346a –0.346a –0.281a –0.281a –0.281a
41212 –0.361a –0.361a –0.344a –0.344a –0.344a
23424 –0.385a –0.385a –0.388a –0.388a –0.388a
44221 –0.448a –0.448a –0.411a –0.411a –0.411a
43442 –0.601a –0.601a –0.552a –0.552a –0.552a
44444 –0.800a –0.800a –0.765a –0.765a –0.765a
Patient –0.206a
Patient interaction terms
11111 × patient –0.139b –0.134c –0.106
12231 × patient –0.261a –0.257a –0.235a
32143 × patient –0.274a –0.270a –0.236a
41212 × patient –0.175a –0.171b –0.164b
23424 × patient –0.131b –0.127c –0.125c
44221 × patient –0.217a –0.213a –0.181a
43442 × patient –0.241a –0.237a –0.211a
44444 × patient –0.213a –0.208a –0.194a
Sociodemographics
Female –0.073 –0.123a
Unemployed –0.116 –0.137
Long-term sick –0.077 –0.111
Retired –0.036 –0.030
Student –0.290 –0.263
Homemaker –0.147 –0.138
Secondary school 
is highest level of 
education
0.008 –0.025
Renting accommodation 0.021 0.096c
Constant 0.888a 0.987a 0.954a 1.023a 1.046a
Observations 1192 1192 1192 1192 1120
Number of subjects 149 149 149 149 140
Within R2 0.000 0.478 0.483 0.483 0.489
Between R2 0.000 0.137 0.137 0.181 0.234
Overall R2 0.287 0.341 0.385 0.362 0.394
Root MSE 0.264 0.264 0.264 0.264 0.261
Wald χ2 948.43 971.76 986.02 993.39 962.79
a Significant at 10% level.
b Significant at 5% level.
c Significant at 1% level.
Reference state is 11111 valued by the general population.
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TABLE 27 Regression analysis of DEMQOL-Proxy-U health-state values across general population and carer respondents
(6) (7) (8) (9) (10)
States
1222 –0.087a –0.087a –0.050 –0.050 –0.050
3112 –0.151a –0.151a –0.114a –0.114a –0.114a
1341 –0.163a –0.163a –0.112a –0.112a –0.112a
3234 –0.320a –0.320a –0.246a –0.246a –0.246a
2424 –0.335a –0.335a –0.280a –0.280a –0.280a
4411 –0.405a –0.405a –0.338a –0.338a –0.338a
4444 –0.673a –0.673a –0.548a –0.548a –0.548a
Carer –0.177a
Carer interaction terms
1111 × carer –0.061 –0.053 –0.044
1222 × carer –0.138a –0.131b –0.117b
3112 × carer –0.138a –0.131b –0.111c
1341 × carer –0.167a –0.159a –0.138b
3234 × carer –0.215a –0.207a –0.203a
2424 × carer –0.174a –0.167a –0.156a
4411 × carer –0.200a –0.192a –0.180a
4444 × carer –0.321a –0.314a –0.313a
Sociodemographics
Female –0.022 –0.020
Unemployed 0.025 0.027
Long-term sick –0.447c –0.449c
Retired –0.062 –0.066
Student –0.075 –0.067
Homemaker 0.080 0.126
Secondary school is highest 
level of education
0.031 0.046
Renting accommodation –0.023 –0.029
Constant 0.889a 0.974a 0.918a 0.950a 0.943a
Observations 1184 1184 1184 1184 1144
Number of subjects 148 148 148 148 143
Within R2 0.000 0.431 0.445 0.445 0.450
Between R2 0.000 0.131 0.131 0.180 0.181
Overall R2 0.263 0.314 0.322 0.341 0.344
Root MSE 0.246 0.246 0.244 0.244 0.243
Wald χ2 780.38 802.48 840.11 848.25 837.676
a Significant at 10% level.
b Significant at 5% level.
c Significant at 1% level.
Reference state is 1111 valued by general population.
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FIGURE 9 Histogram of observed TTO values: (a) DEMQOL-U valued by the general population sample; (b) DEMQOL-U 
valued by the patient sample; (c) DEMQOL-Proxy-U valued by the general population sample; (d) DEMQOL-Proxy-U 
valued by the carer sample.
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FIGURE 9 Histogram of observed TTO values: (a) DEMQOL-U valued by the general population sample; (b) DEMQOL-U 
valued by the patient sample; (c) DEMQOL-Proxy-U valued by the general population sample; (d) DEMQOL-Proxy-U 
valued by the carer sample. (continued)
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Spearman correlation coefficients were used to indicate correlations among the sociodemographic 
characteristics that can be used as potential explanatory variables. All sociodemographic variables 
included in the regression had poor intercorrelation (< |0.3|) with the exception of moderate correlation 
(< |0.7|) between retired and patient variables for DEMQOL-U (correlation 0.67) and between renting 
and unemployed variables for DEMQOL-Proxy-U (correlation 0.32). This means that there was no problem 
of multicollinearity in the explanatory variables included in the regressions. Age was not included as an 
explanatory variable as it was correlated with the employment status predictors, which had a greater 
improvement in model performance than age and age-squared. Health status using EQ-5D was not 
included as an explanatory variable because of a concern that it was not an accurate measure of health 
status for the patient population. Furthermore, inclusion of health status was not significant and did not 
improve model performance for the DEMQOL-Proxy-U models. The population variable was not included in 
models (3), (4), (5), (8), (9) and (10) because of perfect collinearity between the population label and the 
eight population × state interaction terms.
The results show that health-state dummy variables were significant at the 1% level in all models except 
for state 12231 in models (3), (4) and (5) and state 1222 in models (8), (9) and (10). The size of the 
coefficients was consistent as the decrement in the elicited utility value was larger for more severe health 
states (indicated using the modelled utility values from the original valuation study). The only exception is 
an inconsistency between health states 3112 and 1341 in models (8), (9) and (10) for DEMQOL-Proxy-U.
The inclusion of a dummy variable to represent population in models (2) and (7) was significant at the 1% 
level and improved model performance across all goodness of fit statistics. The coefficient was negative, 
demonstrating that respondents with dementia and carers value states significantly lower than the 
general population.
Interaction effects reflecting the interaction between the specific health state and the person with 
dementia or carer population had negative coefficients, meaning that there is a reduction in utility value 
for respondents from the patient or carer populations. The inclusion of the interaction terms reduced the 
absolute size of the coefficient for the health-state dummy variables with the exception of DEMQOL-U 
state 23424 in model (3). The size of the interaction coefficients varied by health state, indicating that the 
impact of population differs by health-state severity, but there was not a clear pattern. Interaction effects 
for DEMQOL-U health states valued by people with dementia with more severe health problems in the 
(fourth) negative emotion dimension (health states 12231, 32143, 43442, 44444) had larger coefficients 
than the other health states, but this could be due to coincidence. Interaction effects for DEMQOL-
Proxy-U health states valued by carers with the most severe level in one or more dimensions (health 
states 1341, 2424, 3234, 4411, 4444) had larger coefficients than other states, but again this could 
be due to coincidence. The coefficient for the interaction effect for the worst health state for DEMQOL-
Proxy-U valued by carers is noticeably larger than those for the other interaction effects. The inclusion of 
interaction effects improved model performance as measured using within and overall R-squared and Wald 
chi-squared.
The addition of the sociodemographic characteristics in models (4) and (9) had only a minor impact 
on the coefficients of the other variables and led to only a small improvement in model performance. 
Few sociodemographic variables were significant. For the DEMQOL-U models, employment status 
variables of ‘homemaker’ and ‘retired’ were significant in model (1) but not in models (2) and (3). 
No sociodemographic variables were significant in model (4) while the variables ‘female’ and ‘renting 
accommodation’ were significant in model (5). For the DEMQOL-Proxy-U models the employment status 
variable ‘long-term sick’ was significant in models (9) and (10) (although note that the number of 
respondents in this category was small). This suggests that, although the sociodemographics are different 
for the different samples, as found in Table 1, these differences do not impact on elicited health-state 
utility values.
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Excluding respondents whose understanding of the TTO task was doubted by the interviewers did not have 
a noticeable impact on coefficients for health-state severity and interaction effects. However, the ‘female’ 
and ‘renting accommodation’ sociodemographic variables became significant in model (5) for DEMQOL-U.
Discussion
The results demonstrate that the population used to value dementia health states affects health-state 
utility values elicited using TTO. This is in accordance with the literature.80 Health-state utility values elicited 
from people with dementia and carers of people with dementia were lower than health-state utility values 
elicited from the general population. This is different from many studies which have found that patients 
provide higher values than the general population for other health states using a variety of valuation 
techniques, but is consistent with a recent review and meta-analysis which found that patient values were 
significantly lower using the TTO elicitation technique in particular.80 Furthermore, the majority of the 
literature focuses on physical health states whereas this study focused on mental health and cognition, 
with previous research suggesting that patients and the general population weight problems in physical 
and mental health differently.82
Modelling of the health-state utility values indicated that the differences in values were due to the 
population per se and not to differences in the sociodemographic composition of the populations. This 
was demonstrated because controlling for sociodemographic characteristics had a minimal impact on the 
coefficients of the other variables and resulted in only a minor improvement in model performance and 
few of the sociodemographic coefficients were significant. Regression analysis and descriptive statistics 
of observed values indicated that the difference in values by population differed for each health state, 
sometimes indicating a different ordering of the health states. This different ordering of health states is 
not an inconsistency across populations; it represents differences in the valuation of and trade-off between 
different dimensions. This suggests that the choice of whose values are used to produce utility values for 
use in cost-effectiveness analysis will have an impact on the results and could potentially affect resource 
allocation decisions. This suggests the need to produce a full value set for all DEMQOL-U and DEMQOL-
Proxy-U health states using values elicited from people with dementia and from carers of people with 
dementia respectively.
The finding that general population values are higher than patient values for dementia states suggests 
that members of the general population may be systematically undervaluing the impact on quality of life 
arising from problems with cognition and mental health. This may reflect public perception in general of 
health problems such as dementia. However, it is important to note that it may be due to the wording and 
labelling of the classification system. General population respondents were not informed at any point that 
the study was about dementia, whereas people with dementia and carers knew that the study was about 
dementia. This contextualised health states for the people with dementia and carers, meaning that they 
had a greater understanding of the health states, but it also meant that they knew the underlying cause 
of the health state. A recent study examining labelling effects found that introducing condition labels into 
health-state descriptions impacted on health-state utility values elicited from the general population, and 
that the impact differed by condition and health-state severity.37,71 It can be argued that the inclusion of 
a condition label can better inform the general population about the health state because respondents 
may value differently, for example, feeling frustration as a result of epilepsy and feeling frustration as a 
result of dementia. However, it can also be argued that the inclusion of a condition label may mean that 
respondents take into account preconceptions of the condition or mortality of the condition, and these are 
factors that should not be taken into account in the elicitation of health-state utility values. As the aim of 
the general population valuation survey was to elicit values to inform resource allocation decisions across 
all conditions and patient groups, there must be comparability between the health-state descriptions used 
here and in other valuation surveys, regardless of the underlying condition. Otherwise, this could imply 
that, for example, a given generic EQ-5D state has a lower utility value for a patient with epilepsy than for 
a patient with diabetes. The exclusion of a dementia health-state label in the general population study may 
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therefore have impacted on elicited utility values, and there is a possibility that if general population values 
were obtained with the inclusion of a dementia label these values may be closer to the values elicited from 
people with dementia and carers. However, an important difference is likely to remain: the difference in 
the valuation of and trade-off between the different dimensions in the classification system. Qualitative 
research or a full-scale valuation study similar to the study outlined in Chapter 5 for people with dementia 
and carers would indicate differences in the trade-off between and relative importance of the dimensions 
in comparison with the general population. Further research in this area is encouraged but is likely to be 
constrained by the difficulties of conducting this type of research in these populations.
One potential limitation in the comparisons made between the general population values and the values 
from people with dementia and carers is that the general population study involved ranking as a warm-up 
task prior to the TTO task whereas this was excluded from the survey for people with dementia and carers. 
Starting the TTO task without the rank task, which helps respondents think about how they would value 
different health states, may have affected the understanding of the TTO task and may also have affected 
the values provided by people with dementia and carers. However, it could be argued that people with 
dementia and carers knew that the states were dementia states and may already have an idea before the 
interview about how they value different dementia health states.
Among people with dementia and carers there were significantly higher proportions of respondents who 
were reported by the interviewers as doubtful that they understood the TTO task, but at 12.7% and 7.0% 
of respondents, respectively, these proportions are not especially high. The preferred regression models 
were also estimated on samples excluding respondents whose understanding of the TTO task was doubted 
by the interviewers. The exclusion of these respondents did not have a large impact on the coefficients 
for health-state severity and interaction effects but some sociodemographic characteristic variables 
became significant.
Another potential limitation of this study is the involvement of people with dementia with 
neuropsychological and cognitive problems to value health states using a cognitively demanding elicitation 
technique. The study was designed at all stages to take into consideration the health and competencies 
of the patient population: the team was engaged in conversation with the Alzheimer’s Society through 
its Quality Research in Dementia panel prior to designing the study; patients were referred to the study 
by clinicians specialising in dementia; and the interviews were immediately terminated if the person with 
dementia suffered from fatigue, misunderstanding or distress. For these reasons the samples are made 
up of patients with mild dementia and carers of people with mild dementia. This means that the samples 
may not be representative of people with more severe dementia and their carers but this is a constraint 
of conducting a valuation study for this patient group. The MVH TTO protocol has been widely used in 
valuation studies of the general population but may be more challenging for respondents with cognitive 
problems. The TTO is no more challenging than many other elicitation techniques, such as SG or person 
trade-off, and arguably is less cognitively demanding than ranking, which requires the simultaneous 
consideration of multiple health states. Other options that may be less cognitively demanding include 
ordinal techniques such as discrete choice techniques and best–worst scaling. However, these require 
many more data and either increase the burden on each respondent and/or require a much larger sample. 
There are also challenges regarding the anchoring of these values onto the 1–0 full health–dead scale 
(see reference 19 for an overview). A VAS may be cognitively easier for respondents, but to obtain values 
anchored onto the 1–0 full health–dead scale would require the valuation of dead alongside each state.
The study used the same valuation protocol as the EQ-5D as recommended by NICE to ensure that elicited 
utilities are comparable with the UK tariff of the EQ-5D. However, the choice of TTO and the valuation 
protocol may have impacted on results. A recent meta-analysis of patient and general population values 
found that results differed by valuation technique80 and other research has found that valuation results 
may in general differ by protocol.87 Further research in this area is needed.
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Mulhern et al. under the terms of a commissioning contract issued by the Secretary of State for 
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17050 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 5
77
Conclusion
Dementia health-state utility values elicited using TTO differ by the population used to elicit the utility 
values, with people with dementia and carers of people with dementia giving systematically lower utility 
values than members of the general population. These differences in values were due to the population 
per se and not to differences in the sociodemographic characteristics of the populations. The general 
population underestimated the impact of dementia compared with people with dementia and their carers. 
The ordering of health states also differed by population for some health states, indicating a difference 
in the valuation of and trade-off between different dimensions. These results suggest that the population 
used to produce dementia health-state utility values could impact on the results of cost-effectiveness 
analysis and potentially affect resource allocation decisions.
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Chapter 7 Application of the preference-based 
index to the Health Technology Assessment Study of 
Antidepressants for Depression in Dementia trial data
Introduction
If the DEMQOL-U and DEMQOL-Proxy-U are to be used alongside or instead of generic preference-based 
measures it is important to assess their psychometric validity, responsiveness and level of agreement 
between patient and carer report. This can be assessed by applying psychometric methods to data sets 
containing responses to the DEMQOL system alongside generic preference-based and non-preference-
based measures. The issue of how condition-specific preference-based measures compare with generic 
preference-based measures is particularly important as this indicates the likely impact of using DEMQOL-U 
and DEMQOL-Proxy-U instead of generic measures to generate QALY values for use in economic 
evaluation. The psychometric testing of DEMQOL-U and DEMQOL-Proxy-U is reported in this chapter using 
data from the HTA-SADD trial, a multicentre randomised double-blind placebo-controlled trial of the 
clinical effectiveness of sertraline and mirtazapine.46 This study included an assessment of HRQL using the 
generic preference-based measure EQ-5D and the DEMQOL system.
In this chapter we compared the validity, patient/proxy agreement and responsiveness of the EQ-5D and 
the DEMQOL-U and DEMQOL-Proxy-U utility measures. Validity was examined in terms of the ability to 
discriminate between different levels of severity (i.e. known group validity), the convergence between 
the DEMQOL utility measures and the other measures of dementia-related constructs, and the level of 
agreement between DEMQOL-U, DEMQOL-Proxy-U and patient- and carer-reported EQ-5D. Agreement 
between patient- and carer-reported utilities was assessed. Responsiveness was assessed by investigating 
sensitivity to change in quality of life over time.
Method
Data source
The data used for the psychometric analyses were from the HTA-SADD study of the use of antidepressants 
for depression in dementia.46 HTA-SADD is a multicentre parallel-group double-blind placebo-controlled 
pragmatic RCT of the clinical effectiveness of sertraline and mirtazapine. Participants were eligible to 
participate in the study if they had probable or possible Alzheimer’s disease and depression (4+ weeks’ 
duration), and a CSDD score of 8+ (indicating significant depressive symptoms). They were drawn from 
nine English old age psychiatry services. Patients were excluded only if they were clinically too critical (e.g. 
were at risk of suicide), had a contraindication to medication, were taking antidepressants, were in another 
trial or had no carer. Participants were randomly allocated to one of three treatment arms, sertraline, 
mirtazapine or placebo, all with usual care. Target doses were 150 mg of sertraline or 45 mg of mirtazapine 
daily. The objective of the study was to determine the clinical effectiveness of sertraline and mirtazapine 
compared with placebo in reducing depression at 13 weeks post randomisation. In total, 326 participants 
were randomised. The study found no statistically significant differences in depression score between 
groups at 13 or 39 weeks. The placebo group had fewer adverse reactions (26%) than the sertraline (43%) 
or mirtazapine (41%) groups and fewer serious adverse events rated as severe.
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Measures
DEMQOL-U and DEMQOL–Proxy-U 
The DEMQOL-U and DEMQOL-Proxy-U utility scores were generated using the general population 
algorithms reported in Chapter 5. The utility scores are anchored on the 1–0 full health–dead scale, with 
scores < 0 equivalent to states worse than dead. The range of scores for DEMQOL-U is from 0.243 to 
0.986 and that for DEMQOL-Proxy-U is from 0.363 to 0.937.
European Quality of Life-5 Dimensions
The EQ-5D53 is a standardised instrument used as a measure of health outcome and in the assessment 
of cost–utility. It is designed for self-completion by respondents and can also be completed by proxy. The 
EQ-5D consists of a descriptive health-state classification system with five domains (mobility, self-care, 
usual activity, pain/discomfort and anxiety/depression) and a VAS ‘health thermometer’. Each attribute 
in the classification system has three levels (‘no problem’, ‘some problems’ and ‘major problems’), thus 
defining a total of 243 possible health states, to which ‘unconscious’ and ‘dead’ have been added for a 
total of 245 health states. Preferences for the scoring function used in the HTA-SADD trial were measured 
using the MVH UK value set produced using modelled utility values obtained using the TTO technique on 
a random sample of approximately 3000 adults in the UK.45 EQ-5D utility scores range from –0.594 to 1. 
The ‘health thermometer’ is a subjective evaluation of the respondent’s health status on a scale between 0 
and 100, with 0 representing the worst imaginable health state and 100 representing the best imaginable 
health. In the HTA-SADD trial the EQ-5D was reported by both the patient and the carer (CEQ-5D). The 
patient completion data were compared with DEMQOL-U data and the carer completion data were 
compared with DEMQOL-Proxy-U data.
Cornell Scale for Depression in Dementia
The CSDD was specifically developed to assess signs and symptoms of depression in patients with 
dementia using both patient and carer report.49 The final ratings of the 19 CSDD items represent the 
research worker’s impression rather than the responses of the informant or the patient. Each item is rated 
on symptom severity (‘absent’, ‘mild or intermittent’ and ‘severe’). A score of ≥ 11 indicates probable 
depression and a score of ≥ 18 indicates definite depression. The scale has been described as the best 
available to assess mood in the presence of cognitive impairment.88
Mini Mental State Examination
The MMSE is widely used in screening for dementia. It generates scores between 0 and 30, with 
scores between 0 and 9 indicating severe impairment, scores between 10 and 20 indicating moderate 
impairment and scores between 21 and 30 indicating mild impairment.50 The person with dementia 
is assessed on orientation, memory and attention, and ability to follow commands on tasks, including 
copying a diagram of overlapping hexagons, writing a sentence and reading and following a 
printed instruction.
Bristol Activity of Daily Living Scale
The BADLS was specifically designed for use with people with dementia living in the community and 
participating in clinical trials.51 The levels of disability between which the scale aims to discriminate were 
generated by carers. The BADLS is sensitive to change and has good test–retest reliability. Scores range 
from 0 to 60, with 0 representing unimpaired daily activities and 60 representing impaired daily activities.51 
The BADLS is completed using proxy report by carers.
Neuropsychiatric Inventory
The NPI assesses 12 behavioural disturbances in dementia using a screening strategy. The nature, frequency 
and severity of behaviour and psychiatric symptoms in dementia are assessed. NPI scores range from 0 
(no disturbance) to 144 (maximum disturbance). In the original validation study, the NPI demonstrated 
content and concurrent validity as well as inter-rater, test–retest and internal consistency reliability.52 NPI is 
completed using proxy report by carers.
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Analysis
Descriptive analysis 
Summary statistics were generated to describe the distribution of responses on the self-report EQ-5D, CEQ-
5D, DEMQOL-U and DEMQOL-Proxy-U. The proportion of responses endorsing the best (i.e. ceiling effect) 
and worst (i.e. floor effect) ratings was explored. This is because large numbers at the ceiling or floor 
imply that the measure cannot capture an improvement or deterioration in health status respectively. The 
extent of missing data was also calculated to provide an indication of the acceptability of each measure for 
respondents with cognitive impairment.
Agreement 
Bland–Altman plots89 were employed to assess agreement between responses to EQ-5D and responses to 
DEMQOL-U and DEMQOL-Proxy-U to see if the DEMQOL measures displayed a similar pattern of response. 
As the true tariff for each participant is not known, the horizontal (x) axis uses the average of the two 
utility values for every individual [e.g. x = (utility 1 + utility 2)/2]. The vertical (y) axis is the difference 
between the utility scores. To assess agreement at the less severe end of the scale (where a ceiling effect is 
commonly reported for EQ-5D90), we also assessed respondent scores on the DEMQOL-U and DEMQOL-
Proxy-U for those who reported full health on EQ-5D and CEQ-5D respectively.
Patient/proxy agreement
The utility values generated from self-report were compared with those generated from carer report 
to examine the extent of agreement between the two sets of values. Good agreement would suggest 
that self- and carer-based utility scores could possibly be used interchangeably for evaluation studies or 
alongside each other as complementary measures. The mean difference between the rater scores was 
assessed. Intraclass correlation coefficients, or ICCs,91 were employed to quantify the extent of agreement, 
while Bland–Altman plots provided a graphical representation of the discrepancy between self- and carer-
based utility values. The y-axis of these plots represents the discrepancy between self- and carer-based 
utility values (e.g. y = DEMQOL-U – DEMQOL-Proxy-U) while the x-axis represents the participants’ utility 
values. However, as the true utility for each participant is not known, the horizontal axis uses the average 
of self- and carer-based utility values for every individual [e.g. x = (DEMQOL-U + DEMQOL-Proxy-U)/2]. 
When there is good agreement (i.e. DEMQOL-U – DEMQOL-Proxy-U ≈ 0), a scatter of points would cluster 
horizontally around the line y = 0 (which indicates no discrepancy) for all possible utility values on the 
x-axis. All the plots were generated using the Stata module provided by Mander.92
Convergent validity
Convergent validity assesses the association between the DEMQOL utility measures and existing validated 
measures of similar constructs. Evidence of convergent validity would require a reliable association 
between the utility scores, which represent the value placed on health, and the scores of the other 
indicators, which measure perceptions of health across a number of related constructs. The convergent 
validity of the EQ-5D, DEMQOL and DEMQOL-U, and the CEQ-5D, DEMQOL-Proxy and DEMQOL-
Proxy-U was examined in relation to measures of cognitive impairment (MMSE), depression (CSDD), 
neurobehavioural problems (NPI) and daily functioning (BADLS). A range of measures were assessed as 
there is no gold standard for the measurement of populations with cognitive impairment. Correlations 
were assessed as very strong (≥ 0.6), strong (< 0.6 to ≥ 0.5), moderate (< 0.5 to ≥ 0.3) and weak (< 0.3).
Known-group validity
Known-group validity was assessed using severity thresholds recommended for the MMSE and CSDD. 
Specifically, we hypothesised that the group with mild cognitive impairment (MMSE score > 20) would 
have the highest utility values relative to those with moderate (MMSE score 10–20) and severe (MMSE 
score < 10) impairment. Similarly, patients with less severe depressive symptoms (CSDD score ≤ 10) should 
have utility values that are higher than those of the groups with moderate (CSDD score 11–17) and severe 
(CSDD score ≥ 18) depression. Effect size indices were also calculated to provide an indication of the 
average group difference taking into account the variability observed in the group with least impairment 
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(MMSE score > 20; CSDD score ≤ 10). Based on commonly cited guidelines,93 values of 0.2, 0.5 and 0.8 
denote small, medium and large effect sizes respectively.
Responsiveness to change
Responsiveness to change was examined using the MCID thresholds recommended by the DOMINO 
trial group.56 Specifically, a score change of 1.4 on the MMSE, 3.5 on the BADLS and 8.0 on the NPI 
was deemed a clinically significant change in health status. Based on these thresholds, we classified 
the participants into three groups: MCID improvement, no MCID change and MCID deterioration. We 
hypothesised that the group with MCID improvement (in MMSE, BADLS or NPI) should demonstrate the 
largest increment in utility or HRQL score relative to the other groups at follow-up. On the other hand, 
the group with MCID deterioration should demonstrate a decline in utility or HRQL score at follow-up. 
In the absence of MCID guidelines for the CSDD, we adopted a common practice in antidepressant trial 
investigations of defining clinically significant changes as a percentage of the baseline score for each 
patient. Specifically, a 30% reduction from baseline CSDD score was classified as clinical improvement. 
Conversely, a 30% increase from baseline CSDD score would be classified as clinical deterioration. As 
before, patients with clinical improvement should demonstrate the largest increment in utility or HRQL 
score. Those with clinical deterioration, on the other hand, should demonstrate a decline in utility or 
HRQL score. Standardised response means (SRMs) were also used to compare the responsiveness of the 
respective utility and non-preference-based measures. Based on commonly cited guidelines,93 SRM values 
of 0.2, 0.5 and 0.8 denote fair, moderate and strong responsiveness respectively.
Results
Sample characteristics
The study sample comprised participants recruited from the HTA-SADD trial. The current analyses are 
based on data from 326 patients (Table 28). All but one had data for at least one of the preference-based 
measures. The mean age of the sample was 79 years, and 68% were female. The majority of the sample 
reported a mild or moderate level of cognitive impairment (88%), and 69% self-reported depression for a 
duration of > 6 months.
Descriptive statistics
Considering patient responses, the mean utility score at baseline for the EQ-5D was 0.68 and for 
DEMQOL-U was 0.80 (Table 29). The median value for the EQ-5D is 0.75, and as the median value exceeds 
the mean the EQ-5D scores are positively skewed. The median for DEMQOL-U is 0.82. For both measures 
the scores improved at 13 and 39 weeks’ follow-up, although the mean EQ-5D score increased by more 
than the mean DEMQOL-U score (0.10 vs 0.02). The mean carer-reported EQ-5D score at baseline was 
0.47 and the mean carer-reported DEMQOL-Proxy-U score was 0.79. Again, scores on both measures 
improved at 13 weeks’ follow-up but CEQ-5D scores decreased slightly at 39 weeks. However, the overall 
increase in CEQ-5D scores was larger than the increase in DEMQOL-Proxy-U scores (0.06 vs 0.02).
Ceiling effects were higher for the patient-reported EQ-5D utilities than for DEMQOL-U utilities (16.0 vs 
3.3) at baseline (Table 30). There was no evidence of a floor effect. At week 13, the proportion of the 
sample at the ceiling on the EQ-5D increased to 27.7% in comparison with 5.8% on DEMQOL-U. At week 
39, the EQ-5D ceiling effect is maintained (28.7%) but the proportion at the ceiling on DEMQOL-U drops 
to 1.9%. In terms of the dimension scores, both measures display evidence of a ceiling effect at baseline, 
which increases at follow-up (data not shown). However, the dimensions cannot directly be compared 
because of differences in wording and number of dimension levels. The DEMQOL-U also displays some 
evidence of a floor effect for some dimensions. The high ceiling effects observed for the EQ-5D and 
DEMQOL-U for some dimensions means that it may be difficult for some dimensions to be sensitive to 
improvements in health over the course of a study.
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The ceiling effect is not as high for the CEQ-5D and DEMQOL-Proxy-U utility scores at baseline (2.5% and 
6.0% respectively), but the EQ-5D still displays a higher proportion at the ceiling. This is maintained at 
week 13 (6.0% and 1.2%) and week 39 (8.5% and 1.5%). CEQ-5D has less of a ceiling effect than EQ-5D 
at the dimension level, but direct comparisons are not possible. The only dimension that can be directly 
compared across the DEMQOL-U and DEMQOL-Proxy-U is negative emotion, and the patient-reported 
measure displays more evidence of a ceiling effect on this dimension.
TABLE 28 Summary of baseline characteristics
Characteristic na Mean (SD) or %
Participant profile
Age (years) 325 79.4 (8.5)
Female 220 67.7
Residence (care home) 50 15.4
Dementia vascularity 240 2.1 (1.3)
Cognitive impairment
MMSE total score 250 18.1 (6.6)
Mild (MMSE score > 20) 102 40.8
Moderate (MMSE score 10–20) 118 47.2
Severe (MMSE score < 10) 30 12.0
Depression duration
Duration < 1 month 10 3.1
Duration 1–2 months 20 6.3
Duration 2–6 months 68 21.3
Duration > 6 months 221 69.3
Severity of depression
CSDD total score 295 12.9 (4.2)
Non-case (CSDD score < 6) 96 32.5
Probable (CSDD score 6–10) 165 55.9
Definite (CSDD score > 10) 34 11.5
Activities of daily living
BADLS total score 179 17.6 (11.9)
Neurobehavioral problems
NPI total score 325 28.9 (18.6)
Carer profile
Age (years) 260 63.0 (14.5)
Female 213 65.7
Living with participant 185 66.6
a Subgroup sizes do not add up because of missing data.
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TABLE 29 Summary statistics for the EQ-5D, CEQ-5D, DEMQOL-U and DEMQOL-Proxy-U across the study period
Measure n Mean Median
EQ-5D
Baseline 293 0.68 0.75
Week 13 220 0.75 0.80
Week 39 174 0.78 0.81
DEMQOL-U
Baseline 277 0.80 0.82
Week 13 207 0.81 0.84
Week 39 161 0.82 0.85
CEQ-5D
Baseline 321 0.47 0.59
Week 13 251 0.56 0.66
Week 39 211 0.53 0.64
DEMQOL-Proxy-U
Baseline 317 0.79 0.79
Week 13 244 0.81 0.82
Week 39 207 0.81 0.82
TABLE 30 Baseline missing data and floor and ceiling effects for the EQ-5D, CEQ-5D, DEMQOL-U and DEMQOL-Proxy-U 
across the study period
Measure n % missing % floor % ceiling
EQ-5D
Tariff 293 10.1 0 16.0
Mobility 305 6.4 0.7 58.0
Self-care 303 7.1 3.3 77.6
Usual activities 296 9.2 7.8 59.5
Pain/discomfort 304 6.7 5.6 59.5
DEMQOL-U
Tariff 277 15.0 0 3.3
Positive emotion 296 9.2 18.2 7.8
Memory 285 12.6 12.3 37.9
Relationship 283 13.2 7.4 62.9
Negative emotion 292 10.4 20.2 35.6
Loneliness 293 10.1 11.6 51.5
CEQ-5D
Tariff 321 1.5 3.0 2.5
Mobility 325 0.3 2.2 45.8
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Acceptability
DEMQOL-U displays higher missing data rates at baseline than EQ-5D both for the overall utility score and 
at the dimension level (see Table 30). The carer-reported measures display lower missing data rates than 
the patient-reported measures.
Agreement
Figure 10 presents Bland–Altman plots depicting the extent of the agreement between the patient 
measures (EQ-5D and DEMQOL-U) and between the carer measures (CEQ-5D and DEMQOL-Proxy-U) 
across the range of possible utility values. For the patient measures at baseline, 4.78% of the responses 
fall outside the 95% limits of agreement, and there is a small increase at follow-up. The same pattern 
is apparent for the CEQ-5D and DEMQOL-Proxy-U, for which 3.81% of responses fall outside the 95% 
limits of agreement at baseline. The charts indicate that the majority of the disagreement occurs at the 
more severe end of the scale, where a small number of respondents are providing a higher utility score for 
DEMQOL-U than for the EQ-5D. This may be related to the difference in the ranges of the utility scales, 
which means that respondents in poor health may generate a substantially lower utility score on EQ-5D 
than on DEMQOL-U. Agreement between the measures is increased at the higher end of the utility scale, 
and the mean difference decreases at follow-up. This indicates that measurement convergence between 
the generic and the condition-specific indicators is better among those in better health at baseline, 
and also as health status improves over the course of a trial. The mean difference for the CEQ-5D and 
DEMQOL-Proxy-U is larger, indicating more disagreement between the proxy-reported measures.
Table 31 presents respondent scores for DEMQOL-U and DEMQOL-Proxy-U when the patient is in full 
health according to the EQ-5D (state 11111 is equivalent to a utility score of 1). There is wide variation 
in the DEMQOL-U and DEMQOL-Proxy-U utility values when the same respondents report optimal health 
on the EQ-5D (or CEQ-5D). At baseline the DEMQOL-U scores that are found when the EQ-5D utility is 1 
range from 0.63 to 0.96. The range increases at the 39-week follow-up (0.48–0.96). The same pattern 
is apparent for DEMQOL-Proxy-U, where the range at baseline is 0.60–0.81, increasing to 0.65–0.94 at 
39 weeks’ follow-up.
TABLE 30 Baseline missing data and floor and ceiling effects for the EQ-5D, CEQ-5D, DEMQOL-U and DEMQOL-Proxy-U 
across the study period (continued)
Measure n % missing % floor % ceiling
Self-care 325 0.3 15.1 44.6
Usual activities 323 0.9 22.3 29.1
Pain/discomfort 324 0.6 11.1 41.7
Anxiety/depression 324 0.6 17.3 14.5
DEMQOL-Proxy-U
Tariff 317 2.8 3.0 6.0
Positive emotion 322 1.2 55.9 2.5
Memory 320 1.8 21.6 43.1
Appearance 322 1.2 5.6 67.7
Negative emotion 322 1.2 18.6 18.0
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FIGURE 10 Agreement between DEMQOL-U and EQ-5D, and CEQ-5D and DEMQOL-Proxy-U utility values at baseline, 
week 13 and week 39. (a) DEMQOL-U vs EQ-5D; (b) DEMQOL-Proxy-U vs CEQ-5D.
Patient/proxy agreement
In light of the common reliance on carer reports for people with cognitive impairment, the agreement 
between carer- and patient-reported utility values was examined (Table 32). In terms of mean differences, 
DEMQOL-Proxy-U utilities differed very little from DEMQOL-U utilities. The difference between the EQ-5D 
and CEQ-5D scores was relatively larger (0.18–0.20). However, the ICC values indicated that there was 
better agreement between the EQ-5D and the CEQ-5D than between DEMQOL-U and DEMQOL-Proxy-U. 
This means that the EQ-5D may have better agreement between patients and carers. However, the patient- 
and carer-reported EQ-5D utilities did have greater variability than was observed for DEMQOL-U and 
DEMQOL-Proxy-U, and this may be related to the substantially larger utility range of EQ-5D.
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Agreement between patients and carers on DEMQOL-U and DEMQOL-Proxy-U and on the EQ-5D and 
CEQ-5D was also examined using Bland–Altman plots (Figure 11). Although the mean difference between 
DEMQOL-U and DEMQOL-Proxy-U is less than that between the EQ-5D and the CEQ-5D, a higher 
percentage of responses are outside the 95% agreement limits at baseline (6.23% vs 5.86%). However, the 
magnitude of the difference is not large and this indicates that agreement is similar across the DEMQOL 
and EQ-5D measure pairs. The difference in the magnitude of agreement remains low across all time 
points, with the percentage outside the 95% agreement limits lower for the DEMQOL-U and DEMQOL-
Proxy-U response pairs. The plots indicate that most of the difference occurs at the more severe end of the 
scale, where the mean utility score is lower. This means that patients are rating their utility as substantially 
better than their carer perceives it, or vice versa. The mean difference between ratings is higher for the 
EQ-5D, but this is explained by the larger range of utility values generated by this instrument.
Convergent validity
Table 33 reports the associations between the EQ-5D, DEMQOL-U and DEMQOL and the non-preference 
indicators of dementia-related health status. All three measures are significantly associated with depression 
scores (with a better EQ-5D, DEMQOL-U or DEMQOL score associated with lower levels of depression, 
as measured by CSDD, with DEMQOL-U displaying the highest correlation); however, the correlations 
TABLE 31 Distribution of DEMQOL-U AND DEMQOL-Proxy-U utility values when EQ-5D is in full health
Measure n Mean SD Median Min. Max.
EQ-5D = 11111
DEMQOL-U week 0 43 0.85 0.09 0.87 0.63 0.96
DEMQOL-U week 13 57 0.82 0.10 0.84 0.61 0.99
DEMQOL-U week 39 45 0.85 0.10 0.89 0.48 0.96
CEQ-5D = 11111
DEMQOL-Proxy-U week 0 8 0.74 0.07 0.76 0.60 0.81
DEMQOL-Proxy-U week 13 15 0.79 0.09 0.77 0.67 0.94
DEMQOL-Proxy-U week 39 18 0.83 0.10 0.86 0.65 0.94
TABLE 32 Agreement between utility values derived from self- and carer-rated HRQL data
Measure n
Mean 
differencea 95% LoAb ICCc 95% CI 
DEMQOL-U and DEMQOL-Proxy-U
Baseline 273 0.02 –0.24 to 0.28 0.15 0.04 to 0.26
Week 13 202 0.01 –0.01 to 0.03 0.25 0.12 to 0.38
Week 39 154 0 –0.26 to 0.26 0.17 0.01 to 0.32
EQ-5D and CEQ-5D
Baseline 290 0.20 –0.46 to 0.85 0.32 0.12 to 0.47
Week 13 216 0.18 –0.42 to 0.79 0.36 0.14 to 0.53
Week 39 170 0.19 –0.43 to 0.81 0.23 0.04 to 0.39
CI, confidence interval; LoA, limits of agreement.
a Mean difference = self-rating – proxy rating.
b Bland–Altman plots.
c ICC model: two-way random absolute agreement.
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are in the range defined as low, indicating little convergence. There is no significant association between 
DEMQOL-U and EQ-5D and the external indicators of cognition (MMSE), daily activities (BADLS) and 
behavioural disturbances (NPI). This indicates that there is little or no association between the patient-
report utility scores and the dementia-specific indicators.
The CEQ-5D was significantly associated with depression, cognition, daily activities and behavioural 
disturbances in the expected direction. The correlations with the BADLS and NPI were in the moderate 
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FIGURE 11 Agreement between self- and carer-based utility values at baseline, week 13 and week 39. (a) DEMQOL-U 
vs DEMQOL-Proxy-U; (b) EQ-5D vs CEQ-5D.
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range, indicating some convergence between generic health status as measured by CEQ-5D and 
daily activities/behavioural disturbances. DEMQOL-Proxy-U was mildly associated with depression and 
behavioural disturbances and DEMQOL-Proxy with daily activities and behavioural disturbances. This 
indicates little association between DEMQOL-Proxy-U and the condition-specific measures.
Known-group validity
Table 34 indicates that EQ-5D and DEMQOL-U scores decrease slightly across cognition severity groups in 
the expected direction, but the effect sizes are in the range defined as small to moderate. The magnitude 
of the change on the EQ-5D and DEMQOL-U between the severity groups is similar, but the DEMQOL-U 
effect sizes are larger because of the bigger SD of the EQ-5D scores, which is related to the larger range in 
utility score of this instrument. Both measures have a small level of known-group validity across cognitive 
impairment groups as measured by the MMSE. The original DEMQOL measure does not discriminate as 
well as the utility measures as there are slight increases in HRQL as measured by DEMQOL as cognitive 
functioning decreases, but the magnitude of the effect is smaller than for the utility measures. The n of the 
severe impairment group is small and so the results need to be interpreted with caution. For depression 
the utility scores decrease as depression worsens. The effect size for the probable depression sample is 
small across the patient utility measures indicating a low level of discriminant validity, with the DEMQOL 
measure displaying a slightly larger effect size indicating increased discriminative ability. There is a large 
effect size for both the EQ-5D and DEMQOL-U for those with a definite case of depression; however, the n 
is small and so again this result needs to be interpreted with caution.
In terms of carer report, CEQ-5D scores decrease across cognition severity groups, with effect sizes in 
the moderate range. This is in contrast to DEMQOL-Proxy-U, for which scores remain relatively stable, 
indicating that the CEQ-5D displays a higher level of known-group validity. The original DEMQOL-Proxy 
scores display a low effect size, and the direction of change is not stable across the severity groups. In 
terms of depression severity, both CEQ-5D and DEMQOL-Proxy-U effect sizes are in the range defined as 
small for the probable group. The effect sizes are larger for the definite depression group, but again the n 
is small and so the results need to be interpreted with caution. Overall, DEMQOL-U displays a higher level 
of known-group validity than DEMQOL-Proxy-U. In contrast, CEQ-5D discriminates better between severity 
groups than EQ-5D.
TABLE 33 Spearman correlation between HRQL utilities/scores and health status at baseline
Measure n EQ-5D n DEMQOL-U n DEMQOL
MMSE 240 0.01 235 0.03 223 –0.05
CSDD 213 –0.16a 198 –0.30b 187 –0.16a
BADLS 168 –0.08 159 0.03 150 0.08
NPI 293 –0.06 277 –0.07 260 0.02
Measure n CEQ-5D n
DEMQOL-
Proxy-U n
DEMQOL-
Proxy
MMSE 250 0.22c 247 –0.01 247 –0.01
CSDD 230 –0.17d 226 –0.14a 200 –0.08
BADLS 179 –0.50b 174 –0.05 157 –0.18a
NPI 325 –0.39b 317 –0.20c 279 –0.39b
a p < 0.05.
b p < 0.0001.
c p < 0.001.
d p < 0.01.
NIHR Journals Library
HEALTH TECHNOLOGY ASSESSMENT STUDY OF ANTIDEPRESSANTS FOR DEPRESSION IN DEMENTIA TRIAL DATA
90
TABLE 34 HRQL utilities and scores (mean and SD) by health status (MMSE, CSDD) at baseline 
Measure n EQ-5D
Effect 
size n DEMQOL-U
Effect 
size n DEMQOL
Effect 
size
Cognitive impairment
Mild (MMSE score 
> 20)
101 0.71 
(0.26)
– 100 0.82 (0.09) – 93 84.5 (14.0) –
Moderate (MMSE score 
20–10) 
114 0.69 
(0.27)
0.08 113 0.80 (0.11) 0.21 109 84.7 (13.5) 0.01a
Severe (MMSE score 
< 10)
25 0.67 
(0.33)
0.13 22 0.79 (0.12) 0.29 21 85.5 (17.7) 0.06a
Measure n
CEQ-
5D 
Effect 
size n
DEMQOL-
Proxy-U
Effect 
size n
DEMQOL-
Proxy
Effect 
size
Mild (MMSE score 
> 20)
101 0.57 
(0.28)
– 99 0.79 (0.09) – 89 87.6 (13.2) –
Moderate (MMSE score 
20–10) 
118 0.47 
(0.33)
0.33 118 0.78 (0.10) 0.11 104 85.8 (16.3) 0.12
Severe (MMSE score 
< 10)
30 0.43 
(0.31)
0.47 30 0.79 (0.11) 0.00 26 90.0 (15.1) 0.17a
n EQ-5D
Effect 
size n DEMQOL-U
Effect 
size n DEMQOL
Effect 
size
Depression
Non-case (CSDD score 
< 11)
163 0.72 
(0.26)
– 153 0.81 (0.11) – 147 85.8 (13.1) –
Probable (CSDD score 
11–17) 
41 0.70 
(0.29)
0.07 36 0.79 (0.09) 0.20 35 81.3 (17.5) 0.29
Definite (CSDD score 
> 17)
9 0.46 
(0.35)
0.84 9 0.70 (0.14) 0.87 5 86.6 (20.3) 0.05a
n
CEQ-
5D 
Effect 
size n
DEMQOL-
Proxy-U
Effect 
size n
DEMQOL-
Proxy
Effect 
size
Non-case (CSDD score 
< 11)
170 0.52 
(0.30)
– 169 0.79 (0.09) – 152 88.7 (13.3) –
Probable (CSDD score 
11–17) 
46 0.46 
(0.33)
0.19 47 0.78 (0.09) 0.11 39 88.7 (15.6) 0
Definite (CSDD score 
> 17)
11 0.16 
(0.33)
1.14 10 0.74 (0.08) 0.59 9 79.0 (15.6) 0.60
a Difference from reference group not in hypothesised direction.
Effect size indices refer to the magnitude of the difference from the reference group (MMSE mild, CSDD non-case).
Responsiveness to change
Table 35 reports the observed change in HRQL utilities and scores for three groups of clinical progression 
using the EQ-5D, DEMQOL-U and DEMQOL: (1) MCID/clinical improvement, (2) no clinical change and (3) 
MCID/clinical deterioration. We expected HRQL utilities and scores to decline in general for the groups with 
MCID/clinical deterioration. At week 13 there is no evidence for responsiveness in the clinical deterioration 
groups for the EQ-5D and DEMQOL-U. DEMQOL responded to a decrease in depression but as the n is 
small this needs to be interpreted with caution. At week 39 the DEMQOL-U responds to deterioration 
in cognition, daily activities and behavioural disturbances with SRMs in the small range (Table 36). The 
SRM for depression is higher but again the n is small and so this must be interpreted carefully. In terms of 
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TABLE 35 Mean change in HRQL utilities and scores by clinical change in MMSE, BADLS, NPI and CSDD (baseline to 
week 13)
Measure n
∆ EQ-5D, 
mean (SD) SRM n
∆ DEMQOL-U, 
mean (SD) SRM n
∆ DEMQOL, 
mean (SD) SRM
MCID: MMSE
Improved (+1.4) 45 0.07 (0.21) 0.35 41 0.02 (0.09) 0.24 36 5.42 (9.08) 0.60
No MCID ∆ 63 0.09 (0.29) 0.32 61 0.02 (0.12) 0.17 58 2.88 (11.18) 0.26
Deteriorated 64 0.02 (0.21) 0.08 60 0.00 (0.12) 0.01 55 2.27 (12.78) 0.18
MCID: BADLS
Improved (–3.5) 15 0.14 (0.40) 0.35 15 0.02 (0.11) 0.17 13 7.46 (8.91) 0.84
No MCID ∆ 59 0.02 (0.22) 0.10 50 0.01 (0.10) 0.08 44 4.55 (11.80) 0.39
Deteriorated 30 0.08 (0.24) 0.32 26 0.02 (0.10) 0.19 25 2.76 (14.30) 0.19
MCID: NPI
Improved (–8.0) 98 0.08 (0.28) 0.27 90 0.01 (0.13) 0.04 79 6.44 (11.68) 0.55
No MCID ∆ 81 0.01 (0.25) 0.03 76 0.02 (0.10) 0.23 72 1.33 (10.70) 0.12
Deteriorated 34 0.06 (0.21) 0.30 29 0.02 (0.09) 0.26 28 2.79 (13.66) 0.20
Clinical ∆ CSDD
Improved (–30%) 120 0.07 (0.27) 0.26 111 0.02 (0.12) 0.16 102 5.57 (10.81) 0.52
No clinical ∆ 55 –0.02 (0.27) 0.09a 50 0.02 (0.11) 0.16 45 1.82 (12.06) 0.15
Deteriorated 12 0.06 (0.22) 0.29 9 0.00 (0.08) 0.00 7 –9.14 (10.56) 0.87a
Measure n
∆ CEQ-5D, 
mean (SD) SRM n
∆ DEMQOL-U-
Proxy, mean 
(SD) SRM n
∆ DEMQOL-
Proxy, mean 
(SD) SRM
MCID: MMSE
Improved (+1.4) 48 0.14 (0.29) 0.49 48 0.03 (0.08) 0.34 37 9.54 (11.37) 0.84
No MCID ∆ 66 0.01 (0.29) 0.03 64 0.03 (0.11) 0.26 54 7.85 (14.62) 0.54
Deteriorated 68 0.08 (0.27) 0.31 66 0.02 (0.10) 0.25 53 7.36 (13.61) 0.54
MCID: BADLS
Improved (–3.5) 16 0.25 (0.48) 0.52 14 0.04 (0.10) 0.41 12 12.83 (9.57) 1.34
No MCID ∆ 63 0.08 (0.30) 0.28 59 0.01 (0.09) 0.14 50 5.98 (14.22) 0.42
Deteriorated 35 –0.04 (0.29) 0.13a 35 0.02 (0.10) 0.23 28 6.32 (14.14) 0.45
MCID: NPI
Improved (–8.0) 114 0.13 (0.32) 0.41 112 0.03 (0.10) 0.35 90 11.31 (12.55) 0.90
No MCID ∆ 96 0.06 (0.26) 0.23 92 0.02 (0.09) 0.16 73 3.40 (13.13) 0.26
Deteriorated 38 –0.03 (0.30) 0.10a 36 0.02 (0.09) 0.19 30 2.00 (14.85) 0.13
Clinical ∆ CSDD
Improved (–30%) 132 0.11 (0.30) 0.36 128 0.02 (0.10) 0.25 106 8.49 (13.53) 0.63
No clinical ∆ 65 0.00 (0.25) 0.02 65 0.01 (0.08) 0.16 54 2.63 (13.55) 0.19
Deteriorated 11 –0.02 (0.40) 0.05a 10 0.03 (0.04) 0.84 7 5.43 (6.08) 0.89
a SRM value for decline in HRQL utility/score.
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TABLE 36 Mean change in HRQL utilities and scores by clinical change in MMSE, BADLS, NPI and CSDD (baseline to 
week 39)
Measure n
∆ EQ-5D, 
mean (SD) SRM n
∆ DEMQOL-U, 
mean (SD) SRM n
∆ DEMQOL, 
mean (SD) SRM
MCID: MMSE
Improved (+1.4) 23 0.02 (0.31) 0.05 23 0.06 (0.12) 0.51 22 5.27 (8.69) 0.61
No MCID ∆ 49 0.07 (0.22) 0.30 46 0.00 (0.12) 0.01 42 4.81 (9.68) 0.50
Deteriorated 71 0.07 (0.24) 0.27 67 –0.02 (0.14) 0.14a 63 4.30 (10.64) 0.40
MCID: BADLS
Improved (–3.5) 9 0.13 (0.41) 0.31 10 0.03 (0.05) 0.65 10 13.00 (8.89) 1.46
No MCID ∆ 34 0.07 (0.20) 0.35 32 –0.01 (0.14) 0.07a 26 5.23 (10.08) 0.52
Deteriorated 39 0.03 (0.22) 0.13 31 –0.02 (0.19) 0.09a 28 6.29 (11.01) 0.57
MCID: NPI
Improved (–8.0) 82 0.11 (0.23) 0.46 75 0.02 (0.13) 0.11 70 7.26 (11.45) 0.63
No MCID ∆ 62 0.01 (,18) 0.06 58 0.02 (0.14) 0.15 54 5.59 (8.60) 0.65
Deteriorated 27 0.02 (0.37) 0.06 25 –0.04 (0.12) 0.30a 23 0.09 (12.49) 0.01
Clinical ∆ CSDD
Improved (–30%) 94 0.07 (0.22) 0.32 85 0.02 (0.14) 0.18 81 7.43 (10.48) 0.71
No clinical ∆ 48 0.05 (0.28) 0.19 45 0.00 (0.14) 0.01a 40 0.90 (11.14) 0.08
Deteriorated 7 –0.12 (0.30) 0.41a 5 –0.07 (0.09) 0.85a 5 –4.00 (11.22) 0.36a
Measure n
∆ CEQ-5D, 
mean (SD) SRM n
∆ DEMQOL-U-
Proxy, mean 
(SD) SRM n
∆ DEMQOL-
Proxy, mean 
(SD) SRM
MCID: MMSE
Improved (+1.4) 26 0.05 (0.43) 0.11 25 0.07 (0.07) 0.92 23 6.30 (8.92) 0.71
No MCID ∆ 48 0.07 (0.27) 0.25 47 0.04 (0.11) 0.36 44 7.34 (17.73) 0.41
Deteriorated 73 0.05 (0.24) 0.21 68 0.02 (0.10) 0.24 54 7.65 (13.07) 0.58
MCID: BADLS
Improved (–3.5) 10 0.35 (0.40) 0.87 11 0.09 (0.08) 1.15 7 15.86 (13.75) 1.15
No MCID ∆ 38 0.08 (0.31) 0.27 36 0.02 (0.10) 0.19 32 7.22 (11.43) 0.63
Deteriorated 47 –0.07 (0.25) 0.27a 43 0.03 (0.10) 0.32 36 3.78 (16.05) 0.24
MCID: NPI
Improved (–8.0) 108 0.09 (0.33) 0.28 105 0.03 (0.11) 0.31 84 12.08 (14.43) 0.84
No MCID ∆ 66 –0.01 (0.24) 0.03a 67 0.01 (0.11) 0.06 59 4.36 (14.14) 0.31
Deteriorated 33 –0.01 (0.40) 0.02a 29 0.08 (0.12) 0.67 23 2.39 (13.07) 0.18
Clinical ∆ CSDD
Improved (–30%) 107 0.09 (0.27) 0.33 107 0.03 (0.11) 0.25 91 9.23 (13.22) 0.70
No clinical ∆ 56 –0.03 (0.34) 0.10a 53 0.02 (0.09) 0.23 45 7.18 (14.02) 0.51
Deteriorated 11 –0.08 (0.35) 0.23a 11 0.08 (0.11) 0.72 10 –2.10 (17.89) 0.12a
a SRM value for decline in HRQL utility/score.
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sensitivity to improvement, both the EQ-5D and DEMQOL-U display evidence of responsiveness, but at a 
lower level than the original DEMQOL measure.
For proxy report, the CEQ-5D responds to deterioration in daily activities, behavioural disturbances and 
depression in the small effect size range, but DEMQOL-Proxy-U does not. This effect is maintained at 
39 weeks when, again, the DEMQOL-Proxy-U does not respond to health deterioration. Both measures 
respond to health improvements, with SRMs in the small to moderate range. The original DEMQOL-Proxy 
proved to be more responsive than CEQ-5D and DEMQOL-Proxy-U.
Discussion
In this chapter we have documented initial evidence regarding the acceptability, validity, patient/carer 
agreement and responsiveness of the DEMQOL-U and DEMQOL-Proxy-U dementia-specific preference-
based HRQL measurement system (DEMQOL-U and DEMQOL-Proxy-U) and the EQ-5D generic preference-
based measure in comparison with external indicators of dementia-related health status and the original 
DEMQOL and DEMQOL-Proxy. We also assessed agreement between the preference-based instruments 
and found that overall there is a good level of agreement and that the majority of the disagreement 
between the measures occurs at the more severe end of the utility scale. There is some evidence for the 
acceptability of the DEMQOL system, in particular the DEMQOL-Proxy-U, which displays low missing data 
rates. However, missing data rates are lower for the EQ-5D. There is less evidence regarding the convergent 
validity of DEMQOL-U and DEMQOL-Proxy-U in comparison with other measures of cognition, depression 
and activity level in dementia. DEMQOL-U displays a higher level of known-group validity between 
cognition and depression severity groups than DEMQOL-Proxy-U, but the effect sizes are in the low range 
and there are differences from the discriminative ability of the patient- and carer-reported EQ-5D. There 
is no clear pattern regarding agreement between patients and carers. In terms of responsiveness, there 
is evidence that the DEMQOL utility measures and EQ-5D are less sensitive to change than the original 
DEMQOL and DEMQOL-Proxy.
The patient- and carer-reported EQ-5D have lower missing data rates than DEMQOL-U and DEMQOL-
Proxy-U respectively. This may indicate that the EQ-5D is more acceptable to respondents. However, the 
differences in missing data rates are not large and may be expected because of the size of the instruments 
(EQ-5D includes five items whereas DEMQOL and DEMQOL-Proxy, which are used to generate the utility 
values, include 29 and 32 items respectively). Therefore, it is more likely that data will be missing from the 
DEMQOL utility measures.
DEMQOL-U displays a lower level of agreement with the patient-reported EQ-5D than DEMQOL-Proxy-U 
does with the CEQ-5D, and this may be because carers are more likely to report stable responses than 
people with dementia in terms of the general level of severity reported. However, for both pairs the 
majority of the scores fall within the 95% agreement range, indicating a good level of agreement. The 
majority of the disagreement occurs when the mean utility value is at the more severe end of the scale 
(where DEMQOL utility measure scores are substantially higher than EQ-5D/CEQ-5D scores). This may be 
due to differences in the classification systems, which may be sensitive to different HRQL issues, and also 
to large differences in the possible utility scale range.
Exploring the distribution of the utility values of each measure revealed that DEMQOL-U and DEMQOL-
Proxy-U utility values tend to be higher than EQ-5D values for poorer health states. This may be expected 
as the lowest possible EQ-5D utility score is –0.594 whereas the lowest possible utility scores for 
DEMQOL-U and DEMQOL-Proxy-U are 0.243 and 0.363 respectively. Similarly, EQ-5D utility values tend 
to be higher than DEMQOL-U and DEMQOL-Proxy-U values for better health states. The EQ-5D had high 
ceiling effects and therefore may not be sensitive to mild HRQL impairment in patients with better health 
states. This is also consistent with the considerable variation observed in DEMQOL-U and DEMQOL-Proxy-U 
utility values, which suggests that patients with full health on EQ-5D may be experiencing varying levels 
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of impaired HRQL. A likely reason for the ceiling effects observed in the EQ-5D is that there are three 
levels of responses for each dimension, which may result in insensitivity for detecting small differences in 
health states.94
As carer report may be a necessary substitute for self-report among people with dementia, a utility 
measure that allows for good agreement between the carer and the patient perspective would be 
preferred. Results regarding the agreement between patients and carers across the DEMQOL utility 
measures and patient- and carer-reported EQ-5D are mixed. There is a higher level of patient/carer 
agreement between the EQ-5D and the CEQ-5D at each time point, and more agreement between 
the ratings at baseline; however, DEMQOL-U and DEMQOL-Proxy-U ratings display more agreement at 
follow-up. However, overall, the agreement as measured using ICC values is low for both measures. As the 
dimensions included in the EQ-5D are matched across the patient and carer versions, it might be expected 
that the EQ-5D displays a higher level of agreement between ratings than the DEMQOL measures, for 
which the dimensions and questions used vary. However, it is well established that dementia patients and 
proxies give different reports,14,68 and therefore agreement level cannot be seen as a clear indicator of the 
performance of the measures. Further work in this area could investigate the pattern of agreement further, 
and this could be done by investigating agreement at different dementia severity levels, both for the 
DEMQOL utility measures and the EQ-5D.
We psychometrically assessed the convergent and known-group validity of DEMQOL-U and DEMQOL-
Proxy-U. DEMQOL-U displayed a moderate correlation with the CSDD (at a higher level than the EQ-5D 
and DEMQOL), suggesting some convergence in terms of measurement of depression related to dementia. 
However, correlations between DEMQOL-U and the EQ-5D and the indicators of cognition, daily activities 
and behavioural disturbances are low. The correlations between the CEQ-5D and the external condition-
specific indicators (which are low to moderate) are higher than the DEMQOL-Proxy-U correlations (which 
are low).
There is no clear pattern to the convergent validity results, which makes interpretation difficult. It could 
be argued that the lack of convergence for the patient measures is due to differences in the focus of the 
classification systems in terms of both the dimensions included and the dimensions omitted. However, 
the EQ-5D has dimensions directly assessing depression and daily activities and DEMQOL-U includes 
a cognition dimension and so better correlations may be expected. Further analysis should investigate 
relationships between the measures at the dimension level and also investigate convergence using a range 
of other indicators. The CEQ-5D correlations are higher, particularly with the other measures completed by 
carers, and this may mean that patient report in dementia is unreliable and unstable across assessments.
There is also no clear pattern to the known-group validity of the DEMQOL utility measures or the EQ-5D 
across cognitive impairment and depression severity groups. Overall, DEMQOL-U performs better than 
DEMQOL-Proxy-U, but the CEQ-5D performs better than the EQ-5D. This may be because the DEMQOL-U 
descriptive system generates more health states than DEMQOL-Proxy-U and so therefore has more 
discriminative ability. The better performance of the CEQ-5D may be due to the more stable nature of 
proxy report in dementia.
For the patient utility measures across the cognitive impairment and depression severity groups (excluding 
the definite depression group for which the sample size is low), the effect sizes are in the small to 
moderate range. The magnitude of the change is similar, but the DEMQOL-U effect sizes are larger 
because the SD of the EQ-5D scores is larger because of differences in utility score range. This means that, 
in trials, the DEMQOL utility values can be estimated with more precision. This has also been found for 
other condition-specific preference-based measures in comparison with the EQ-5D.37
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In terms of carer report, the CEQ-5D is more sensitive to differences across cognition severity groups than 
DEMQOL-Proxy-U. However, both measures display effect sizes in a similar range for depression severity. 
Again, there is no clear pattern and further research could investigate the discriminative ability of the 
DEMQOL utility measures using a range of further indicators. Furthermore, more work needs to be carried 
out on the discriminative ability of the measures among those with severe problems, as the sample size 
used in this study is too small to draw any conclusions.
Although the DEMQOL utility instruments and the EQ-5D respond to improvements in health status over 
time, this is not at the same level as with the original DEMQOL and DEMQOL-Proxy. DEMQOL-U was 
sensitive to deterioration at a higher level than DEMQOL-Proxy-U. The reasons for these differences in 
results are not clear and more research is required to assess responsiveness in more detail using a range of 
indicators and different data sets.
For the psychometric analysis reported above we used the utility values derived from the general 
population, and this allows for a level of comparability with the EQ-5D value set, which was also derived 
from the general population. However, the difference between the general population and patient/carer 
valuations of DEMQOL-U and DEMQOL-Proxy-U health states reported in Chapter 6 suggests that a full 
valuation study with patients and carers would produce a substantially different utility scale. If a full 
valuation study was to be carried out it would be important to investigate the psychometric performance 
of the patient- and carer-derived utility scales in comparison with both the general population values and 
external dementia-related indicators. It was not possible to compare the valuations produced in Chapter 5 
as only mean TTO values were produced.
It is important to note that the psychometric performance of the DEMQOL utility measures may be 
impacted by the HTA-SADD sample used (in which the focus was on depression). DEMQOL-U and 
DEMQOL-Proxy-U are designed specifically for dementia and therefore further testing on other dementia 
samples is recommended. Furthermore, this analysis has focused on the psychometric properties of 
each measure and has not combined the utility values with duration to produce QALY estimates. Further 
comparative research using QALY estimates is also recommended.
Conclusions
Health outcomes in economic evaluation are often measured using a composite measure of both quality 
and length of life – the QALY. This composite measure can be used in health policy decision-making to 
compare the efficiency of different treatment strategies. For utilities (such as those derived here) to be 
of any value for decision-makers, they must be included in a QALY measure that also considers length 
of life. The analysis described above presents some early evidence of the level of validity, patient/carer 
agreement level and responsiveness of the DEMQOL utility measures in comparison with the widely used 
generic preference-based measure EQ-5D. The results suggest that both the EQ-5D and the DEMQOL 
utility instruments have advantages and disadvantages over each over, but the pattern is unclear. Further 
research investigating the complex psychometric performance of the measures is required using different 
data sets incorporating a range of clinical indicators and dementia severity levels. We originally planned 
to carry out the analysis described above on a second data set but these data did not become available 
during the study period. Until further results are available we would recommend using both the EQ-5D 
and the DEMQOL utility measures alongside each other in dementia studies to allow for both generic and 
condition-specific utilities to be generated.
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Chapter 8 Conclusions
This report has detailed the development and application of two dementia-specific preference-based measures, one for self-completion (DEMQOL-U) and the other to be completed by carers (DEMQOL-
Proxy-U). These measures can be used to generate health-state utility values on the QALY scale for use 
in economic evaluation of interventions in this group of patients. These are the first condition-specific 
preference-based measures in dementia. The results of the psychometric analysis presented in this report 
are encouraging but there are a number of concerns regarding the validity and responsiveness of the 
instruments that require further investigation. Therefore, before more evidence is available we would 
recommend that the DEMQOL instruments are used alongside a generic measure such as the EQ-5D in 
future evaluations of interventions for dementia.
A detailed discussion of each part of the study is provided in each chapter, which covers specific concerns 
over the methods used and the main findings and their implications. In this final chapter we review and 
summarise our findings and check these against the study aims to determine the extent to which these 
aims have been met. This chapter also provides an overview of the implications of the work for economic 
evaluation and for future research.
The following sections show that we have been able to deliver on all four major aims.
To derive health-state classification systems from DEMQOL and 
DEMQOL-Proxy that can be used to categorise all patients with 
responses to the measures
This project has used an established multistage process to guide the derivation of preference-based 
measures from the DEMQOL instruments. The first stage was to identify the dimensions to be used in 
the health-state classification using factor analysis as a guide to the dimensionality. We chose to use 
exploratory analysis because of the inconclusive nature of the earlier factor analysis of the DEMQOL system 
(in comparison with the original conceptual framework), which means that we did not have an a priori 
structure to confirm. However, the factor structures established here provide some support for the original 
conceptual framework. The factor structures are robust enough to provide the basis for the development 
of dementia-specific health-state classification systems: a five-dimensional structure was found for both 
DEMQOL and DEMQOL-Proxy.
We then used Rasch analyses to select an item to represent each factor. Using stringent criteria to 
investigate item performance we were able to select one item for each of the five DEMQOL domains 
and one item for four of the DEMQOL-Proxy domains (one domain was dropped as none of the items 
performed at an acceptable level in the Rasch analysis). Each dimension has four-level responses 
corresponding to the response choices for the items in the original DEMQOL instruments. These new 
instruments were named DEMQOL-U (which produces a possible 1024 health states) and DEMQOL-
Proxy-U (which produces 256 possible states). These health-state classifications generate health states that 
are amenable to valuation and the subsequent generation of dementia-specific QALYs.
To generate utility values for every health state defined by the 
health-state classification systems derived from DEMQOL and 
DEMQOL-Proxy
Interviews were successfully conducted with a representative sample of 593 members of the general 
population who were able to complete the rank and TTO tasks and provide valuations of a sample of 
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health states generated by DEMQOL-U and DEMQOL-Proxy-U. The TTO valuations were modelled to 
estimate two preference-based algorithms, one each for DEMQOL-U and DEMQOL-Proxy-U. This means 
that utility values can be estimated for all 1024 DEMQOL-U health states and all 256 DEMQOL-Proxy-U 
health states. We applied a range of models to the TTO and rank data and selected the TTO model that 
fitted best overall, with the highest number of significant variables and best-fit statistics. The models fitted 
to the data performed favourably compared with similar models estimated for other preference-based 
measures in terms of fit, prediction and the consistency of the coefficients with the descriptive system. The 
DEMQOL-U model did not have any inconsistent variables (in which a decrease in health status leads to an 
increase in utility) and DEMQOL-Proxy-U had just one. The modelling process means that it is now possible 
to generate health-state utility values from any data set in which one or both of DEMQOL and DEMQOL-
Proxy have been completed.
To examine whether or not utility values elicited from the 
general population differ from utility values elicited from 
patients and carers for dementia health states generated by 
the classification systems
We interviewed a sample of 71 people with mild dementia and 71 family carers. They were able to 
complete the TTO task and assign values to a limited number of the health states generated from the new 
instruments. This is the first time that the values of dementia health states from the general population 
have been compared with patient and carer values in this way. The main finding was that the values 
obtained from people with dementia and carers were systematically different from those obtained from 
the general public. The general public tended to undervalue the impact of dementia compared with 
people with dementia and carers. This finding is in contrast to the general finding in the literature – that 
patients tend to give higher values than the general public, at least for physical health conditions.79 Patient 
values are thought to be higher because of processes related to adaptating to the condition. In mental 
health the opposite has been observed, and this may reflect an inability of the general population to 
understand the consequences for quality of life of problems associated with mental disorders compared 
with physical health.82 This finding may reflect a similar inability to understand the consequences of the 
syndrome of dementia, even though they are described in everyday terms.
It is not possible to model the pattern of the difference between patients and carers and the general 
population. Too few states were valued to estimate specific algorithms for patients and carers, as the aim 
of this part of the project was only to test the hypothesis that there are differences. However, it was also 
observed that there were differences in the ordering of states, which suggests that there may well be 
differences in the relative weight being given to different dimensions. This requires further investigation.
These results suggest that the population used to produce dementia health-state utility values could 
impact on the results of cost-effectiveness analysis and potentially affect resource allocation decisions.
To examine the psychometric performance of the dementia-
specific preference-based measures using trial data
Finally, we tested the new measures using a data set from a recently completed trial. In comparing the 
psychometric performance of DEMQOL-U and DEMQOL-U-Proxy with that of their non-preference-based 
as well as generic preference-based counterparts, this report documents the first early evidence of validity 
and responsiveness of a condition-specific preference-based measure for people with dementia. We also 
assessed the utility measures in comparison with clinically based measures. However, these measures may 
be indirectly related to many of the dimensions covered by the DEMQOL utility instruments and the EQ-5D 
and further research should test the measures using a range of clinical indicators.
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The DEMQOL utility instruments and the EQ-5D have advantages and disadvantages over each other in 
terms of psychometric performance; however, the pattern is unclear. There is evidence for the acceptability 
of the DEMQOL system but missing data rates are higher than for EQ-5D. EQ-5D displays high ceiling 
effects and therefore may not be as sensitive as the DEMQOL utility measures to mild HRQL impairment in 
patients with better health states.
There is a good level of agreement between the preference-based instruments. The majority of the 
disagreement between the measures occurs at the more severe end of the utility scale. This may be linked 
to differences in the dimensions described by the classification system, which may be sensitive to different 
HRQL issues, and also to large differences in the possible utility scale range. In terms of agreement 
between patients and carers we found that carer report was more stable. In dementia, carer report is often 
essential and therefore a utility measure that allows for good agreement between the carer and the patient 
perspective is important.
There is no clear pattern to the convergent validity results. Correlations between DEMQOL-U and the 
EQ-5D and the external indicators are low. However, DEMQOL-U displays some convergence in terms 
of measurement of depression related to dementia. The correlations between the CEQ-5D and the 
external indicators are higher than the DEMQOL-Proxy-U correlations. It could be argued that the lack of 
convergence for the patient measures is due to differences in the focus of the classification systems in 
comparison with the external indicators. Assessment against a wider range of indicators is required.
DEMQOL-U discriminates better than DEMQOL-Proxy-U but the CEQ-5D discriminates better than 
the EQ-5D. This may be linked to classification system differences in that DEMQOL-U generates more 
health states than DEMQOL-Proxy-U and so has increased discriminative ability. The better performance 
of the CEQ-5D may be linked to the more stable nature of proxy report in dementia across matched 
classification systems.
In terms of responsiveness, there is evidence that the DEMQOL utility measures and the EQ-5D are less 
sensitive to change than the original DEMQOL and DEMQOL-Proxy. The reasons for these differences are 
not clear and responsiveness needs to be assessed in more detail using a range of indicators and different 
dementia-specific data sets.
The psychometric performance of the DEMQOL utility measures may be impacted by the sample used, 
which focused on depression. The inconclusive nature of the results means that further testing on a range 
of samples is required.
Limitations of the study
There are a number of limitations in the development process and testing of the DEMQOL utility measures 
that currently limit the use of the instruments.
The first limitation relates to the lack of an external data set to validate the DEMQOL-U and DEMQOL-
Proxy-U classification systems. This is an important step in the process of deriving a condition-specific 
preference based measure from an existing measure but is reliant on the data available to developers. In 
this study, no external DEMQOL or DEMQOL-Proxy data were available to validate the system, and the 
HTA-SADD data were available only towards the end of the study when the psychometric validation stage 
of the project had been completed and the valuation phase had commenced. It is also possible to use a 
split-half approach to validation in which a subsample of the development data are used. However, the 
optimum sample size for Rasch analysis is 500 and splitting the sample used in this study into two would 
result in data sets that are too small for the task. This problem is made worse for those factors with a small 
number of items, as the Rasch programme excludes extreme scores within the dimension (i.e. respondents 
at the floor or ceiling), resulting in a smaller sample size.
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Throughout the development process we have made decisions about which methodology to use. There 
are other valid techniques that could have been used and it is possible to criticise the choices that we 
have made. First, it is possible to criticise the use of EFA to investigate the dimensional structure of the 
instruments, and this study may be limited by not investigating a wider range of possible methods for 
deriving a dimensional structure. We used EFA as the earlier factor analysis of the DEMQOL system was 
inconclusive and so we were not confirming an existing structure. However, EFA may not be as robust as 
CFA and it may have benefited the development process to also study some CFA models.
The health-state classification systems that we have derived are a result of the original measure and the 
sample and analysis techniques used. It is possible that the use of a mild to moderate dementia sample 
has resulted in classification systems describing a comparatively mild conceptualisation of dementia. This 
is supported by the results of the valuation study. However, we used the mild to moderate sample as 
DEMQOL has been validated for use in this group, and it was decided to use a matched sample in terms of 
severity for DEMQOL-Proxy. It is also possible that the resultant classification systems are missing important 
dimensions, in particular daily activity limitations (this did not appear as a dimension in DEMQOL-U 
and was excluded from DEMQOL-Proxy-U because of poorly performing items). However, it should also 
be noted that the lack of association between dementia-related HRQL and activity limitations has been 
found elsewhere.20
Another concern might be the absence of the direct involvement of patients and their carers in the 
development of the health-state classifications. The process benefited from the results of in-depth 
interviews with patients and their carers, a detailed psychometric analysis of patient- and carer-reported 
outcomes and the expertise of clinicians working with patients on a daily basis. However, the process of 
selection might have been further improved with more direct patient involvement in the decisions and this 
is something to consider in any further qualitative work that might be undertaken with the measure (see 
Recommendations for future research).
In the original proposal it was suggested that health-state utility values could also be derived using 
ranking and a further DCE study. The field has developed since the time that this study was designed and 
the proposed methods of estimating values on the 0–1 scale required for calculating QALYs have been 
superseded.95 Although we have conducted the analysis of the rank data collected in the valuation study, it 
was decided not to send respondents an additional postal survey given that the results would not be used 
to inform policy as the TTO results provide greater comparability with the EQ-5D and other measures.
Conclusions for evaluation in dementia
We would recommend that those designing trials and studies on dementia consider the use of DEMQOL-U 
and DEMQOL-Proxy-U. However, to clarify the nature and extent of the advantages and disadvantages 
of the new preference-based measures developed here we need further research into the psychometric 
performance and acceptability of the instruments. Ongoing and future trials and studies using the 
DEMQOL system will allow for further analyses to be carried out comparing the output of the generic 
measures with the general population utility values derived from DEMQOL-U and DEMQOL-Proxy-U.
More generally there are important issues surrounding whether or not QALYs estimated from condition-
specific preference-based measures can be used to inform resource allocation across programmes. This 
issue has been examined in detail in a recent HTA report reviewing the development of preference-based 
measures from existing condition-specific measures.37 Policy-makers must weigh the potential gains 
in terms of greater relevance and sensitivity to the condition from using a particular condition-specific 
preference-based measure with the reduction in comparability. Condition-specific preference-based 
measures have a number of potential disadvantages including missing side effects of treatment and the 
impact of comorbidities (where their effect is not additive). There are also concerns that the values for the 
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condition-specific states are subject to focusing effects from respondents failing to take into account their 
overall health.
Currently there is not enough evidence to be able to determine the likely benefits of using the DEMQOL-U 
and DEMQOL-Proxy-U measures compared with using the EQ-5D or other generic measures. At this stage 
it is not possible to recommend that they are used in place of the EQ-5D. We recommend that they are 
used together with the EQ-5D (or other generic measures depending on jurisdiction) in future studies to 
ensure that the needs of policy-makers can be met. This will also provide further evidence for testing these 
new instruments and examining their impact on the cost-effectiveness of interventions.
Recommendations for future research
1. The selection of dimensions and items in DEMQOL-U and DEMQOL-PROXY-U from the original 
instruments needs to be validated in another data set. The lack of validation is a limitation of the 
DEMQOL utility measures and we would aim to carry out this process when relevant data become 
available. This would complete stage IV of the six-step process and provide more evidence regarding 
the stability and robustness of the classification systems.
2. Further evaluation of DEMQOL-U and DEMQOL-Proxy-U compared with generic preference-based 
measures such as the EQ-5D, other relevant dementia-specific indicators and the original DEMQOL 
system should be carried out. The initial psychometric validation reported here is inconclusive, with 
evidence both for and against the validity and responsiveness of the DEMQOL utility measures, and 
agreement between preference-based measures and self- and carer report. Therefore, there is a 
need to expand the analyses completed for the HTA-SADD trial to other trials and evaluations that 
have used the DEMQOL system using a range of other relevant indicators. This will provide further 
evidence regarding the psychometric performance of the utility measures, and the samples in which 
the measures perform best. Further psychometric analysis will allow policy-makers to understand 
the implications of using these new dementia-specific preference-based measures to estimate QALYs 
compared with EQ-5D in cost-effectiveness analyses of new interventions.
3. We have shown that it is feasible to obtain health-state values from people with dementia and carers 
and that the valuations differ from those provided by the general population. A future study is needed 
to value a sufficient number of health states to estimate patient and carer preference weights for all 
states defined by the classification system so that economic evaluations can be conducted using both 
patient and carer and general population utility weights. This will inform an important policy debate 
about the consequences of using patient or carer values rather than those of the general population.
4. When there are data sets that share the use of the EQ-5D and DEMQOL and the proxy versions, 
these should be pooled to allow for further analysis of the system. Studies are ongoing that include 
the DEMQOL system and the EQ-5D and these data may become available to the authors for 
further analysis.
5. One potential area for future research is to investigate the acceptability and validity of the classification 
systems qualitatively with dementia patients and their carers.
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Appendix 1 Time trade-off process
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Appendix 2 Protocol
GENERATION OF PREFERENCE-BASED INDICES FROM DEMQOL AND DEMQOL-PROXY FOR 
USE IN ECONOMIC EVALUATION
DETAILED PROJECT DESCRIPTION
1.0 Background
1.1 The challenge of dementia
Dementia is one of the most common and serious disorders in later life with a prevalence of 5% and an 
incidence of 2% per year in the over 65s (Hofman et al 1991; Launer et al 1992) equating to 700,000 
people with dementia at any one time (Knapp et al 2007) and 200,000 new cases every year in the UK.  It 
causes irreversible decline in global intellectual, social and physical functioning. Abnormalities in behaviour, 
insight and judgement are part of the disorder, as are neuropsychiatric symptoms such as psychosis, 
anxiety and depression. The economic cost of caring for people with dementia is immense. In the UK the 
costs of dementia are around £17 billion (Knapp et al 2007), greater than stroke (£3 billion), heart disease 
(£4 billion) and cancer (£2 billion) (Lowin et al 2001). We can also predict that the challenges posed by 
dementia will only grow in the next decades. In the next 30 years the number of people with dementia 
in the UK will double to 1.4 million (Knapp et al 2007) and the costs will treble, with the growth in costs 
faster than the costs of caring for an ageing population more generally (Comas-Herrera et al 2007). 
More importantly, the negative impacts of dementia on those with the disorder, in terms of deteriorating 
function, and on carers (Murray et al 1999; Schneider et al 1999) are profound. The need to improve care 
for people with dementia is a policy priority (DH 2001, 2005; NAO 2007).
1.2 Evaluation of clinical effectiveness in dementia
Given its importance in public health terms and its devastating effects, it is understandable that there 
is a large and growing volume of basic, translational, and applied research underway. This includes 
evaluations of psychological and social interventions as well as trials of pharmacological treatments. 
Given the complexity of dementia, there has been discussion about how best to measure the effects 
of interventions in dementia. There is an emerging consensus that we need to measure broad patient-
reported outcomes such as health-related quality of life (HRQL) in dementia as well as discrete areas like 
cognition or behaviour (Whitehouse 2000). The technologies for measuring discrete areas of function 
are well developed with a variety of psychometric robust instruments available for evaluating all major 
domains (eg cognition, behaviour, activities of daily living, depression) often using proxy reports of 
observable behaviour.
Measuring HRQL in dementia is more challenging, not least because of poor recall, time perception, 
insight and communication. However, recent studies indicate that meaningful measurements can be made 
using disease-specific measures, based on self- and proxy-report (Brod et al 1999, Logsdon et al 2002, 
Smith et al 2005, 2007).
Funded by the HTA we have developed the DEMQOL system, a disease-specific measure of HRQL in 
dementia (Smith et al 2005; 2007). The DEMQOL system consists of two interviewer-administered tools: 
DEMQOL (28 items) is completed by the person with dementia (score range 28 to 112; higher scores 
indicate better HRQL); and DEMQOL-Proxy (31 items) a proxy report of the person with dementia’s HRQL 
completed by the main carer (score range 31 to 124; higher scores indicate better HRQL). The system 
was designed according to best psychometric practice and has undergone extensive validation in the UK. 
NIHR Journals Library
APPENDIX 2
116
DEMQOL has good psychometric properties for people with mild to moderate dementia (defined as a 
MMSE score of 10+). DEMQOL-Proxy can be used across disease severity from mild to severe.
The development of such instruments has lagged behind the measures of discrete function. So they 
have not yet been widely employed in randomised controlled trials (RCTs) of anti-dementia medication 
(ADM) and other treatments as have measures of discrete areas of function, most commonly cognition. 
We have analysed associations between commonly used measures of specific outcomes in dementia and 
HRQL (Banerjee et al 2006). The data suggest that HRQL in dementia does not have a simple relationship 
with cognition or functional limitation. This and other studies (Woods et al 2006) suggest that cognitive 
impairment is an inadequate proxy for HRQL improvement in dementia. They suggest that there may 
be considerable value in including measures of HRQL along with measures of specific function such as 
cognition and behaviour in treatment trials in dementia. A failure to include broad outcome measures 
such as HRQL, and a reliance on measures of discrete functions (eg cognition), could lead to the positive 
effects of interventions being overlooked or to potential negative effects of intervention being missed 
(Banerjee 2007).
1.3 Economic evaluation in dementia
Things are not quite so clear for the economic evaluation of treatments in dementia. Even though we can 
be relatively confident on data on the clinical effectiveness of treatments for dementia, there is a real lack 
of directly relevant data with which to ascertain the cost-effectiveness of treatments. The last decade has 
seen the increased use of economics to inform the allocation of resources between competing health care 
interventions around the world and particularly the use of cost-effectiveness analysis, where interventions 
are assessed in terms of their cost per Quality-Adjusted Life Year (QALY) gained. The QALY provides a way 
of measuring the benefits of health care interventions, including improvements in HRQL. Brief generic 
(ie not disease-specific) measures of HRQL are most commonly used to put the ‘Q’ into the QALY. Such 
measures include the EQ-5D (Brook, 1996) and other generic preference-based measures such as SF-6D 
(Brazier et al, 2002). It is suggested that these generic measures are applicable to all interventions and 
patient groups, a claim that has some support in some conditions, such as rheumatoid arthritis where 
it has managed to pass conventional psychometric tests of reliability and validity (eg Marra et al, 2006), 
but is more questionable in others, such as visual impairment (Espallargues et al, 2006) and hearing loss 
(Barton et al, 2004).
Such brief generic measures of HRQL do not work well in dementia. As noted above the inherent 
impairments in dementia of recall, time perception, insight and expressive and receptive communication, 
mean that it is not possible to assume that what works for a general non-cognitively impaired population 
will work in those with dementia. This means that instruments to be used in dementia need to be 
psychometrically tested in populations of people with dementia. In fact, where self or proxy report is 
needed, this generally means that disease-specific measures need to be generated which can measure 
accurately in dementia whatever attribute is under consideration. Brief generic measures of HRQL have 
been tested in dementia and there is data that these can be completed by people with dementia (Jonsson 
et al, 2006; Coucill et al, 2001; Naglie et al, 2006), the questions revolve around the validity of the 
data generated. There are questions about how patient insight into cognitive impairments and activity 
limitations affect preference ratings (Vogel et al, 2006). Equally the instruments used have limits in the 
validation available data especially with respect to the complex co-morbidities found in dementia. The 
EQ5D has been reported to have more correlations than the HUI3 but limitations were observed for both 
instruments, with for example 43% to 57% of people with dementia rating themselves as having perfect 
health (Naglie et al, 2006). The likelihood that such instruments may well not capture the impact of 
dementia is raised by their not specifically having been developed for use in this population and the fact 
that the HUI2 includes a single item on cognition and the EQ-5D none.
In practical terms, the unsatisfactory nature of the current evidence base is very clearly illustrated by the 
major difficulties presented to the National Institute for Health and Clinical Excellence (NICE) in generating 
their recent (2006) Technology Appraisal Guidance (TAG111). There has been a great deal of concern 
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raised (including referral to Judicial Review) about the assumptions they had to make with respect to their 
cost-effectiveness models. The challenges encountered can be attributed to a lack of direct data on cost 
and quality of life. The conclusions of TAG111 make clear the need for a technology that can be used in 
dementia trials to generate direct and accurate measurements of cost and effectiveness in quality-of-life 
terms. This conclusion is echoed in systematic reviews and trials in dementia (AD2000 2004, Loveman et al 
2006; Takeda et al 2006).
What then is needed to enable cost-effectiveness evaluation in dementia? If the use of the brief generic 
measures is problematic due to the error inherent in their use, might it be possible to use instruments that 
can measure HRQL in dementia such as the QOL-AD or DEMQOL and DEMQOL-proxy? These instruments 
essentially cannot be used in cost–utility evaluations directly in their current form because they are too 
large to incorporate preference information. They therefore cannot be used to calculate QALYs for use in 
incremental cost-effectiveness analysis.  This is a major limitation in the current available measurement 
technology. However the methodology is available to allow the benefits of the DEMQOL system in being 
able to measure HRQL in dementia accurately to be applied to valuing the benefits of interventions in 
this area in economic evaluation. This study therefore aims to generate a preference-based single index 
for these two instruments (DEMQOL and DEMQOL-Proxy) for use in economic evaluation using general 
population and patient/carer values.
2.0 Method
2.1 Overview of the plan of investigation
To derive preference-based single index measures from the two DEMQOL instruments, we propose to 
apply the methods that have been developed by one of the applicants (JB) in Sheffield. These methods 
have been applied with success to the SF-36 (Brazier 1998, 2002), the King’s Health Questionnaire (Brazier 
et al 2007), the Asthma Quality of Life Questionnaire (AQLQ – Yang et al 2006b), and the Over Active 
Bladder Questionnaire (OABq – Yang et al 2006a). The problem with deriving preference-based measures 
from such measures of HRQL is that they are simply too large. With multiple dimensions and numerous 
items they would define many millions of potential health states and produce health states too large for 
valuation by respondents.  
The first stage in this type of work is therefore to fashion a health-state classification (like the EQ-5D in 
structure) by sampling items from the original instruments using conventional and advanced psychometric 
methods. We will use existing data sets in which DEMQOL and DEMQOL-Proxy have been used. The 
overall aim will be to develop two brief health-state classifications, one from DEMQOL and one from 
DEMQOL-Proxy. These will be used to generate health states for valuation. They will consist of existing 
items from DEMQOL and DEMQOL-Proxy respectively, and so can be derived from any study using the 
existing DEMQOL and DEMQOL-Proxy instruments. They will be known as DEMQOL-nD and DEMQOL-
Proxy-nD (where n is the number of items in the shortened measure). Consensus from organisations such 
as NICE around the world require HRQL to be valued using a choice-based technique. We have selected a 
time trade-off technique (TTO) for this study, where respondents are asked how many years they would 
be willing to sacrifice in order to be in full health. TTO was selected over standard gamble, since the 
latter asks respondents to consider how much they are willing to risk their life; given that dementia is 
predominantly a disorder of later life TTO seemed a more appropriate line of questioning. We propose 
to use the TTO version developed in York for the EQ-5D since this will allow comparison with the EQ-5D 
population value set used by NICE. In addition we propose to use two ordinal methods for valuation, 
ranking and a discrete choice experiment (DCE).
The question of whose values should be used to value health is ultimately political and beyond the scope 
of this proposal (Brazier et al 2007). We propose that the main valuation survey in this study should 
use a representative sample of the general public to conform to the requirements of NICE and other 
reimbursement authorities. However there are active issues in whether this is the right group given the 
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nature of the disorder and the state of public attitudes and understandings of dementia. We therefore 
also propose to complete a supplementary valuation survey of people with dementia and their carers in 
order to explore the size and direction of any deviation from the general public’s values. In preparing this 
proposal we have engaged in conversation with the Alzheimer’s Society through its Quality Research in 
Dementia (QRD). They are clear that they would wish the values of people with dementia and their family 
carers to be directly investigated as part of this research.
Data from the general population survey will be modelled to estimate preference-based scoring algorithms 
that can be applied to existing and future DEMQOL and DEMQOL-Proxy data. The final phase of the study 
will be to apply these algorithms to two trial data sets that are underway (HTA-SADD, a placebo-controlled 
RCT of the treatment of depression in dementia, Chief Investigator (CI) SB; and MRC-DOMINO, a placebo-
controlled RCT of donepezil and memantine alone and in combination for the treatment of those where 
treatment response is questioned, CI RH) to estimate QALYs directly. In each case, the trial proposal agreed 
by the funding body explicitly noted our intention to explore the possibility of generating QALY measures 
to run alongside the disease-specific outcome measures. MK is responsible for the economic evaluation 
in both HTA-SADD and MRC-DOMINO. We will also test the psychometric properties of the indices; 
and compare the results of using the two DEMQOL indices, the EQ-5D, and population and patient/
carer valuations.
The project divides itself into five linked phases. These are:
 z derivation of the health-state classification 
 z main population valuation survey 
 z patient/carer valuation survey 
 z modelling, and
 z application to trial data
2.2 Phase 1: Derivation of health states from DEMQOL and DEMQOL-Proxy
The first task is to derive two health-state classifications, one from DEMQOL and the other from the 
DEMQOL-Proxy.  To accomplish this, extensive psychometric analyses will be undertaken to: i) confirm 
the dimensional structure of the measures, and (ii) select items from each domain to construct the 
health-state classifications.
2.2.1 Dimensional structure 
The conceptual framework which guided the development of the DEMQOL instruments covers five 
domains (daily activities, health and well-being, cognitive functioning, social relationships, self-concept). 
In our initial validation study (Smith et al 2005, 2007) factor analyses identified a 4-factor model for 
DEMQOL and a 2-factor model for DEMQOL-Proxy. The first stage in this proposed research will be to 
investigate further the factor structure of DEMQOL and DEMQOL-Proxy in data obtained in our subsequent 
work including: clinical evaluation of the Croydon Memory Service (CMS) – over 1,000 DEMQOL and 
DEMQOL-Proxy scores (Banerjee at al 2007); and a longitudinal study of the natural history of HRQL in 
dementia – 100 baseline and six month follow-up DEMQOL scores. The results of these further factor 
analyses will be compared with those from the initial validation work, and new Rasch analyses undertaken 
on all three data sets to derive a final set of dimensions for the health-state classification.
2.2.2 Item selection
The purpose of this stage of the psychometric analyses is to reduce the 28-item DEMQOL and the 31-item 
DEMQOL-Proxy to the minimum number of items needed to derive a classification system for a preference-
based utility index.
We will undertake item reduction using a clearly defined strategy developed in our previous work (Lamping 
et al 2002a, 2002b, 2003; Hilari et al 2003; Hobart et al, 2004; Smith et al 2005, 2007) and based 
on state-of-the-art psychometric methods (Nunnally & Bernstein, 1994; Scientific Advisory Committee, 
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2002; Streiner & Norman, 2003), including Rasch analyses (refs). Our strategy defines a priori the 
psychometric tests to be conducted and the specific criteria for item elimination/retention (see Table 1). 
During item reduction, we will use both classical psychometric tests and Rasch analyses to consider items 
for elimination, based on examination of missing data, maximum endorsement frequencies, aggregate 
adjacent endorsement frequencies, redundancy, item–total correlations, factor analysis, item convergent/
discriminant analysis, responsiveness (where available) and Rasch item threshold probability curves.
Table 1 shows the psychometric tests and criteria used in the development and validation of DEMQOL. 
Tests and criteria for the proposed Rasch analyses are described below. Given that the aim of this study 
is to produce a preference-based measure from an existing validated, item-reduced questionnaire, more 
conservative psychometric criteria for item reduction will be applied than those used in our previous work 
in order to carry out more extensive item elimination. For example, a more stringent criterion than the 
standard < 5% for missing data will be used to determine whether an item should be retained. Criteria for 
all other psychometric tests applied during the item reduction phase (eg internal consistency, item–total 
correlations, item convergent and discriminant validity, etc.) will be reviewed by DL, JB, SS and TY to reach 
a consensus agreement about the more conservative criteria to be applied in this stage of the analyses.
Rasch analysis
Rasch analysis is a mathematical technique that converts qualitative (categorical) responses to a continuous 
(unmeasured) latent scale using a logit model. This technique has been used successfully to assist in the 
selection of items from the AQLQ and OABq in the development of preference-based indices (Young et al 
2005, 2007). RUMM2020 will be used for the analysis. 
Prior to item selection and having fitted the data to the Rasch model, the first step is to see whether 
items from the DEMQOL instruments fit the Rasch model. The assumption from Rasch analysis being that 
each set of items measure an underlying trait, eg self esteem related HRQOL and that this HRQOL can 
be measured on a unidimensional scale. The first step in this process is to see whether the levels of each 
item are ordered correctly on the logit scale. If levels of a given item are unordered or even disordered, it 
indicates that responders are unable to distinguish between these levels so these should be merged. Rasch 
analysis is then repeated until ordering is achieved. To achieve uniformity across all items, the same levels 
will be merged across items. This could potentially leave some items with disordered responses, and these 
will be considered for removal from the final item selection of the preference based indices.
The second step in the initial Rasch model fitting is to examine items for the presence of differential item 
function (DIF). DIF indicates that the way items are answered varies between responders by background 
characteristics such as age (eg less than or greater than 75), gender, and symptom severity (mild, moderate 
and severe). For example if women consistently answer items differently to males and those consistently 
have a worse/better QOL score for a particular item. If items are consistently answered better than 
others with a different characteristic, this suggests such items must be interpreted separately by these 
characteristics, or ‘split’. In normal applications of Rasch analysis such items can be modified or treated 
separately, but given the aims of this phase of the work, such items will be considered for removal.
The third step in producing a well-fitting Rasch model is to remove individual items which do not fit 
the model – these are identified by studying the item goodness of fit statistics. Poor fitting items will 
be removed one by one until the overall Rasch model goodness of fit becomes insignificant (χ2 p-value 
> 0.01). These items will not be considered further in the development of the preference based indices. 
Rasch models will be fitted for each dimension of the DEMQOL instrument as determined from the 
factor analysis.
After achieving a good fitting Rasch model the final step is to check each of the remaining items, by 
domain, in terms of the Rasch statistics that could be used in the selection process of items from the 
DEMQOL instruments. The spread across the latent variable (spread at logit 0) will be used as the main 
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criterion to choose the item to represent a given domain. The goodness-of-fit statistics (χ2 and p-value) 
and results from the psychometric analysis will also be taken into account. 
The final selection of items will be made by a panel of the study investigators. They will take into account 
the results of all the analyses described above, combined with their own understanding of the instrument 
and the need to derive a health-state classification that will be amenable to valuation.
2.2.3 Final derivation of health states
The aim will be to derive two multi-dimensional health-state classifications. We have achieved this with 
success in a number of instruments, including the AQLQ and OABq. In a study being undertaken by a PhD 
student supervised by JB it was found that it was only possible to derive two dimensions from a mental 
health outcome measure, the CORE-OM. This was because the items were very highly correlated and there 
were only two factors possible. Given the nature of the subject, this is possible in the work proposed here. 
Therefore, rather than limit the descriptive systems to two items in such circumstances which would risk 
the measure being unreliable and loosing a lot of information, the approach we will use is to use the 
Rasch model to define typical respondents (and hence health states) at different points along the latent 
variable as defined by 5 or 6 items. The health states valued in this way can then be mapped onto the 
latent variable in order to generate values for other states generated by the selected items. Clearly, until the 
full psychometric analyses have been completed it is not possible to predict the best way to generate states 
(whether by a health-state classification or not) or the precise number of health states. The remainder 
of the proposal assumes it will be possible to generate a health-state classification for DEMQOL and 
DEMQOL-Proxy. 
2.3 Phase 2: Main valuation survey
The aim of this phase of the project will be to obtain valuations of states defined by items from the 
DEMQOL and DEMQOL-Proxy questionnaires. 
2.3.1 Sample of states
Health-state classifications are likely to define many thousands of states, so a sample of states will be 
valued and modelling techniques will extrapolate values for all other states. The selection will be based on 
a balanced design, which ensures that any dimension-level (level λ of dimension δ) has an equal chance of 
being combined with all levels of the other dimensions. Deciding the number of states to value is rather 
more difficult to do formally, but recent studies of condition specific measures have successfully used 100 
states to estimate additive functions and explore simple summary terms to reflect interactions (Yang et 
al 2006). The design of the DCE will be developed using the library of orthogonal arrays at http://www.
research.att.com/~njas/oadir/ to enable all states to be valued. 
2.3.2 Respondents
The main sample of respondents in this survey will be representative of the general population and reflect 
the variability of the population in terms of characteristics such as age, socio-economic status and level of 
education.  The sample will be drawn using a two-stage cluster random selection design. The primary units 
will be postcode sectors stratified by percentage of households with a non-manual occupation. Postcode 
sectors will be selected, and addresses randomly selected from each of these. Where more than one adult 
(ie 16 or over) is found in household, one will be selected at random by the interviewer using a standard 
Kish selection grid. 
2.3.3 The interview
A study of 20 respondents, comprising members of the general population will be undertaken prior to the 
main study to check respondents’ understanding of the tasks and to check that they are completing each 
task as expected.  At the interview, respondents will be taken through the descriptive system and asked to 
confirm that they understand it. They will then be asked to rank and value 8 states using TTO. Respondents 
will be taken through one TTO to ensure they understand the task. They will also be asked a number of 
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background questions. Assuming there are 100 states to value for each descriptive system and each state 
is valued 30 times, the required sample size for one health-state classification is 375. This sample size or 
less has been successfully used to value a number of descriptive systems (Brazier et al 2002; Brazier et 
al 2007; Yang et al 2006). A further 25 interviews will be conducted to provide the 64 required for the 
comparison with user values in phase 4. Assuming the same level of complexity for the items derives from 
DEMQOL-Proxy this will require a further 375 interviews, suggesting a final sample size of 775.
After the interview, general public respondents will be asked to consent to being sent a postal 
questionnaire containing the DCE exercise. Consenting respondents will be sent the questionnaire four 
weeks after their interview.  This approach has been used in two previous valuation surveys undertaken 
at the University of Sheffield, achieving response rates of over 50% (Brazier et al 2006). To increase 
the sample size, the questionnaire will also be sent to a sample of 600 individuals who have not been 
interviewed in order to supplement this sample and to ascertain whether the interview itself altered 
people’s valuations.
2.4 Phase 3: Patient and carer valuation survey
The aim will be to examine whether health-state values elicited for health states defined by the DEMQOL 
and DEMQOL-Proxy by patients and cares respectively, differ significantly from the general public. 
Respondents from these two groups will be recruited from clinical contacts in South London. We have 
been successful in recruiting large cohorts of people with dementia and their family carers for study in 
this way. The people with dementia to be interviewed will be assessed as having mild dementia (defined 
by MMSE > 18) and their main family carers will also be recruited where possible. In addition the family 
carer group will be enhanced by a balanced sample of those caring for people with moderate and 
severe dementia.
Respondents will be asked to value a set of 8 states using the same methods as the general population 
valuation survey. These interviews will be undertaken in people’s own homes at times that are convenient 
for them with great care by researchers from the Institute of Psychiatry experienced in interviewing 
people with dementia patients and their carers. Training in the valuation methods will be provided by the 
Sheffield team.
Assuming a power of 0.8, significance level of 0.05, standard deviation of 0.3 and an expected difference 
of 0.1, then this requires a sample of 71 interviews to compare to mean valuations per state from the 
main survey for each of the instruments. Given the separate work needed on DEMQOL-nD and DEMQOL-
Proxy-nD and the need to minimise respondent burden to enable the completion of the cognitively 
complex tasks, we will therefore need to recruit 142 people with dementia and 142 family carers who can 
complete the assessments.  Mean values will be compared using simple t-tests.
The participants in the patient and carer valuation survey will also be used to carry out a direct evaluation 
of the psychometric properties of the item-reduced, preference-based DEMQOL-nD and DEMQOL-Proxy-nD 
instruments embedded within DEMQOL in an independent sample. This will use standard psychometric 
methods (as described above and in Table 1) to evaluate acceptability, reliability (internal consistency and 
test–retest), validity (content, convergent, discriminant and known group differences).
2.5 Phase 4: Modelling health-state values
The econometric models will have an additive specification, with the TTO value as the dependent variable 
and each level of each domain, other than the baseline, entered as dummy variables. A range of different 
specifications will be explored, including aggregate models using mean health-state values and random 
effects models using individual level data (Brazier et al 2002). The DCE data will be analysed using a 
random effects probit model that also assumes an additive relationship between the dimensions. The 
impact of adding interaction terms and various transformations will be explored. All models will be 
subjected to the standard tests of goodness of fit, t-tests of the coefficients, heteroskedasticity, normality 
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of errors, and robustness (Brazier et al 2002). A new Bayesian statistical model will also be estimated that 
is more theoretically appropriate than conventional models and has been found to perform better in terms 
of predicting out of sample values (Kharroubi et al 2007). This will also be used to examine the impact of 
covariates, including the respondent’s mental health.
The best models will be selected and converted into scoring algorithms that can be applied to existing and 
future DEMQOL and DEMQOL-Proxy data sets. The algorithms will be produced in SPSS, SAS and Excel and 
will be made publicly available free of charge.
2.6 Phase 5: application to trial data
2.6.1 HTA-SADD
HTA-SADD is a multi-centre double-blind placebo-controlled RCT of the clinical and cost effectiveness 
of two classes of antidepressants, and more specifically, mirtazapine and sertraline, from baseline to 
3 months (13 weeks) and 9 months (39 weeks), enabling estimation of short and long-term impacts of 
these antidepressants on depression in dementia. The primary objective of the study is to determine the 
clinical and cost-effectiveness of the two classes of antidepressants for depression in dementia (compared 
with placebo) as measured by the Cornell Scale for Depression in Dementia and (on the cost side) the 
societal resource impacts. Secondary objectives include an investigation of: differences in the clinical 
and cost-effectiveness, and, in terms of adverse events, withdrawals from treatment and adherence 
to treatment; differences in the clinical and cost-effectiveness of mirtazapine or sertraline compared 
to placebo on patient (eg quality of life, cognition) and family carer (eg carer burden, carer quality of 
life) outcomes; and the influence on clinical and cost-effectiveness of clinical characteristics including: 
dementia severity, dementia type, depression type, depression severity, care arrangements, neuropsychiatric 
symptoms, and physical illness.
Setting and selection
The trial is set in secondary care, using referrals to old age psychiatric services and memory clinics in 
9 regional sites each covering a catchment area of 100,000 older people (Birmingham, Cambridge, 
Leicester, Liverpool, Manchester, Newcastle, North London, Southampton and South London) aided by 
the Department of Health Mental Health Research Network (MHRN) and DeNDRoN. This is a pragmatic 
trial. The criteria for inclusion are as close to clinical practice as possible. We will recruit those where a 
secondary care doctor makes a clinical diagnosis of mild to moderate probable or possible Alzheimer’s 
Disease and a co-existing depressive illness of at least four weeks duration, likely to need treatment with 
antidepressants. The local research worker (RW) will then assess the patient’s depression severity and those 
with a Cornell Scale for Depression in Dementia (CSDD) of 8+ will be eligible for entry into the trial. The 
other trial exclusions will be: currently taking antidepressants, the case being too critical to be randomised; 
absolute contra-indications to trial medications, being on another trial, treatment with antidepressants in 
the past four weeks, and no family or professional carer to give collateral information.
Randomisation and assessment
Patients will be allocated to placebo, sertraline or mirtazapine (ratio 1 : 1 : 1) by the Mental Health & 
Neurology Clinical Trials Unit based at the Institute of Psychiatry. Allocation will be stratified by centre by 
stratified block randomisation with randomly varying block sizes. Cases identified will be assessed by RW 
who will collect baseline and follow-up data (0 m, 3 m, and 9 m). The primary outcomes will be depression 
score – CSDD and cost – Client Service Receipt Inventory (CSRI). Secondary outcomes will include: 
adverse events, compliance, patient quality of life (disease-specific DEMQOL, generic EQ5D), cognition 
(MMSE), behavioural and psychological symptoms (NPI), carer burden (Zarit), carer stress (GHQ12), and 
carer quality of life (SF12 v2). The analysis of the economic impact of the interventions is a central, fully 
integrated element of the proposed study. The comprehensive costs of care for all participants will be 
calculated (including the costs of formal care such as that provided by health and social services and 
also the costs of informal care) using data gathered using the CSRI completed by key workers or family 
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carers at baseline, 13 w and 39 w. Unit costs will be best national estimates of the long-run marginal 
opportunity costs.  Informal care will be costed. An overall sample size of 507 patients will provide 90% 
power to detect a 2 point difference in CSDD (SD 5; SES 0.4) for the primary comparisons of mirtazapine 
vs. placebo and sertraline vs. placebo at 13 weeks and 86% power for the secondary analysis of these 
comparisons at 39 weeks. This allows for 10% loss to follow-up at 13 weeks and 20% loss to follow-up at 
39 weeks, correlation between baseline and outcome CSDD > 0.6, and up to 12.5% of those randomized 
(per comparison) to be either drop-outs or drop-ins using an analysis of covariance with 2-sided 5% 
significance levels. Allowing for the same levels of loss to follow-up, an overall sample of 507 patients 
would also enable us to calculate 2-sided 95% confidence intervals for the difference in the proportion of 
pre-specified adverse events between the antidepressant arms of (a clinically significant) 10% (i.e. 5% vs. 
15%) ± 6% at 13 weeks and ± 7% at 39 weeks. 
Analyses
CSDD score at 13 weeks will be analysed by ANCOVA adjusted for baseline CSDD and centre with contrasts 
for (a) sertraline vs. placebo and (b) mirtazipine vs. placebo. Secondary Analyses – The ANCOVA of CSDD 
score at 13 weeks will further include a contrast for mirtazapine vs. sertraline. CSDD score at 39 weeks will 
be analysed by ANCOVA adjusted for baseline CSDD and centre with contrasts for (a) sertraline vs. placebo; 
(b) mirtazipine vs. placebo, and (c) mirtazapine vs. sertraline. Secondary outcomes will be compared using 
the same contrasts as above within a [longitudinal] generalised linear model framework adjusting for the 
respective baseline scores and centre. The significance level will be 5% (2-sided) for all specified analyses of 
the primary outcome variable and 1% (2-sided) for all specified analyses of secondary outcome variables. 
From the cost and the outcome data, we will compare total and component (by service or agency) costs, 
incremental cost-effectiveness ratios and net benefits (using the primary outcome measure CSDD), cost–
utility ratios (using utility scores computed from the EQ-5D and societal weights) and cost–consequences 
results (using all non-cost outcomes measures). The primary evaluation will be the cost-effectiveness 
analyses with CSDD change as the outcome. The evaluation will include the plotting of cost-effectiveness 
acceptability curves generated from bootstrap analyses. Sensitivity analyses will explore the impact of 
differences in key costs and outcome assumptions. Modelling will be conducted to predict costs and 
outcomes beyond the duration of the trial. The evaluation will be conducted from (a) societal, (b) public 
sector and (c) NHS perspectives. The projected date for a full data set for evaluation is September 2008, 
fitting well with the time frame of this proposal.
Application the new system to the HTA-SADD data set
We will work with the existing trial statisticians and economists to generate a further analysis strategy that 
will be applied to the trial data set. This will include the derivation of DEMQOL-nD and DEMQOL-Proxy-nD 
scales from the trial data, application of both the population and the patient/carer valuations and leading 
to the generation of cost effectiveness analyses using the derived dementia QALY. This will allow us to go 
beyond the originally (and funded) plan of analysis which was to generate utility scores from the EQ-5D for 
the purposes of the cost-effectiveness analyses. This further work will be led by MK.
2.6.2 MRC-DOMINO
MRC-DOMINO is a pragmatic, multi-centre, double-blind, randomised, placebo-controlled (double 
dummy), parallel group, 2 × 2 factorial clinical trial. The aim of the DOMINO study is to determine, in a 
factorial (2 × 2) design whether there is worthwhile benefit for patients for whom there is uncertainty 
on whether or not to continue cholinesterase inhibitors from: 1) adding memantine to cholinestease 
inhibitors, 2) switching to memantine, or 3) continuing cholinesterase inhibitors, as compared to 4) 
placebo.
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Memantine
Donepezil
Continue Discontinue
Add Group 1 Group 2
Donepezil Donepezil placebo
Memantine Memantine
No Group 3 Group 4
Donepezil Donepezil placebo
Memantine placebo Memantine placebo
Setting and selection
There will be 15 clinical recruiting centres: 1. The Institute of Psychiatry and South London and Maudsley 
NHS Trust, (Professors Howard, Ballard, Banerjee), 2. Bristol (Professor Wilcock), 3. Bath (Professor 
Jones), 4. Birmingham (Dr Bentham), 5. Manchester (Professor Burns), 6. Leicester (Professor Lindsay), 
7. Newcastle (Professors McKeith, O’Brien), 8. Warwick (Dr Sheehan), 9. Perth and Tayside (Dr Findlay), 
10. Imperial College (Dr Ritchie), 11. Paisley (Dr Hughes), 12. Oxford (Professor Jacoby), 13. Cambridge 
(Dr Dening), 14. Southampton (Professor Holmes), and 15. Belfast (Dr Passmore).  Inclusion Criteria – 
participants will be patients who meet NINCDS-ADRDA criteria for probable or possible Alzheimer’s disease 
(McKhann et al, 1984). In addition they will meet all of the following criteria: (1) Continuously prescribed 
donepezil for at least 3 months; (2) No change in dosage of donepezil in previous 6 weeks; (3) No changes 
in prescription of any psychotropic (antipsychotic, antidepressant, benzodiazepine) medication in previous 
4 weeks; (4) Prescribing clinician considers (based on NICE guidance, discussions with patient and carer 
and clinical judgement) that change of drug treatment (i.e. stop donepezil or introduce memantine) may 
be appropriate and  MMSE = 5 to 13 (13 chosen as NICE threshold of 10 plus 1 SD on MMSE score); (5) 
Patient is community resident and has family or professional carer or is visited on at least a daily basis by 
carer; (6) Patient agrees to participate; (7) Main carer (informal or institutional) consents to their own 
involvement. Exclusion Criteria – To maximise the generalisability of the study data, exclusions will be kept 
to a minimum. These will include: (1) Patient has severe, unstable or poorly controlled medical conditions 
apparent from physical examination or clinical history; (2) Patient is already prescribed memantine; (3) 
Patient is unable to take trial medications; (4) Patient is involved in another clinical trial; (5) Patient has 
absolute contraindication to either donepezil or memantine.
Randomisation and assessment
Randomisation will be done centrally by telephone to the MRC Clinical Trials Unit (CTU) in London, using a 
dedicated hotline. Proposed duration of treatment period. 52 weeks. All study measures will be assessed 
at randomisation, at 5 weeks to address the acute effects of withdrawal of donepezil, at 26 weeks and at 
52 weeks. Finally, participants will be followed up every 26 weeks for 208 weeks by telephone interview 
to establish whether and on what date they have entered a care institution. There will be three Primary 
outcome measures. (1) Cognitive Function measured with the Severe Impairment Battery (SIB) (Panisset 
et al 1994). The SIB is a 51-item scale with scores ranging from 0 to 100 which has shown greater 
sensitivity to change in cognitive function than the Standardized MMSE in similarly affected populations 
of patients to the participants in DOMINO (Feldman et al 2001, Tariot et al 2004). (2) Activities of Daily 
Living measured with the Bristol Activities of Daily Living scale (BADLS) (Bucks et al 1996). The BADLS is 
well validated psychometrically and as a surrogate for estimating costs and scores deteriorate at a steady 
rate of 5 points per year in AD across a wide range of functional disability. (3) Cost-effectiveness measured 
as the combination of costs generated from the CSRI (Beecham et al 1992) and the SIB, BADLS, DEMQOL 
or utility measure generated from the EQ-5D. Secondary outcome measures. (1) Non-cognitive dementia 
symptoms measured with the NPI (Cummings et al 1994) and the Cohen-Mansfield Agitation Inventory 
(Cohen-Mansfield et al 1992). (2) Cognition with the MMSE (Folstein et al 1975). Although this is less 
sensitive to change than the SIB within the dementia severity range under study, the MMSE has been 
used in so many studies that its inclusion is important to allow comparisons with earlier trial data and 
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to increase generalisability of DOMINO’s outcome data. (3) HRQL measured with the EQ-5D (Euroqol 
Group 1990) and the DEMQOL-Proxy. (4) Institutionalisation defined as permanent transition from living 
in an independent household to a care home, NHS continuing care unit or hospital and measured with 
questions taken from the CSRI over 4-year follow up. (5) Caregiver burden measured with the GHQ-12 
(Goldberg et al 1988).
Analyses
The primary comparisons will be performed on an intention-to-treat basis. The results from the trial 
will be presented as comparative summary statistics (difference in response rates or means) with 95% 
confidence intervals. Primary outcomes SIB/BADLS: Depending on the distribution of the change in the 
SIB/BADLS from baseline over the study period (52 weeks), if appropriate, an analysis using linear mixed 
effects models with repeated measures will be performed, adjusting for baseline value and stratification 
covariates, plus other variables that the physicians consider of prognostic importance. We will formally 
assess the distribution of the change from baseline for evidence of departure from normality. If necessary, 
data will either be transformed or analysed using a non-parametric equivalent. Cost comparisons will be 
made between interventions to match the cognitive and ADL comparisons, with adjustments probably 
needed to adjust for non-normality of data (transformation or non-parametric test). For each hypothesis, 
relevant perspective and outcome, an incremental cost-effectiveness ratio will be computed using SIB, 
BADLS, DEMQOL and utility (from EQ5D) measures and compared with results from other studies where 
appropriate. Cost-effectiveness acceptability curves will be plotted for appropriate pairwise comparisons. 
For secondary outcomes we will formally assess the distributions of the changes in the continuous 
secondary outcome measures for evidence of departure from normality. In instances where such changes 
in outcome are not normally distributed, data will be transformed and analysed as detailed above, or 
tested using non-parametric equivalents. Service utilisation patterns, carer inputs and all associated 
costs will be calculated for each patient, based on data collected using a modified version of the CSRI, 
completed by a family carer or care professional. Unit costs to reflect long-run marginal opportunity costs 
will be attached using national figures where available. Each cost-effectiveness analysis will be conducted 
from the perspective of (a) the NHS and social services, and (b) society. The SIB, BADLS, DEMQOL and a 
utility measure generated from the EQ-5D will be used in turn in a series of cost-effectiveness analyses, 
the last of these to generate QALY measures (with societal weights). We will also examine the associations 
between EQ-5D, DEMQOL and SIB scores and changes therein, given uncertainty about the validity of 
EQ-5D measures as QALY generators within this population. Parallel work is needed to explore the utility 
generating properties of the DEMQOL but is beyond this study’s scope. Cost-effectiveness acceptability 
curves will be plotted using bootstrap analyses to locate the findings of the economic evaluation in their 
wider decision-making context. Sensitivity analyses will also examine the consequences of key assumptions 
in the cost-effectiveness analysis. In addition, we will use a mathematical model, developed from the 
AD2000 database and using NPI and BADLS data, to estimate risks of institutionalisation in treatment 
groups over four years.
Application the new system to the MRC-DOMINO data set
We will work with the existing trial statisticians and economists to generate a further Analysis Strategy that 
will be applied to the trial data set. This will include the derivation of DEMQOL-nD and DEMQOL-Proxy-nD 
scales from the trial data, application of both the population and the patient/carer valuations and leading 
to the generation of cost effective analyses using the derived dementia QALY. This will allow us to go 
beyond the originally (and funded) plan of analysis which was to generate utility scores from the EQ-5D for 
the purposes of the cost-effectiveness analyses. This further work will be led by MK.  
2.6.3 Further application and development 
Testing the preference-based index
Using the participants in the patient and carer valuation survey, the psychometric properties of the 
item-reduced, preference-based DEMQOL-nD and DEMQOL-Proxy-nD will be evaluated using standard 
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psychometric methods (as described above and in Table 1) to evaluate acceptability, reliability (internal 
consistency and test–retest), validity (content, convergent, discriminant and known group differences)
Comparison of indices with the original sub-scale scores
The aim will be to test whether moving from the full DEMQOL sub-scale scores to the indices 
results in a significant loss of psychometric performance in terms of missing data, reliability, validity 
and responsiveness.  
Comparison with EQ-5D
An important issue is whether the measures derived from DEMQOL and DEMQOL-Proxy perform any 
differently to the EQ-5D in terms of psychometric properties. The disease-specific measure must be 
demonstrated to be psychometrically superior in order to justify its further use rather than the generic 
EQ-5D. The size of any differences in health-state utility values found in the trials and the implications of 
this in terms of the incremental cost-effectiveness ratios will also be examined using the data generated by 
the economic evaluations in the HTA-SADD and MRC-DOMINO trials. 
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TABLE 1 DEMQOL and DEMQOL-Proxy: Psychometric Tests and Criteria 
Psychometric Property Definition/Test Criteria for Acceptability
1. Item analysis/reduction Identify items for possible elimination due to weak psychometric 
performance; assessed on the basis of: i) unrotated principal component 
factor analysis to determine whether all items are measuring a single 
factor; and ii) item analyses for all items
Principal component factor analysis
 z All items should load on the first unrotated factor > 0.30
Item analyses (applied to all items)
 z Missing data < 5%
 z No item redundancy (inter-item correlations ≤ 0.75)
 z Item–total correlations > 0.25 
 z Maximum endorsement frequencies ≤ 80% (i.e. the proportion of 
respondents who endorse each response category), including floor/
ceiling effects < 80% (i.e. response categories with high endorsement 
rates at the bottom/top ends of the scale, respectively)
 z Aggregate adjacent endorsement frequencies ≥ 10% (Liang et al 1990)
2. Acceptability The quality of data; assessed by completeness of data and score 
distributions
 z Missing data for summary scores < 5%
 z Even distribution of endorsement frequencies across response categories
 z Floor/ceiling effects for summary scores < 10%
3. Reliability
3.1 Internal consistency The extent to which items comprising a scale measure the same 
construct (e.g. homogeneity of the scale); assessed by Cronbach’s alpha 
(160) and item–total correlations
 z Cronbach’s alphas for summary scores ≥ 0.70 (Streiner and Norman 
2003) 
 z Item–total correlations ≥ 0.20 (Streiner and Norman 2003)
3.2 Test–retest reliability The stability of a measuring instrument; assessed by administering the 
instrument to respondents on two different occasions and examining the 
correlation between test and retest scores
 z Test–retest reliability correlations for summary scores ≥ 0.70 (Scientific 
Advisory Committee of the Medical Outcomes Trust 2002)
3.3 Inter-rater reliability Agreement between independent raters/observers; assessed by intra-class 
correlations (ICC)
 z ICC ≥ 0.70 (Scientific Advisory Committee of the Medical Outcomes Trust 
2002)
3.4 Parallel (alternate) forms 
reliability
Agreement between two or more parallel/alternate forms or different 
versions of the same measure (e.g. form A/B, short/long form, etc.) that 
indicates that they can be used interchangeably; assessed on the basis of 
correlations between parallel/alternate forms of a measure
 z High correlation between parallel/alternate forms of the measure (e.g. 
between long and short form)
4. Validity 
4.1 Content validity The extent to which the content of a scale is representative of the 
conceptual domain it is intended to cover; assessed qualitatively during 
the questionnaire development stage through pre-testing with patients, 
expert opinion and literature review
 z Qualitative evidence from pre-testing with patients, expert opinion and 
literature review that items in the scale are representative of the construct 
being measured
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Psychometric Property Definition/Test Criteria for Acceptability
4.2 Criterion-related validity
4.2.1 Concurrent validity Evidence that the scale predicts a gold standard criterion that is 
measured at the same time; assessed on the basis of correlations 
between the scale and the criterion measure 
 z High correlation between the scale and the criterion measure
4.2.1 Predictive validity Evidence that the scale predicts a gold standard criterion that is 
measured in the future; assessed on the basis of correlations between the 
scale and the criterion measure
 z High correlation between the scale and the criterion measure
4.3 Construct validity
4.3.1 Within-scale analyses Evidence that a single entity (construct) is being measured and that 
items can be combined to form a summary score; assessed on the basis 
of evidence of good internal consistency and correlations between scale 
scores (which purport to measure related aspects of the construct)
 z Internal consistency (Cronbach’s alpha) ≥ 0.70
 z Moderate to high correlations between scale scores
4.3.2 Analyses against external criteria
4.3.2.1 Convergent validity Evidence that the scale is correlated with other measures of the same 
or similar constructs; assessed on the basis of correlations between the 
measure and other similar measures 
 z Correlations are expected to vary according to the degree of similarity 
between the constructs that are being measured by each instrument. 
Specific hypotheses are formulated and predictions tested on the basis of 
correlations
4.3.2.2 Discriminant validity Evidence that the scale is not correlated with measures of different 
constructs; assessed on the basis of correlations with measures of 
different constructs
 z Low correlations between the instrument and measures of different 
constructs
4.3.2.3 Known groups 
differences
The ability of a scale to differentiate known groups; assessed by 
comparing scores for subgroups who are expected to differ on the 
construct being measured
 z Significant differences between known groups or difference of expected 
magnitude
5. Responsiveness Tthe ability of a scale to detect clinically important change over time; 
assessed by comparing scores before and after an intervention of known 
efficacy (on the basis of various methods including t-tests (161), effect 
sizes (162, 163), standardised response means (164), or responsiveness 
statistics (165)
 z Significant differences between known groups or difference of expected 
magnitude
Smith et al. 2005; adapted from Lamping et al., 2002a, 2002b, 2003; Hilari et al., 2003.
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For all of the questions I’m going to ask you, I want you to think about the last week.   
First I’m going to ask about your feelings.   In the last week, have you felt……. 
1. cheerful? **          a lot     quite a bit        a little      not at all    
2. worried or anxious?          a lot     quite a bit        a little      not at all    
3. that you are enjoying life? **     a lot      quite a bit        a little      not at all    
4. frustrated?          a lot      quite a bit        a little      not at all    
5. confident? **           a lot      quite a bit        a little      not at all    
6. full of energy? **         a lot      quite a bit        a little      not at all    
7. sad?           a lot      quite a bit        a little      not at all    
8. lonely?           a lot      quite a bit        a little      not at all    
9. distressed?         a lot      quite a bit        a little      not at all    
10. lively? **           a lot      quite a bit        a little      not at all    
11. irritable?            a lot      quite a bit        a little      not at all    
12. fed‐up?            a lot      quite a bit        a little      not at all    
13. that there are things that you  
wanted to do but couldn’t?     a lot      quite a bit        a little      not at all  
Next, I’m going to ask you about your memory.  In the last week, how worried have you been about………. 
14. forgetting things that 
 happened recently?       a lot     quite a bit        a little      not at all  
15.  forgetting who people are?     a lot      quite a bit        a little      not at all  
16.  forgetting what day it is?      a lot      quite a bit        a little      not at all    
17. your thoughts being muddled?     a lot      quite a bit        a little      not at all    
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18. difficulty making decisions?     a lot      quite a bit        a little      not at all    
19.  poor concentration?       a lot      quite a bit        a little      not at all  
Now, I’m going to ask you about your everyday life.  In the last week, how worried have you been about………. 
20. not having enough company?     a lot      quite a bit        a little      not at all    
21. how you get on with people  
close to you?         a lot      quite a bit        a little      not at all    
22. getting the affection that  
you want?          a lot      quite a bit        a little      not at all    
23.  people not listening to you?     a lot      quite a bit        a little      not at all    
24. making yourself understood?     a lot     quite a bit        a little      not at all    
25. getting help when you need it?     a lot      quite a bit        a little      not at all   
26. getting to the toilet in time?     a lot      quite a bit        a little      not at all    
27. how you feel in yourself?      a lot      quite a bit        a little      not at all    
28. your health overall?       a lot      quite a bit        a little      not at all    
We’ve already talked about lots of things:  your feelings, memory and everyday life.  Thinking about all of these things in the last week, how would you 
rate………. 
29. your quality of life overall? **       very good       good      fair       poor    
** items that need to be reversed before scoring 
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For all of the questions I’m going to ask you, I want you to think about the last week.   
First I’m going to ask you about _________ (your relative’s) feelings.  In the last week, would you say that _________ (your relative) has 
felt……….     
1. cheerful?  **           a lot     quite a bit       a little     not at all 
2. worried or anxious?          a lot     quite a bit       a little     not at all 
3. frustrated?           a lot     quite a bit       a little     not at all 
4. full of energy? **           a lot     quite a bit       a little     not at all 
5. sad?             a lot     quite a bit       a little     not at all 
6. content?  **           a lot     quite a bit       a little     not at all 
7. distressed?           a lot     quite a bit       a little     not at all 
8. lively? **             a lot     quite a bit       a little     not at all 
9. irritable?              a lot     quite a bit       a little     not at all 
10. fed‐up             a lot     quite a bit       a little     not at all 
11. that he/she has things 
to look forward to? **         a lot     quite a bit       a little     not at all 
Next, I’m going to ask you about _________ (your relative’s) memory.  In the last week, how worried would you say _________ (your 
relative) has been about………. 
12. his/her memory in general?       a lot     quite a bit        a little      not at all  
13. forgetting things that  
happened a long time ago?       a lot      quite a bit        a little      not at all  
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14. forgetting things that 
 happened recently?         a lot      quite a bit        a little      not at all  
15. forgetting people’s names?    a lot    quite a bit     a little    not at all  
16. forgetting where he/she is?       a lot      quite a bit        a little      not at all  
17. forgetting what day it is?        a lot      quite a bit        a little      not at all  
18. his/her thoughts being muddled?     a lot      quite a bit        a little      not at all  
19. difficulty making decisions?       a lot      quite a bit        a little      not at all  
20. making him/herself understood?     a lot      quite a bit        a little      not at all  
Now, I’m going to ask about _________ (your relative’s) everyday life.  In the last week, how worried would you say _________ (your 
relative) has been about………. 
21. keeping him/herself clean  
(eg washing and bathing)?       a lot     quite a bit       a little      not at all  
22. keeping him/herself looking nice?     a lot      quite a bit        a little      not at all  
23. getting what he/she wants  
from the shops?           a lot      quite a bit        a little      not at all  
24. using money to pay for things?       a lot      quite a bit        a little      not at all  
25. looking after his/her finances?       a lot      quite a bit        a little      not at all  
26. things taking longer than  
they used to?           a lot      quite a bit        a little      not at all  
27. getting in touch with people?       a lot      quite a bit        a little      not at all  
28. not having enough company?       a lot      quite a bit        a little      not at all  
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29. not being able to help other 
 people?             a lot      quite a bit        a little      not at all  
30. not playing a useful part   
 in things?             a lot      quite a bit        a little      not at all  
31. his/her physical health?          a lot      quite a bit        a little      not at all  
We’ve already talked about lots of things: _________ (your relative’s) feelings, memory and everyday life.  Thinking about all of these things 
in the last week, how would you say _________ (your relative) would rate…….. 
32. his/her quality of life overall?  **   very good   good    fair    poor  
** items that need to be reversed before scoring 
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